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Abstract
The importance of DNA methylation in neuronal function is highlighted by mutations in the neuronally
enriched “reader” of DNA methylation, methyl-CpG-binding protein 2 (MECP2), causing Rett Syndrome
(RTT), a severe neurodevelopmental disorder. Although MeCP2 displays broad genomic binding, gene
expression changes in Mecp2 mutant mice are very subtle, and brain region-specific, making it difficult to
determine how MeCP2 regulates gene expression. Therefore, we developed an approach to assess cell
type-specific effects of Mecp2 mutations on the transcriptome, epigenome, and chromatin architecture to
determine whether epigenomic features can explain gene misregulation in RTT. Differentially expressed
genes (DEGs) in R106W Mecp2 mutants (R106W) are enriched for MeCP2 binding in the WT setting and
are preferentially demethylated in R106W, suggesting that the loss of MeCP2 binding results in the
exposure of unbound cytosines to demethylation, thus contributing to gene dysregulation. Given that
DEGs are enriched for MeCP2 binding, we next determined unique features of DEGs to gain an
understanding of why MeCP2 preferentially targets DEGs. We find that DEGs are cell type-specific, lowly
expressed, and intragenically associated with heterochromatin, active enhancer, and CTCF chromatin
states, suggesting that MeCP2 is essential for the regulation of lowly expressed genes. Upregulated and
downregulated DEGs are differentially enriched for particular chromatin states, providing an insight into
the directionality of gene dysregulation. Given the enrichment of DEGs for active enhancer and CTCF
chromatin states, we next investigated transcription factor (TF) footprints and found thousands of altered
TF footprints in R106W, with the CTCF motif being the most significantly associated. In WT, these sites
are enriched for MeCP2 binding, and in R106W, these sites, which are associated with downregulated
DEGs, become demethylated, enabling CTCF binding. This therefore suggests that MeCP2 can affect
CTCF recruitment to chromatin. Given CTCF’s known role in chromatin organization, we employed
Oligopaint and found large-scale condensation of euchromatin and heterochromatin, as well as
decondensation of long genes. Together, this work provides insight into why DEGs are differentially
susceptible to dysregulation in RTT and posits MeCP2 as a key player in global maintenance of the
methylome and chromatin architecture for the preservation of neuronal gene expression.
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ABSTRACT

EPIGENOMIC AND NUCLEAR ARCHITECTURAL INSIGHTS INTO
RETT SYNDROME

Maria Fasolino

Dr. Zhaolan Zhou

The importance of DNA methylation in neuronal function is highlighted by
mutations in the neuronally enriched “reader” of DNA methylation, methyl-CpG-binding
protein 2 (MECP2), causing Rett Syndrome (RTT), a severe neurodevelopmental
disorder. Although MeCP2 displays broad genomic binding, gene expression changes in
Mecp2 mutant mice are very subtle, and brain region-specific, making it difficult to
determine how MeCP2 regulates gene expression. Therefore, we developed an approach
to assess cell type-specific effects of Mecp2 mutations on the transcriptome, epigenome,
and chromatin architecture to determine whether epigenomic features can explain gene
misregulation in RTT. Differentially expressed genes (DEGs) in R106W Mecp2 mutants
(R106W) are enriched for MeCP2 binding in the WT setting and are preferentially
demethylated in R106W, suggesting that the loss of MeCP2 binding results in the
exposure of unbound cytosines to demethylation, thus contributing to gene
dysregulation. Given that DEGs are enriched for MeCP2 binding, we next determined
unique features of DEGs to gain an understanding of why MeCP2 preferentially targets
DEGs. We find that DEGs are cell type-specific, lowly expressed, and intragenically
associated with heterochromatin, active enhancer, and CTCF chromatin states,
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suggesting that MeCP2 is essential for the regulation of lowly expressed genes.
Upregulated and downregulated DEGs are differentially enriched for particular
chromatin states, providing an insight into the directionality of gene dysregulation.
Given the enrichment of DEGs for active enhancer and CTCF chromatin states, we next
investigated transcription factor (TF) footprints and found thousands of altered TF
footprints in R106W, with the CTCF motif being the most significantly associated. In
WT, these sites are enriched for MeCP2 binding, and in R106W, these sites, which are
associated with downregulated DEGs, become demethylated, enabling CTCF binding.
This therefore suggests that MeCP2 can affect CTCF recruitment to chromatin. Given
CTCF’s known role in chromatin organization, we employed Oligopaint and found largescale condensation of euchromatin and heterochromatin, as well as decondensation of
long genes. Together, this work provides insight into why DEGs are differentially
susceptible to dysregulation in RTT and posits MeCP2 as a key player in global
maintenance of the methylome and chromatin architecture for the preservation of
neuronal gene expression.
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CHAPTER 1
Introduction

One Sentence Summary
This chapter provides an introduction to the concepts presented in subsequent
chapters, with a focus on the outstanding questions in MeCP2 research, and has been
accepted for publication as a review article in the journal Genes.

Overview
A neuron is unique in its ability to dynamically modify its transcriptional output
in response to synaptic activity while maintaining a core gene expression program that
preserves cellular identity throughout a lifetime that is longer than almost every other
cell type in the body. A contributing factor to the immense adaptability of a neuron is
attributed to its unique epigenetic landscape that elicits rapid, locus-specific alterations
in chromatin architecture, which in turn influences gene expression. One such epigenetic
modification that is sensitive to changes in synaptic activity, as well as essential for
maintaining cellular identity, is DNA methylation. The focus of this chapter is on the
importance of DNA methylation in neuronal function, summarizing the recent studies on
critical players in the establishment of (the “writing”), the modifying or erasing of (the
“editing”), and the mediation of (the “reading”) DNA methylation in neuroplasticity. One
“reader” of DNA methylation in particular, methyl-CpG-binding protein 2 (MeCP2), is
highlighted given that understanding the molecular function of this protein, which has
undisputed importance in neuronal function, has been the main focus of my graduate
work.
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The adaptability of gene expression programs in response to neuronal
activity
Neuroplasticity is the ability of the brain to alter neural function in response to
environmental input. This adaptability, also expressed as long-lasting plasticity, is the
basis of learning and memory formation. Two neuronal mechanisms that are essential
for long-lasting plasticity are long-term depression (LTD) and long-term potentiation
(LTP), which decrease or increase synaptic strength, respectively, in response to activity
(Malenka and Bear, 2004; McClung and Nestler, 2007). Here we will focus on LTP, as
key molecules in this process are frequently referenced throughout this review.
LTP is generally broken down into two phases: a transient “early” phase (30-60
minutes) that is dependent upon the activation of pre-existing proteins and a stable
“late” phase (hours, days, or even weeks) that is contingent upon new gene transcription
and translation (Malenka and Bear, 2004). The induction of early phase LTP is
dependent upon postsynaptic depolarization that leads to an influx of calcium (Ca2+)
through NMDA receptors (NMDARs). Ca2+ entry in turn triggers a biochemical cascade
starting with the activation of calcium/calmodulin-dependent protein kinase II
(CaMKII) via phosphorylation, which translocates to active synapses where it binds to
NMDARs and phosphorylates AMPA receptors (AMPAR) and activates RASextracellular signal-regulated kinase (ERK) pathway that leads to an increase in the
insertion of AMPAR into the synapse. This leads to an increase in the conductance of
Ca2+ through AMPARs in stimulated spines, which subsequently activates a molecular
cascade that strengthens potentiated spines (Lisman et al., 2012; Malenka and Bear,
2004). An important modulator of the CaMKII cascade is the protein phosphatase 1
(PP1), which at basal conditions dephosphorylates CaMKII; however, in response to
neuronal activity and subsequent LTP induction, cyclic adenosine monophosphate
(cAMP) activates protein kinase A, which in turn phosphorylates inhibitor 1 (I-1) that
inhibits PP1, leading to an increase in CaMKII phosphorylation and activity (Blitzer,
1998; Brown et al., 2000; Lisman et al., 2012; Malenka and Bear, 2004).
Similarly to the case of CaMKII, many of the early phase LTP signaling cascades
converge upon the activation of ERK, which in turn activates various biochemical
pathways that are essential for late phase LTP. One group of proteins activated by ERK
are transcription factors, such as cAMP response element binding protein (CREB), FBJ
2

osteosarcoma oncogene B (Fosb), and the transcription factor complex NF-κB, which
subsequently induce gene expression changes essential for the potentiation of active
synapses, such as immediate early response genes, ion channels, structural proteins, and
neurotrophins (LYNCH, 2004; McClung and Nestler, 2007). One neurotrophin that is
particularly important in the maintenance of LTP is brain-derived neurotrophic factor
(Bdnf), which acts through mitogen-activated protein kinase (MAPK)/ERK kinase
(MEK) to increase the expression of activity-regulated cytoskeleton-associated protein
(Arc), a gene important in cytoskeleton organization at activated synapses (LYNCH,
2004; Ying et al., 2002). It is during this late phase of LTP where DNA methylation in
thought to contribute to the regulation of the expression of key genes necessary for the
maintenance of long-term neuronal plasticity, and in this review, we will summarize the
substantial body of work supporting this notion. We will begin with an overview of the
important forms of DNA methylation in the mammalian brain.

Types of DNA methylation in neurons
5mCG: a repressive epigenetic mark
DNA methylation is an epigenetic mechanism that allows for sustained
adaptability of gene expression in response to developmental or environmental factors; it
plays an essential role in various biological functions such as regulation of gene
transcription and the establishment and maintenance of cellular identity (Golshani et al.,
2007; Hutnick et al., 2009; Jaenisch and Bird, 2003). DNA methylation at the 5-carbon
of cytosine (5mC) is widely distributed throughout the mammalian genome, with ~5% of
cytosines being methylated in the adult mouse brain. In most mammalian cell types,
methylation predominately occurs at cytosine-phosphate-guanine dinucleotides (CpG),
with methylation occurring at 60-90% of CpGs depending on tissue type, and in the
mammalian brain, ~62% of CpGs are methylated (methylated CpG will subsequently
referred to as 5mCG) (Lister et al., 2013; Schultz et al., 2015; Varley et al., 2013; Xie et
al., 2012). DNA methylation is deposited on cytosine by family of enzymes known as the
DNA methyltransferases (DNMTs). This enzyme family is divided into two broad classes:
the de novo DNMTs, DNMT3A and DNMT3B, that establish methylation on
3

unmethylated DNA and methylate the complementary strand of DNA strand on
hemimethylated DNA, and the maintenance DNMT, DNMT1, which can only methylate
hemimethylated DNA (Klose and Bird, 2006). Whereas Dnmt3a and Dnmt1 are
expressed in both the embryonic and adult stages, Dnmt3b is detectable only during
early neurogenesis (Brooks et al., 1996; Feng et al., 2005), suggesting that particular
DNMTs play a role in neuronal function at specific times over neuronal development and
maturation.
DNA methylation at CGs in all somatic types, including the neurons, represses
the expression of genes and repetitive DNA regions given whole genome bisulfite
sequencing (WGBS) findings that 5mCG is enriched at intergenic regions, silenced genes,
and repetitive DNA regions and is depleted at enhancers, promoters, and actively
expressed gene bodies (Lister et al., 2013; 2009; Xie et al., 2012; Ziller et al., 2013).
Additionally, 5’-upstream, intragenic, and 3’-downstream 5mCG inversely correlates
with gene expression in neurons (Mo et al., 2015). Furthermore, 5mCG patterns are
neuronal type-specific, suggesting that this epigenetic mark regulates gene expression in
a cell type-specific manner (Lister et al., 2013; Mo et al., 2015). This epigenetic mark is
also important in nuclear organization and compartmentalization given that DNA
methylation of satellite repeats is an important step in the formation of heterochromatic
regions (Cedar and Bergman, 2009; Lehnertz et al., 2003).

Additional neuronally enriched forms of DNA methylation
Historically, DNA methylation was thought to be a stable, repressive covalent
modification, existing predominately, if not exclusively, as 5mCG. However, this view
has dramatically changed over the past few years with the discovery that neurons, unlike
other adult somatic cells, accumulate two other forms of DNA methylation over
development, 5-hydroxymethylcystosine (5hmC) and non-CG methylation (5mCH,
where H = A, T, or C). 5hmC levels in neurons are up to 10 fold higher than other cell
types, reaching ~17% of all DNA methylation in the mouse frontal cortex (Globisch et al.,
2010; Kriaucionis and Heintz, 2009; Münzel et al., 2010; Song et al., 2011; Tahiliani et
al., 2009). Even though 5mCH is nearly absent in other cell types, except embryonic
stem cells (ESCs), 5mCH accounts for up to 53% of all of DNA methylation in adult
4

human neurons, making it the predominate form of DNA methylation, and ~25-40% of
all DNA methylation in the adult mouse neurons. Although the overall percentage of all
CH dinucleotides that are methylated is relatively low (1.4% of CH dinucleotides in adult
mouse neurons) compared to those methylated in CG dinucleotides (62% of CG
dinucleotides in adult mouse neurons), the relative depletion of CG dinucleotides in
eukaryotic genomes enables the high abundance of methylation in the CH context in
neurons (Guo et al., 2014; Kinde et al., 2015; Lister et al., 2013; Mo et al., 2015; Schultz
et al., 2015; Varley et al., 2013; Xie et al., 2012; Ziller et al., 2011). Therefore, these 5hmC
and 5mCH have added important new dimensions in understanding epigenetic
regulation of neuronal function.

5hmCG: a neuronally enriched form of DNA methylation associated with gene
activation
5mC is oxidized by the ten-eleven translocation (TET) family of enzymes to form
5hmC (Tahiliani et al., 2009). Three Tets are expressed in the brain (Tet1-3), with Tet2
and Tet3 mRNA levels being considerably higher than Tet1 in the postnatally (Klose and
Bird, 2006; Szwagierczak et al., 2010). Recently developed sequencing approaches have
enabled the genomic detection of 5hmC, providing invaluable insight into the biological
functions of this epigenetic mark. Approximately 0.9% of all cytosines are
hydroxymethylated in the mouse brain, predominately (>98%) occurring in the CG
context (Lister et al., 2013). 5hmC is enriched at transcriptionally active sites, such as
gene bodies, transcriptional end sites, DNaseI-hypersensitive sites (DHSs), and both
active and poised enhancers, and is depleted at promoters and major satellite regions
(Lister et al., 2013; Ong and Corces, 2014; Wen et al., 2014). Additionally, gene
expression levels strongly correlate with intragenic 5hmC levels (Lister et al., 2013;
Mellén et al., 2012a; Song et al., 2011). These features suggest that 5hmC is involved in
gene activation, which starkly contrasts with the biological function of 5mC. The
importance of 5hmC in neuronal maturation and function is highlighted by the fact that
5hmC levels increase nearly tenfold over development (Lister et al., 2013), and genes
enriched for 5hmC in the mammalian brain relative to other tissues are related to
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synaptic function (Khare et al., 2012a). The substantial body of literature regarding the
importance of the 5hmC and TETs in neuronal function will be reviewed below.

5mCH: a repressive DNA methylation mark in neurons
Whereas 5mCG is established by three DNMTs (DNMT1, DNMT3a, and
DNMT3b) and levels remain unchanged during development (Klose and Bird, 2006),
5mCH is catalyzed by DNMT3a (Ramsahoye et al., 2000) and levels increase during
synaptogenesis, which coincides with an increase in Dnmt3a mRNA levels during this
same time period (Guo et al., 2014; Lister et al., 2013). Further supporting the unique
role of Dnmt3a in 5mCH formation is a study in which exogenous Dnmt3a expression in
Drosophila lead to the formation of de novo 5mCH (Ramsahoye et al., 2000).
Additionally, conditional deletion of Dnmt3a from the brain during early development
results in a significant reduction in 5mCH, specifically in the 5mCA and 5mCT contexts,
but not in the 5mCG context (Gabel et al., 2015; Guo et al., 2014). Similarly to 5mCG, 5’upstream, intragenic, and 3’-downstream 5mCH levels inversely correlate with gene
expression, with gene body 5mCH outperforming 5mCG as an indicator transcriptional
levels in the brain (Guo et al., 2014; Mo et al., 2015). Additionally, 5mCH patterns are
cell type-specific, which is similar to 5mCG, but 5mCH is an even better indicator than
5mCG in this regard (Guo et al., 2014; Mo et al., 2015). 5mCH-mediated repression has
been confirmed with the use of a methylated quantitative reporter assay in hippocampal
neurons (Guo et al., 2014). Furthermore, 5mCH is abundant at regions with low CpG
density and at linker regions of nucleosomes, whereas it is absent from sites bound by
transcription factors and at nucleosomal cores (Burger et al., 2013; Guo et al., 2014; Mo
et al., 2015). Taken together, this suggests that brain-specific establishment or mediation
of this epigenetic mark may contribute to its unique regulatory effect in neurons (Kinde
et al., 2015), and we will discuss these possibilities below.

The necessity of DNA methylation in neurodevelopment
The importance of DNA methylation in neurons has been demonstrated in
studies in which the loss of key enzymes that regulate DNA methylation, DNMTs and
6

TETs, leads to deficits in neuronal function. Embryonic deletion of Dnmt1 from
forebrain neuronal progenitors in mice results in hypomethylation, deregulation of gene
expression, deficits in cerebral cortical formation and maturation, increased dendritic
branching, reductions in LTP, defects in learning and memory, and severe embryonic
and early postnatal degeneration (Golshani et al., 2007; Hutnick et al., 2009). Similarly,
embryonic deletion of Dnmt3a from the entire central nervous system (CNS) of mice
also results in neuronal dysfunction, such as hypoactivity, motor abnormalities,
decreased grip strength, a reduction in motor neuron number, and a shortened lifespan
(Nguyen et al., 2007). Human genetics also supports the importance of DNMTs in
neuronal function as DNMT1 has been linked to hereditary sensory and neuropathy with
dementia and hearing loss (Klein et al., 2011), DNMT3A with an overgrowth syndrome
with intellectual disability (Tatton-Brown et al., 2014), DNMT3B with recessive
mutations that cause immunodeficiency, centromere instability, and facial anomalies
(ICF) syndrome in which a large percentage of patients have intellectual disability
(Bestor et al., 1999; Bird, 2002; Okano et al., 1999).
Similarly to DNMTs, various studies have also demonstrated the importance of
TETs in brain development. Tet1 constitutive KO mice or mice lacking the catalytic
dioxygenase domain of Tet1 have memory deficits, a reduction in the expression of genes
associated with neurogenesis and neuronal activity (along with hypermethylation at the
promoters of this gene group), LTP deficits, increased LTD, and a reduction in the
proliferating potential of neural progenitor cells (NPCs) (Kaas et al., 2013; Zhang et al.,
2013). Proliferation potential is also influenced by the other two TET family members,
TET2 and TET3, as the knockdown of Tet2 and Tet3 via electroporation of shRNAs into
the cortex of mice leads to defects in the progression of differentiated neurons from the
subventricular zone (Hahn et al., 2013).
Given that these are embryonic perturbations of DNMTs and TETS, these
findings highlight the importance of these enzymes and DNA methylation dynamics
during neuronal development. Studies specifically focusing on these enzymes in
postmitotic neuron have also highlighted the importance of DNA methylation in
neuroplasticity, as discussed below.
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DNA methylation in neuronal maturation and neuroplasticity
Since DNMTs are usually expressed in frequently dividing cells for the
establishment and maintenance of DNA methylation patterns, it was originally
perplexing to find considerable levels of maintenance enzyme Dnmt1 and de novo
enzyme Dnmt3a in adult postmitotic neurons (Feng et al., 2005; Goto et al., 1994).
However, several lines of evidence now support that these enzymes are essential for
neuronal plasticity in postmitotic neurons.
Learning and memory is associated with alterations in the methylation status of
various plasticity-related genes. Fear conditioning causes the memory-suppressor gene
Pp1 to become rapidly methylated, resulting in the repression of this gene. This response
is dependent upon DNMT activity given that chemical inhibition of these enzymes
abolishes this effect (Miller and Sweatt, 2007). Another plasticity gene whose
methylation status is affected in response to contextual fear conditioning is Bdnf, which
undergoes promoter specific methylation that correspond with isoform-specific changes
in gene expression (Lubin et al., 2008; Martinowich, 2003). The regulation of isoformspecific expression of Bdnf is DNMT-dependent since chemical inhibition of DNMTs
results in alterations in promoter methylation and isoform expression (Lubin et al.,
2008). The importance of DNMTs in eliciting the changes in gene expression necessary
for long-term memory formation is corroborated by the observed increase in Dnmt3a
and Dnmt3b expression in the hippocampus in response to fear conditioning in both
mice and rats (Miller and Sweatt, 2007; Morris et al., 2014), and inhibiting DNMT
activity, via intra-hippocampal infusion of a DNMT inhibitor, abolishes memory
formation (Miller and Sweatt, 2007).
Double conditional knockout mice lacking Dnmt1 and Dnmt3a in postnatal
forebrain excitatory neurons (deletion occurring at 2-3 weeks using the Camk2a
promoter-drive Cre recombinase, Camk2a-Cre) results in a decrease in DNA
methylation, misexpression of genes, reduction in soma size, alterations in synaptic
function, and deficits in learning and memory (Feng et al., 2010). Although Dnmt1 single
conditional knockout in postnatal forebrain excitatory neurons (via the use of Camk2aCre) does not appear to affect learning and memory nor a variety of cellular and
molecular characteristics in the hippocampus or cortex, including methylation levels,
neuronal survival, gene expression, soma size, or synaptic function (LTP and LTD) (Fan
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et al., 2001; Feng et al., 2010; Morris et al., 2014); however, this loss of Dnmt1 does
result in an anxiolytic and antidepressant phenotype, suggesting that cell types, brain
regions, or neuronal circuits that underlie specify behaviors can be differentially
vulnerable to the loss of certain DNMTs (Morris et al., 2016). A consensus on the
consequence of Dnmt3a loss in postmitotic forebrain excitatory neurons remains to be
determined, as one group reports no changes in any parameters assessed (DNA
methylation, gene expression genes, soma size, synaptic function, and learning and
memory), and another group finding deficits in LTP in conjunction with associative and
episodic memory dysfunction (Feng et al., 2010; Morris et al., 2014).
Additionally, the importance of the TETs in postmitotic neurons has also been
ascertained. Tet1 is involved in neuronal activity-induced DNA demethylation and gene
expression changes since short-hairpin mediated knockdown of endogenous Tet1 in the
dentate gyrus (DG) completely abolished electroconvulsive stimulation (ECS)-induced
demethylation of Bdnf IX and Fgf1B promoters (Guo et al., 2011b). These findings are in
agreement with another study that has shown that Tet1 knockdown in hippocampal
neurons leads to the hypermethylation of promoter IV of Bdnf and subsequent
repression of transcript from this promoter (Yu et al., 2015). Transcript levels of Tet1,
but not Tet2 or Tet3, is significantly downregulated in the dorsal CA1 of mice after fear
learning (Kaas et al., 2013).
TET2 is also thought to play a role in the demethylation of developmentally
dependent genomic loci. With the use of Tet2 knockout mice, it was found that this TET
family member is responsible for the oxidation of large fraction (19.7%) of CG genomic
regions that gain hydroxymethylation status over development and aging (Lister et al.,
2013). Studies on TET3 function in the brain have confirmed that this most highly
expressed brain Tet family member is essential in mediating neuronal activitydependent gene expression programs. When mice undergo extinction training, there is a
significant increase in Tet3 mRNA in the cortex. Tet3 knockdown via lentiviral plasmids
in the infralimbic prefrontal cortex (ILPFC) have normal fear memory acquisition but
impaired fear memory extinction. Furthermore, inhibiting NMDAR activity blocked the
increase in Tet3 expression associated with fear memory extinction, suggesting that the
rise in Tet3 occurs via an NMDAR-mediated pathway. Fear acquisition and fear
extinction result in genome-wide differences of 5hmC at locations that contain CA or CT
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dinucleotide repeats instead of CGs (Li et al., 2014). Tet3 expression levels correlate with
neuronal activity as well; an increase in synaptic transmission correlates with an increase
in Tet3 mRNA and protein levels, but not Tet1 or Tet2. When Tet3 is knocked down from
hippocampal neurons in culture, mEPSC amplitudes are significantly larger than
controls, and the reciprocal effect occurs when Tet3 is overexpressed. Tet3 is also
essential for the maintenance of homeostatic synaptic plasticity. In Tet3 knockdown
neurons, promoter IV of Bdnf is hypermethylated, resulting in a decrease in expression
from this promoter (Yu et al., 2015). Taken together, these findings implicate that there
are essential locus-specific alterations in DNA methylation during neuronal plasticity
that are mediated by DNMTs and TETs.

Deciphering DNA methylation: An introduction to methyl-CpG-binding
proteins
Methylation is thought to influence transcription by altering DNA-protein
interactions, such as the binding of transcription factors (Becker et al., 1987) or the
recruitment of proteins that bind methylated DNA (Filion et al., 2005; Hendrich and
Bird, 1998; Prokhortchouk et al., 2001; Unoki et al., 2004) The families of proteins that
bind methylated DNA to mediate the molecular consequences of this epigenetic mark,
canonically known as “readers” of DNA methylation, are the SET- and Ring fingerassociated (SRA) domain family, the Kaiso family of proteins, and the methyl-CpGbinding domain (MBD) protein family (Hendrich and Bird, 1998; Nan et al., 1993).
MBDs, consisting of six MBD proteins (MBDs 1-6) and methyl-CpG-binding protein 2
(MeCP2), were originally demarcated as a family due to their shared, highly conserved
MDB domain (Hendrich and Bird, 1998; Roloff et al., 2003); however, it has since been
discovered that two of the family members, MBD5 and MBD6, do not bind to methylated
DNA (Laget et al., 2010) and that some of these family members also have the ability to
bind to other forms of DNA methylation in addition to 5mCG through their MBD: a point
mutation in the MBD of MBD3 renders it able to bind unmodified cytosine, 5mCG, and
5hmCG(Hashimoto et al., 2012; Spruijt et al., 2013) and MeCP2 has recently been
demonstrated to bind with high affinity to 5mCA and 5hmCH (Chen et al., 2015; Gabel et
al., 2015; Guo et al., 2014; Lagger et al., 2016). In this review, we will focus on the most10

well studied reader of DNA methylation, MeCP2, given its recognized importance in
neuronal function and unique ability to bind a neuronal-enriched form of DNA
methylation, 5mCH.
MeCP2’s role in neuronal function
MeCP2 is a nuclear protein found in various tissues in mammals (Meehan et al.,
1989; Shahbazian, 2002), with highest expression in the brain where it is half as
abundant as nucleosomes (Skene et al., 2010). Within the brain, MeCP2 protein levels
are seven times higher in neurons than glia, underscoring the importance of this protein
in neuronal function (Shahbazian, 2002). However, various studies have shown that
MeCP2 is also important for glial function, supporting glial dysfunction as a contributing
factor in RTT pathology (Ballas et al., 2009; Delépine et al., 2016; Lioy et al., 2011;
Maezawa et al., 2009; Nguyen et al., 2012). The levels of MeCP2 in the mammalian brain
increase over postnatal development, suggesting that MeCP2 is important for synapse
maturation (Balmer et al., 2002; Shahbazian, 2002). Clear evidence for the importance
of this gene in CNS came with the discovery that mutations in MECP2 cause Rett
Syndrome (RTT), a severe neurological disorder that affects 1 in 10,000 live female
births, making it one of the most common causes of intellectual disability in females
(Amir et al., 1999). Given that MECP2 is an X-linked gene, RTT is almost exclusive
found in females, as hemizygous loss of MECP2 function in males leads to severe
neonatal encephalopathy and death (Amir et al., 1999; Ellison et al., 1992; Schanen and
Francke, 1998; Schanen et al., 1997; Zoghbi et al., 1990).
RTT is characterized by normal development for the first 6 months of life
followed by regression and symptomatic presentation, which includes loss of acquired
purposeful hand skills and spoken language, gait abnormalities, and hand stereotypies
(Jeffrey L Neul et al., 2010; Percy et al., 2010). Postnatal deceleration of head growth is
another clinical feature of RTT (Jeffrey L Neul et al., 2010; Percy et al., 2010), and
radiological and pathological examination have determined that this is due to a
reduction in brain size (Armstrong et al., 1995). Given the absence of degenerative
features, this change is brain volume is attributed to a reduction the number and length
of dendrites, resulting in more densely pack neurons (Armstrong et al., 1995; Belichenko
et al., 1994). These changes are brain region- and cortical layer-specific, as different
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groups have only observed changes in a subset areas examined (Armstrong et al., 1995;
Wang et al., 2013). Additionally, the cortical layers (layer III and V) are indicative of
deficits initiating during the second period of cortical development when lower layers are
refining their connectivity with layer III postnatally. Furthermore, these dendritic
alterations do not worsen over adulthood, indicating that RTT is not a progressive
disease after development (Armstrong et al., 1995). Supporting a functional consequence
of these anatomical deficits are electrophysiological studies in neurons derived from RTT
induced pluripotent stem cells (iPSCs) that have found a decrease in the amplitude and
frequency of spontaneous excitatory transmission (Marchetto et al., 2010). Taken
together, these findings in RTT patients are clear indications of a disrupted neuronal
network and suggest that RTT is a neuronal maturation and/or maintenance disorder.
To understand the molecular underpinnings of RTT, mice lacking Mecp2 or
carrying RTT patient-associated mutations in Mecp2 have been developed, and the
majority of neurological features are observed in these whole-body Mecp2-mutant mice,
such as normal development during early life followed by symptomatic presentation of
altered gait, motor incoordination, hindlimb clasping, and cognitive deficits (Chen et al.,
2001; Goffin et al., 2012; Guy et al., 2001). Loss of Mecp2 from the CNS either
embryonically (embryonic day 12, E12) or postnatally (postnatal day 21, P21) resulted in
phenotypes that were indistinguishable from whole-body loss of Mecp2 (Chen et al.,
2001), emphasizing the importance of this MBD protein in mature neuronal function
and maintenance. In addition to behavioral phenotypes, Mecp2-mutant mice display
additional pathological and histological features found in RTT patients, namely, a
smaller brain size (Chen et al., 2001; Goffin et al., 2012; Guy et al., 2001) and a reduction
in the number and length of dendrites (Belichenko et al., 2009a; 2009b). Furthermore,
dendritic spines are reduced in number and altered in morphology, resembling
immature spines, in Mecp2-null mice (Belichenko et al., 2009a; 2009b; Wood and
Shepherd, 2010; Wood et al., 2009). The reduction in dendrite branches and dendritic
spines is suggestive of neuronal connectivity deficits in Mecp2-null mice. And in fact,
electrophysiological experiments corroborate these anatomical alterations. A reduction
in excitatory synapses, as well as the quantal excitatory transmission at those synapses,
contributes to a reduction in spontaneous firing rate of cortical neurons in Mecp2-null
mice (Chao et al., 2007; Dani and Nelson, 2009; Dani et al., 2005; Goffin et al., 2012). In
addition to synaptic dysfunction, there are also deficits in LTP and LTD, which is
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thought to occur subsequently to the synaptic dysfunction (Dani and Nelson, 2009). This
alteration in LTP and LTD harkens back to LTP and LTD deficits observed in DNMT and
TET loss of function mice. Given these neuronal deficits, the molecular perturbations
that occur with MeCP2 mutations or loss have been intensely studied in order to
understand the biological function of this protein.

Proposed molecular functions of MeCP2
Multiple functions have been proposed for MeCP2
This year marks the 25th year anniversary of the discovery of MeCP2 (Lewis et al.,
1992). Over this span of time, ~1000 papers have been published with MeCP2 in the
title. This large body of research has greatly advanced our understanding of MeCP2;
however, a consensus on the specific molecular function of MeCP2 has yet to be reached,
with evidence supporting MeCP2’s role as a transcriptional repressor, transcriptional
activator, chromatin organizer, regulator of alternative splicing, and miRNA processor
(Lyst and Bird, 2015). In this review, we will focus on the three prevailing models,
transcriptional repressor, transcriptional activator, and chromatin organizer.

MeCP2: a repressor?
A screen for proteins that bind methylated DNA led to the discovery of MeCP2,
given its high affinity for DNA methylation, as it is capable of binding DNA with a
symmetrically methylated 5mCG (Lewis et al., 1992) through its 85kda MBD (Nan et al.,
1993). In this initial work, it was also found that MeCP2 nuclear localization mirrored
that of 5mCG; it is concentrated at pericentromeric heterochromatin, which is known to
contain ~40% of all genomic 5mCG at major satellite DNA (Lewis et al., 1992). Another
functional domain of MeCP2 is the transcriptional repression domain (TRD), which has
been show to exhibit long range repression, up to 2kb away from a transcriptional start
site (Nan et al., 1997). A small portion of the TRD interacts with the histone deacetylase
(HDAC)-containing co-repressor complexes nuclear receptor co-repressor (NCOR) and
silencing mediator of retinoic acid and thyroid hormone receptor (SMRT), and bridge
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this site of interaction is termed the NCOR-SMRT interaction domain (NID) (Kokura et
al., 2001; Lyst et al., 2013; Stancheva et al., 2003). MeCP2 has also been shown to
interact with the HDAC-containing repressor complex Sin3a (Bird et al., 1998; Jones et
al., 1998). The importance of the MDB and NID is also supported from human genetics
since RTT-causing missense mutations, but not neutral polymorphisms mutations,
predominately cluster in these two protein domains (Lyst and Bird, 2015; Lyst et al.,
2013). Notably, each of the four missense mutations within the NID abrogate MeCP2’s
ability to bind to the NCoR/SMRT co-repressor complex (Lyst et al., 2013), highlighting
the importance of this interaction for MeCP2 function. Since deacetylation of histone
tails leads to transcriptional repression (Grunstein, 1997), these findings on the
functional domains of MeCP2 suggest a model in which MeCP2 acts as a molecular
bridge to connect DNA methylation with chromatin changes that elicit repression (Bird
et al., 1998).
Various studies support that MeCP2 binds globally across the genome at
methylated cytosine sites (Chen et al., 2015; Cohen et al., 2011; Gabel et al., 2015; Skene
et al., 2010). Chromatin immunoprecipitation (ChIP) has demonstrated that MeCP2
binding profiles scale with CG methylation density (Baubec et al., 2013; Chen et al.,
2015; Skene et al., 2010), with high levels of binding at CG methylation dense regions
and lower levels of binding at unmethylated CG islands (CGIs) (Skene et al., 2010). It has
recently been discovered that in addition to 5mCG, MeCP2 can also bind to 5mCH,
specifically 5mCA, with high affinity (Chen et al., 2015; Gabel et al., 2015; Guo et al.,
2014; Kinde et al., 2015; Lagger et al., 2016). When the genome-wide MeCP2 binding
profiles in mouse cortical tissue were compared to base-pair resolution profiles of 5mC
and 5hmC, it was found that MeCP2 binding globally correlates with 5mCG, 5mCA (or
5mCAC), and 5hmCAC density, but not 5hmCG. Additionally, misregulated genes in
Mecp2 KO mice are enriched for MeCP2 binding and 5mCA (Chen et al., 2015; Gabel et
al., 2015; Guo et al., 2014; Kinde et al., 2015; Lagger et al., 2016). However, it remains to
be determined which subsets of misregulated genes show this enrichment. One group
finds that genes enriched with MeCP2 binding tend to be long and also enriched with
5mCA, and that in the absence of Mecp2 in cortical tissue, upregulated genes tend to be
long, implicating MeCP2 as a transcriptional repressor (Gabel et al., 2015). An
independent group confirms this finding in the hypothalamus with the finding that
MeCP2 binding is enriched at genes that are upregulated in Mecp2 KO mice (Lagger et
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al., 2016). However, another group reported that both upregulated and downregulated
genes in Mecp2-null hypothalamus tissue are enriched for MeCP2 binding and 5mCH,
suggesting a more complex model in which MeCP2 is both an activator and repressor
(Chen et al., 2015). An important difference between the analyses carried out by the first
two groups versus the third group is that the former analyzed MeCP2 and 5mCH
enrichment within the gene bodies and surrounding regions of misregulated genes
(Gabel et al., 2015; Lagger et al., 2016) whereas the later normalized intragenic MeCP2
and 5mCH enrichment to the surrounding regions of misregulated genes (Chen et al.,
2015). Given that the raw data used by two opposing groups (Chen et al., 2015; Lagger et
al., 2016) were identical, it is important to keep in mind that data analysis methods can
critically influence the interpretation of MeCP2 function since gene expression changes
are subtle in RTT.

MeCP2: an activator?
In direct opposition of the repressor model, MeCP2 has also been proposed to be a
transcriptional activator. In mouse neurons differentiated from Mecp2-null ES cells,
there is a significant reduction of overall RNA synthesis, which was detected with the use
of a radioactive ribonucleotide incorporation assay (Yazdani et al., 2012). Similarly, in
human neurons derived from MECP2-null ES cells, per-cell total RNA levels are
significantly reduced, and this phenotype gets worse as time passes (Li et al., 2013).
These findings are supported by an independent group that found a significant reduction
of Serine5 phosphorylated RNA polymerase (a proxy for transcriptional activity) in
Mecp2-null mouse neurons in vivo using array tomography (Linhoff et al., 2015).
Additionally, gene expression studies from various brain regions of Mecp2-null mice
have found that more genes are repressed than activated, supporting MeCP2’s role as an
activator (Ben-Shachar et al., 2009; Chahrour et al., 2008; Zhao et al., 2013).
Furthermore, genome-wide promoter analysis revealed that the majority of MeCP2bound promoters are actively expressed genes that are not highly methylated, which
therefore indicates that MeCP2 binding isn’t solely correlated with repression (Yasui et
al., 2007). Molecularly, there is evidence supporting that MeCP2 mediates its activator
role through its interaction with cyclic AMP-responsive element-binding protein 1
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(CREB1) at genes that are activated, but not at those that are repressed (Chahrour et al.,
2008). However, corroboration of this finding by independent groups is lacking. Related
to this, MeCP2 has been found to bind to 5hmCH (more specifically, 5hmCA) in vitro
with the use of the electrophoretic mobility shift assay (EMSA) (Gabel et al., 2015).
However, whether 5hmCA is associated with gene activation, like 5hmCG, or whether the
binding of MeCP2 to 5hmCA is biologically significant given the low percentage of 5hmC
that is in the CH context, remains to be determined. Notably, multiple studies support
that MeCP2 does not bind to 5hmCG, either in vitro, with the use of EMSAs, fluorescent
polarization, or mass spectrometry (Gabel et al., 2015; Hashimoto et al., 2012;
Khrapunov et al., 2014; Spruijt et al., 2013; Valinluck et al., 2004), or in vivo via
correlating MeCP2 ChIP-seq profiles with base-pair resolution profiles of 5hmCG, which
in fact shows an anticorrelation between the two (Gabel et al., 2015). Taken together with
the previous section, these data indicate that more studies are necessary before
classifying MeCP2 as a bona fide transcriptional activator or repressor.

MeCP2: a transcriptional mediator of neuronal activity?
In line with MeCP2 acting as a regulator of transcription, are findings
demonstrating MeCP2’s ability to regulate gene expression in an activity-dependent
manner. In this model, at basal conditions, unmodified MeCP2 functions as a repressor
when bound to gene regions. However, upon stimulation, post-translational
modifications on MeCP2 lead to a reduction in MeCP2 binding and subsequent gene
activation. This function of MeCP2 is particularly intriguing given the necessity of genes
expression changes for the maintenance of long-term neuronal plasticity. One important
neuronal plasticity-related gene affected by the loss of MeCP2 function is Bdnf, with
transcript and protein levels being significantly reduced in the brains of Mecp2-knockout
mice (Chahrour et al., 2008; Chang et al., 2006; Chen et al., 2015). The levels of Bdnf
appear to be critically important for the RTT phenotype since increasing levels of Bdnf in
Mecp2-null mice ameliorates electrophysiological dysfunction, improves locomotor
deficits, and extends lifespan (Chang et al., 2006). In the wild type setting, 5mCH levels
and MeCP2 binding are enriched across the Bdnf locus, suggesting that MeCP2 binding
to developmentally regulated 5mCH sites is critical for the regulation of genes that are
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important in the manifestation of RTT phenotypes (Chen et al., 2015). Under basal
conditions in neuronal cultures, MeCP2 is bound to the methylated promoter III of Bdnf
where it is thought to act as a repressor of transcription through the recruitment of the
Sin3a repression complex which is found to be present via ChIP (Chen, 2003;
Martinowich, 2003; Zhou et al., 2006). However, in response to membrane
depolarization, MeCP2 and the Sin3a complex disassociates from the Bdnf promoter and
a reduction of methylation at the promoter in conjunction with an increase in
expression, dendritic complexity, and spine maturation (Chen, 2003; Martinowich,
2003; Zhou et al., 2006). The release of MeCP2 is mediated by calcium-dependent,
CaMKII-mediated phosphorylation of MeCP2 at serine 421 (pS421) given that loss of this
phosphorylation site on MeCP2 results in the loss of activity-dependent Bdnf expression
(Chen, 2003; Zhou et al., 2006). This phosphorylated form of MeCP2 is brain-specific, as
it is absent in a multitude of tissues, suggesting that this activity-dependent form of
MeCP2 might underlie why RTT is predominately a neurological disorder.
In the mouse brain in response to neuronal activity, 10-30% of total MeCP2
becomes phosphorylated at S421 (Cohen et al., 2011). However, the genomic binding
profile of MeCP2 remains virtually unchanged in response to neuronal activity in the
mouse brain, in opposite to what was observed at Bdnf. To investigate the importance of
MeCP2 phosphorylation at S421 in vivo, knock-in mice have been created in which S421
is converted to alanine (S421A), prevent the phosphorylation of this site. Cortical
pyramidal neurons in these mutants have increased dendritic complexity and an increase
in the amplitude of miniature inhibitory postsynaptic currents (mIPSCs), highlighting
the importance of this phosphorylation site on MeCP2 in neuronal development and
function. When MeCP2 binding is assessed in wild-type and MeCP2-S421A primary
cultures in response to neuronal activity, it was found that the binding patterns are
maintained in the mutant, implicating that this phosphorylation site is not necessary for
the release of MeCP2 from bound sites in response to neuronal activation (Cohen et al.,
2011). Similarly to what was observed in the mouse brain, when MeCP2 binding patterns
are compared in basal and stimulated primary neuronal cultures, no changes are
detectable, which does not support a model in which activity-dependent phosphorylation
of MeCP2 releases repressive binding. Additionally, the employment of a more sensitive
and targeted approach, ChIP-PCR of MeCP2 at activity-dependent genes in neuronal
cultures in response to stimulation, MeCP2 binding remained similar. This suggests that
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additional phosphorylation events might contribute to the release of MeCP2 from
chromatin or that specific stimulation paradigms are require to elicit a release.
Additionally, activity induced gene expression programs are not altered in the MeCP2S241A mutant mice, suggesting that singular phosphorylation site is not responsible for
the release of MeCP2 from genomic regions (Cohen et al., 2011). And in fact, three
additional phosphorylation sites on MeCP2 have been described: S86, S247, and T308.
Phosphorylation of these sites on MeCP2 are differentially induced in response to
various forms of stimulation, such as robust neuronal activity, exogenous BDNF, and
chemically induced elevations of cAMP, suggesting that these phosphorylation sites
induce different expression patterns in response to external stimuli. Supporting the
importance of one of these phosphorylation site is the finding that mice carrying a
T308A mutation in MeCP2 display RTT phenotypes, constitutive NCoR/SMRT binding
to MeCP2, and a reduction in the expression of activity-induced genes (Ebert et al.,
2013). In addition to the S421, S86, S247, and T308 phosphorylation sites on MeCP2,
additional phosphorylation sites and post-translational modifications on MeCP2 have
been identified, suggesting that this protein is regulated in various ways (Gonzales et al.,
2012; Tai et al., 2016). Taken together, these findings highlight the potential importance
of MeCP2 as a mediator of gene expression changes in response to neuronal activity;
however, much remains to be explored to determine the transcriptional effects of the
various post-translation modifications on MeCP2.

MeCP2: an architectural protein?
In addition to the MBD, MeCP2 has three additional domains that enable it to bind
to DNA. These are three basic clusters containing AT-hook-like domains, which bind to
AT-rich sequences of DNA (Baker et al., 2013; Lewis et al., 1992). The recombinant form
of one of these AT-Hook domains, AT-Hook 2 (amino acids 265-272), has been shown to
independently bind to DNA, and an RTT-associated mutation in this domain (R270X)
abolishes this ability. Additionally, the importance of this domain in forming higher
order structures is highlighted by the finding that recombinant MeCP2-WT is able to
compact nucleosomal arrays, but MeCP2-R106X is not (Baker et al., 2013). This also
relates to in vitro work that has demonstrated the necessity of A/T rich DNA (four or
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more A/T bases) adjacent to a methylated CpG site for efficient MeCP2 binding (Klose et
al., 2005). Another region of MeCP2 implicated in chromatin organization is the Cterminal portion of the MBD that has been found to bind to ATRX, a chromatin
remodeler that is mutated in α-thalassemia/mental retardation, X-linked syndrome
(ATRX syndrome) (Nan et al., 2007). MeCP2 is thought to be important for the
localization of ATRX to pericentric heterochromatin, as loss of MeCP2 function in
Mecp2-null mice or in mice carrying several RTT-associated point mutations in Mecp2
abolishes ATRX localization to pericentric heterochromatin specifically in the brain
(Baker et al., 2013; Nan et al., 2007).
Recombinant MeCP2 binds, compacts, and oligomerizes nucleosomal arrays in
vitro (Georgel et al., 2003; Ghosh et al., 2010; Nikitina et al., 2007b). Compaction by
MeCP2 comes in two forms, the clustering of nucleosomes and the formation of DNAMeCP2-DNA complexes (Nikitina et al., 2007b). One striking feature of nucleosomal
array compaction by MeCP2 is the formation of chromatin loops (free DNA emanating
from clusters of nucleosomes) (Ghosh et al., 2010; Horike et al., 2004), which are
implicated in the silencing of loci in vivo (Horike et al., 2004). Further supporting
MeCP2’s role in chromatin compaction is the finding that ectopic expression of the MBD
of MeCP2 in mouse myoblasts is sufficient to cause the clustering of pericentric
heterochromatin (Brero et al., 2005). In a comprehensive study evaluating the effect of
21 RTT-associated mutations to bind and cluster chromocenters in mouse myoblasts, it
was found that half of the mutations lead to deficits in chromatin binding and two-thirds
showed a decrease in the ability to cluster chromocenters (Agarwal et al., 2011). When
the nuclear localization of heterochromatin protein 1 (HP1), a protein essential for
heterochromatin packaging, and MeCP2 were compared over cellular differentiation
using an in vitro system culture system for myogenesis, it was found that both HP1
(specifically the γ isoform (HP1γ) and MeCP2 redistributed to heterochromatin foci
around the same time (Agarwal et al., 2007). Additionally, MeCP2 interacts through its
N-terminal domain (the first 55 amino acids) to the chromo shadow domain of HP1
(Agarwal et al., 2007). Taken together, these in vitro and cell culture studies suggest that
MeCP2 plays a role in the organization and compaction of nucleosomes, especially in
heterochromatin, and suggest that loss of function of MeCP2 would lead to
decondensation of heterochromatin.
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However, although few in number, studies examining the in vivo effects of
MeCP2 loss on heterochromatin compaction in mouse neurons have found an increase,
rather than decrease, in heterochromatinization. Using array tomography (AT) in mosaic
RTT mouse females, it was found that although the total amount of nuclear DAPI
remained similar between WT and MeCP2-null neurons, there was an increase of DAPI
density in heterochromatin, as well as an increase in heterochromatin size in CA1
pyramidal cells. Additionally, it was found that heterochromatin volume and nuclear
volume are negatively correlated, suggesting that chromatin condensation reduces
nuclear size. Interestingly, AT also allowed for quantitative analysis of the distribution of
MeCP2 within the nucleus, finding that only 30% of MeCP2 is localized to
heterochromatin, while the remain 70% localizes to euchromatin and nucleoplasm. AT
imaging allowed for the detection of H4K20me3 overlapping with heterochromatin foci
in MeCP2-null nuclei, which is not found in MeCP2-positive neurons, but rather
H4K20me3 staining was found in a region adjacent to dense, major satellite rich
heterochromatic foci in CA1 pyramidal neurons. The redistribution of H4K20me3 in
Mecp2-null neurons is dramatic, with 65% changing it localization to dense
heterochromatin, while there was a negligible increase (11%) in H4K20me3 nuclear
levels. Additionally, there is a significant distribution of H3K9me3 to dense, majorsatellite rich heterochromatin, as well as a slight increase (10%) in total H3K9me3
abundance (Linhoff et al., 2015). This change in nuclear organization is cell type-specific
given that granule cells of the dentate gyrus show a similar pattern that was observed in
CA1 pyramidal neurons, but this alteration is absent in granule cells of the cerebellum.
Another study found that although heterochromatin size and numbers are affected
embryonically and perinatally in Mecp2-null neurons, these affects are not found later
during development. The importance of chromocenter size is highlighted by a study that
found an increase in heterochromatin size after induced depolarization in primary
neuronal cultures; however, this effect is absent in Mecp2-deficient primary neurons
(Singleton et al., 2011). Given that the findings from the few studies on heterochromatic
changes in vivo are disparate, more research is warranted to determine the
organizational defects that occur when MeCP2
Further support for MeCP2’s role in chromatin organization comes from studies
that have compared the functions of MeCP2 to histone H1 (H1), an essential component
of chromatin that binds to linker DNA and organizes nucleosomes into higher order
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structures. H1 is present at the level of 1 molecule per nucleosome in most somatic cells,
except for neurons, where it is present at the level of 1 molecule for every two
nucleosomes (Allan, 1984; PEARSON et al., 1984; Skene et al., 2010). In vitro, MeCP2 is
able to displace H1 from preassembled chromatin (Ghosh et al., 2010; Ishibashi et al.,
2008; Nan et al., 1997), but not vice versa(Ghosh et al., 2010), suggesting that H1 and
MeCP2 compete for binding to linker DNA regions. Additional in vitro support for this
comes from studies with nucleosomal arrays in which human MeCP2 is found to bind to
11bp of the linker DNA entry-exit site, protecting this portion of linker DNA from
micrococcal nuclease (MNase) digestion, and an RTT-associated mutation in the MDB,
MeCP2-R106W, results in a loss of protection of the linker DNA from MNase digestion
(Nikitina et al., 2007a). Furthermore, linker DNA is essential for MeCP2’s ability to
properly bind to nucleosomes, and this binding induces a variety of conformational
changes to linker DNA (Nikitina et al., 2007a). Additionally, of all the canonically
histone components, MeCP2 is in closest proximity to H3, whose N-terminal region is in
close proximity to the linker region (Nikitina et al., 2007a). When mouse fibroblasts
stably expressing fluorescent MeCP2 are challenged with recombinant H1, and vice versa
(mouse fibroblasts stably expressing fluorescent H1 were challenged by recombinant
MeCP2), it was found that MeCP2 and H1 compete for binding sites, but that similar to
in vitro findings, MeCP2 is more effective at expelling H1 than the reverse (Ghosh et al.,
2010). In mouse fibroblasts, H1 and MeCP2 colocalize at pericentromeric
heterochromatin (Ghosh et al., 2010). MeCP2 induces nucleosomal array compaction in
a zigzag folding pattern that is very similar to the manner in which H1 induces
compaction, which is thought to be essential for 30nm fiber formation that is the basic
building block of heterochromatin (Ghosh et al., 2010). Furthermore, in Mecp2knockout neurons from the cortex, H1 protein levels double, reaching the abundance of 1
molecule per nucleosome in neurons (Skene et al., 2010). Histone H1 levels do not
change in unsorted nuclei from the cortex, which contains both glia and neurons,
suggesting that this change is specific to neurons (Skene et al., 2010). This suggests that
lower levels of H1 in the neurons are due to the presence of MeCP2, and that in the
absence of MeCP2, sites are now open for histone H1 occupancy (Skene et al., 2010). It is
possible that the substitution of MeCP2 by H1 leads to less dynamic transcriptional
changes in response to neuronal activity. However, this remains to be fully addressed.
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MeCP2: a multifunctional protein
Twenty-five years of research on MeCP2 has led to vast insight into the complex,
multifaceted function of this protein, generating numerous hypothesized molecular
models. And yet another model is emerging—a synergistic model that treats many of the
proposed functions as an integrative piece of MeCP2’s function instead of treating them
as mutually exclusive entities. It is possible that MeCP2 is predominately as an
architectural protein that is important for regulating chromatin structural changes that
aid in the activation or repression of genes necessary for long-lasting plasticity in
response to neuronal activity. Therefore, in this model, the transcription activator or
repressor effects that have been attributed to MeCP2 would be secondary to its
organizational role, similar to the function of CCCTC-binding factor (CTCF) (Ong and
Corces, 2014; Phillips and Corces, 2009). However, to prove such a model, additional
studies are necessary to determine nuclear organizational defects, and the consequential
effect on gene expression, elicited by loss of MeCP2 function. And therefore, the goal of
this work was to carryout such analysis for the better understanding of the downstream
molecular effects of MeCP2 loss of function to gain insight into RTT pathology.
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CHAPTER 2:
Biotin tagging of MeCP2 reveals contextual insights into the Rett syndrome
transcriptome

One Sentence Summary

This chapter summarizes our approach that enables cell type-specific biotinylation of
MeCP2 across various contexts, revealing MeCP2 as a unique global modulator of gene
transcription and pointing to new directions for translational research in Rett Syndrome.

Abstract
Mutations in MECP2 cause Rett syndrome (RTT), an X-linked neurological disorder
characterized by regressive loss of neurodevelopmental milestones and acquired
psychomotor deficits. However, the cellular heterogeneity of the brain impedes
understanding of how MECP2 mutations contribute to RTT. We therefore developed cell
type-specific biotin tagging of MeCP2 in mice bearing RTT-associated mutations and
profiled their nuclear transcriptomes. Although most gene expression changes are
largely specific to each mutation and cell type, lowly expressed cell type-enriched genes
are preferentially disrupted by MeCP2 mutations, with upregulated and downregulated
genes reflecting distinct functional categories. Subcellular RNA analysis in MeCP2
mutant neurons further reveals reductions in the nascent transcription of long genes and
uncovers widespread post-transcriptional compensation at the cellular level. Finally, we
overcame cellular mosaicism in female RTT models and identified distinct gene
expression changes between neighboring wild-type and mutant neurons, altogether
providing contextual insights into RTT etiology that support personalized therapeutic
interventions.
Introduction
RTT is a progressive X-linked neurological disorder that represents one of the most
common causes of intellectual disability among young girls. Patients experience a
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characteristic loss of acquired social and psychomotor skills and develop stereotyped
hand movements, hypotonia, breathing irregularities, and seizures after 6-18 months of
normal development1. Approximately 95% of RTT cases are mapped to the X-linked gene
encoding methyl-CpG binding protein 2 (MeCP2), a ubiquitously expressed protein that
is highly enriched in postmitotic neurons2,3. The majority of RTT-associated mutations
cluster within two functionally distinct domains of MeCP2. The Methyl-CpG Binding
Domain (MBD) allows MeCP2 to recognize and bind to methylated cytosines4. The
Transcriptional Repression Domain (TRD) mediates protein-protein interactions with
histone deacetylase-containing co-repressors, such as the NCoR-SMRT and mSin3A
complexes5–7. These domains support MeCP2 as a chromatin factor that mediates
transcriptional repression7,8, although transcriptional activation by MeCP2 has also been
reported9–11.
Different types of mutations in MECP2, together with random X-chromosome
inactivation (XCI), are thought to underlie a spectrum of mild to severe clinical
symptoms among RTT patients12. Mouse models carrying RTT-associated mutations
recapitulate this phenotypic variability, although most studies are limited to hemizygous
male mice13–16. Given that MeCP2 is a chromatin-bound nuclear protein, the
identification of MeCP2 transcriptional targets in the brain remains key towards
illuminating RTT etiology17. However, target identification is confounded by the cellular
heterogeneity of the brain, which contains multiple intermixed cell types that differ in
morphology, function, electrophysiological properties, and transcriptional programs18–22.
Analyses using heterogeneous brain tissues obscures cell type-specific gene expression
changes, impeding the assessment of MeCP2 function at the transcriptional level. The
identification of transcriptional targets is further complicated by the widespread binding
patterns of MeCP2 to methylated cytosines (mCpG and mCpA)8,23,24, hydroxymethylated
cytosines (hmCpG)25, or unmethylated GC-rich regions26 throughout the genome.
Furthermore, although RTT predominantly affects heterozygous females, an
experimental strategy to selectively identify gene expression changes from Mecp2
mutant-expressing cells in a mosaic female brain has not yet been developed.
In this study, we addressed the confounding effects of cellular heterogeneity by
engineering genetically modified mice whereby nuclear MeCP2 is labeled with biotin
using Cre-Lox recombination. To understand the molecular impact of RTT-associated
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mutations on cell type-specific gene expression in vivo, we also developed an allelic
series of knockin mice bearing one of two frequent RTT missense mutations, T158M and
R106W. When combined with Fluorescence-Activated Cell Sorting (FACS), this strategy
effectively circumvents cellular heterogeneity in the brain and allows for the isolation of
neuronal nuclei from targeted cell types. By examining MeCP2-mediated gene
expression changes in different cell types, we identified underlying transcriptional
features that correlate with the severity of the MeCP2 mutation. We also found that
genome-wide transcriptional changes in the nucleus are opposed by post-transcriptional
compensation of RNAs in a gene length-dependent manner. Furthermore, our approach
allows us to circumvent cellular mosaicism and profile the transcriptome of neighboring
wild-type (WT) and mutant neurons in females, thereby discerning cell and non-cell
autonomous transcriptional effects. This comprehensive study across different neuronal
settings allows us to propose a contextualized model by which cell and non-cell
autonomous transcriptional changes in different cell types contribute to the molecular
severity of neuronal deficits observed in RTT, uncovering new directions for therapeutic
development.

Results

Engineering a System to Genetically Biotinylate MeCP2 In Vivo

Biotin-mediated affinity tagging has been widely utilized in cell and animal models for
multiple experimental approaches because of the strong (Kd = 4x10-14M) and specific
interaction between biotin and avidin protein27. We exploited this approach to
investigate MeCP2 function by using homologous recombination to insert a short 23amino acid affinity tag immediately upstream of the Mecp2 stop codon (Fig. 1a and
Supplementary Fig. 1a). This tag comprises a TEV protease cleavage site and a 15-amino
acid biotinylation consensus motif (termed Tavi, TEV and Avidin-binding) that can be
post-translationally labeled with biotin by the E. coli biotin ligase, BirA. To biotinylate
the tag in cell types of interest, we also generated Cre-dependent BirA transgenic mice
(herein R26STOP-BirA; Supplementary Fig. 1b). Therefore, upon crossing mice to a cell
type-specific Cre line, BirA is expressed and subsequently biotinylates MeCP2-Tavi (Fig.
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1b). We used EIIa-Cre28 to ubiquitously express BirA (herein R26BirA) and confirmed that
MeCP2 is specifically biotinylated in vivo under conditions where BirA is expressed and
the Tavi tag is present (R26BirA/+;Mecp2Tavi/y; Fig. 1c and Supplementary Fig. 1c).
To exclude the possibility that tagging MeCP2 adversely affects its molecular
function, we assessed MeCP2 RNA and protein expression levels from age-matched
Mecp2Tavi/y (herein TAVI) and Mecp2+/y mice (herein WT; Supplementary Figs. 1d-f). We
also examined MeCP2 binding to methylated DNA and its known protein interactions.
We found that tagged and untagged MeCP2 both exhibit similar levels of binding at
methylated major satellite repeats and IAP elements (Supplementary Fig. 1g), and
MeCP2-Tavi remains associated with NCoR-SMRT (Supplementary Fig. 1h). We also
found that MeCP2-Tavi protein, but not RNA, is reduced by ~40% when compared to
untagged MeCP2 in mice at 20 weeks of age (Supplementary Fig. 1e-f). Given that we
observed similar levels of MeCP2 chromatin binding between WT and TAVI mice, the
diminution likely affects soluble, rather than chromatin-bound, MeCP2. Notably, a 50%
reduction in MeCP2 expression leads to hypoactivity and altered behavioral phenotypes
in mice by one year of age29. Despite reduced MeCP2 protein expression, we found that
TAVI mice are phenotypically indistinguishable from WT mice (Fig. 1g-j and
Supplementary Fig. 1i), and do not display RTT-like features over an observational
period of 20 weeks (Fig. 1i; data not shown). These data support that TAVI mice appear
functionally equivalent to WT mice, at least up to 20 weeks of age.

MeCP2 Missense Mutations Recapitulate RTT-like Phenotypes in Mice

Four of the eight most frequent RTT mutations are missense mutations, three of which
are located in the MBD of MeCP2 and include R106W (2.76% of RTT patients), R133C
(4.24%), and T158M (8.79%)30. Typical RTT patients bearing the R133C mutation
display milder clinical symptoms, whereas patients carrying the T158M or R106W
mutation exhibit moderate or severe symptoms, respectively12. Although the clinical
severity of these mutations scales with their effects on MeCP2 binding affinity to
methylated DNA13,31–33, this relationship is not fully understood on a molecular level.
We thus generated independent Mecp2T158M-Tavi (herein T158M) and Mecp2R106WTavi

(herein R106W) knock-in mice in parallel with TAVI mice (Fig. 1a). Relative to TAVI
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mice, we found that both Mecp2 mutant mice display significant reductions in MeCP2
protein expression despite comparable levels of mRNA (Fig. 1e-f and Supplementary Fig.
1j), similar to other RTT mutations in the MBD13,14. We further performed MeCP2
immunofluorescent staining (IF) using hippocampal sections of BirA-expressing mice to
examine the subcellular localization of MeCP2 mutant protein. In contrast to MeCP2 WT
and TAVI protein, MeCP2 T158M and R106W are diffuse throughout the nucleus and
not properly localized to heterochromatic foci, indicative of a reduced capacity to bind
mCpGs in vivo (Fig. 1d). Streptavidin IF is also noticeably reduced in Mecp2 mutant
mice, likely due to the reduced protein stability associated with these mutations (Fig. 1d
and Supplementary Fig. 1k). Although streptavidin IF confirmed a loss of MeCP2
localization to heterochromatic foci, this channel also revealed a portion of mutant
MeCP2 redistributed to the nucleolus (Supplementary Fig. 1k-l), similar to GFP-tagged
MeCP2 upon deletion of the MBD34. Upon site-by-site comparison, we found that T158M
and R106W mice also exhibit RTT-like phenotypes similar to that of Mecp2-null mice,
including decreased brain and body weight, and an age-dependent increase in
phenotypic score (Fig. 1g-i). Although lifespan is significantly reduced in all three Mecp2
mutant mice, the median survival of R106W mice more closely resembles that of Mecp2null than T158M mice (Fig. 1j). Statistical analysis revealed a significant difference in the
survival curves of T158M (median survival = 14 weeks) and R106W mice (median
survival = 10 weeks; Mantel Cox P = 0.012). Thus different mutations within the MBD
differentially affect the severity of RTT-like phenotypes in mice.
Given that MeCP2 T158M is known to retain partial affinity for mCpGs, and that
our T158M mice exhibit higher MeCP2 protein levels and longer survivability when
compared to R106W mice, we infer that this mutation represents a partial loss-offunction. In contrast, the R106W mutation, which abolishes affinity for mCpGs, exhibits
lower MeCP2 protein levels and lower survivability on par with Mecp2-null mice,
represents a complete loss-of-function.

Genetic Biotinylation Permits Cell Type-specific Transcriptional Profiling

Given MeCP2’s abundant expression throughout the CNS, we devised a biotinylationbased strategy for cell type-specific nuclei isolation and transcriptional profiling (Fig. 2a27

b). As an example, we used the NeuroD6/NEX-Cre line35 to drive BirA expression and
MeCP2-Tavi biotinylation in forebrain excitatory neurons (Fig. 2a and Supplementary
Fig. 2a-h). Quantification of pan-neuronal (NeuN), pan-inhibitory (GAD67), and
inhibitory-specific (parvalbumin, somatostatin and calretinin) neuronal markers in the
somatosensory cortex of Mecp2Tavi/y;R26cBirA/+;NEXCre/+ (NEX-Cre) mice demonstrated
that biotinylation occurs in ~80% of NeuN+ cortical neurons devoid of inhibitory
markers, consistent with NEX-Cre-mediated recombination in excitatory neurons
(Supplementary Fig. 2h). FACS using stained cortical nuclei from NEX-Cre mice
identified three distinct nuclear populations (Fig. 2c). RT-PCR for cell type-specific
markers confirmed that NeuN+Biotin+ nuclei reflect excitatory neurons, whereas
NeuN+Biotin- nuclei represent a mixture of inhibitory interneuron subtypes (Fig. 2c-d).
Excitatory and inhibitory populations are both depleted of astrocytic, microglial and
oligodendrocytic markers, which are restricted to the third, non-neuronal population of
NeuN-Biotin- nuclei (Fig. 2d). We also used the Dlx5/6-Cre line36 to drive BirA
expression in forebrain GABAergic neurons and obtained results inverse to that of NEXCre mice (Fig. 2a and Supplementary Fig. 2a-j), confirming that MeCP2-Tavi is reliably
biotinylated in Cre-defined cell types.
Having established a cell type-specific nuclei isolation approach, we next
performed transcriptional profiling in mice near the onset of RTT-like phenotypes. We
employed the NEX-Cre driver and isolated 120,000 or 250,000 cortical excitatory and
inhibitory nuclei from 6-week male T158M, R106W and TAVI mice via FACS, followed
by total RNA-seq. We found biological replicates to be well correlated (Fig. 2e and
Supplementary Fig. 3a), and ~74% of total reads mapped to introns. Intron-mapped
reads represent chromatin-associated primary transcripts that are commonly used as a
proxy for transcriptional activity37,38. Because MeCP2 is thought to function as a
transcriptional modulator17, nuclear RNA-seq thus affords an unique opportunity to
study the primary effects of RTT mutations on gene expression.
We first analyzed gene expression profiles from cortical excitatory and inhibitory
neurons in TAVI mice to confirm that a nuclear transcriptome analysis of genic-mapped
reads can be used to study cell types. Unsupervised hierarchical clustering shows that
replicate transcriptomes are highly correlated by cell type, and genic-mapped reads
illustrate genes that are selectively expressed for each cell type (Fig. 2g and
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Supplementary Fig. 3a). We identified 9,379 differentially expressed genes (DEGs, FDR
< 0.05) between excitatory and inhibitory neurons, the majority (86.9%) of which
comprise protein-coding genes (Fig. 2f and Supplementary Fig. 3b). Approximately half
of these cell type-enriched genes display Gene Ontology (GO) functions consistent with
glutamatergic pyramidal cell types (herein EXC-enriched; Supplementary Fig. 3c),
including cell signaling and post-synaptic functions, whereas the remaining half exhibit
GO functions consistent with metabolically active GABAergic interneurons (herein INHenriched; Supplementary Fig. 3d), including cellular respiration and mitochondrial
function. These functional associations demonstrate that total RNA-seq from cell typespecific nuclei discerns known functional differences between excitatory and inhibitory
neurons.

Protein-Coding Genes are More Severely Affected in R106W Mice

We next compared nuclear gene expression profiles in excitatory and inhibitory neurons
between 6-week old mutant (T158M, R106W) and control (TAVI) mice to identify and
characterize DEGs associated with the appearance of RTT-like phenotypes (Fig. 3a). We
identified more DEGs in R106W excitatory and inhibitory neurons than T158M neurons,
indicating that the number of misregulated genes positively scales with the severity of
the Mecp2 mutation (Fig. 3b). More than 90% of MeCP2 DEGs are protein-coding genes
(Supplementary Fig. 4a), significantly higher than the percentage of protein-coding
genes from genomic (60.4%), actively expressed (77.7-78.3%) and cell type-enriched
(86.2-87.7%) gene distributions (Supplementary Fig. 3b). We therefore excluded noncoding genes from further analyses. We note that the number and percentage of proteincoding DEGs overlapping between T158M and R106W genotypes is greater in inhibitory
(74.8% of T158M DEGs) than excitatory neurons (40% of T158M DEGs; Fig. 3c).
Moreover, overlapping DEGs tend to be misregulated in the same direction (Fig. 3c).
The median fold change of T158M and R106W DEGs is consistently small in
mutant neurons, particularly when compared to overall differences in gene expression
between excitatory and inhibitory neurons. Because the R106W mutation leads to a more
severe phenotype, we examined whether this mutation impacts gene expression to a
greater extent than the T158M mutation. We compared fold changes between T158M
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and R106W DEGs, limiting our analysis to protein-coding genes that overlap between
genotypes to account for disproportionate numbers of DEGs. Within this subset, the
median fold change among upregulated and downregulated DEGs is consistently higher
in both cell types of R106W mice than those of T158M mice (Fig. 3d). The differences
between mutations are more apparent in inhibitory neurons as the cumulative fold
change in R106W neurons is significantly shifted to the right of that in T158M neurons
(Fig. 3e). A similar trend is also observed in excitatory neurons (Fig. 3e).
These data suggest that the number of genes and the degree to which they are
misregulated positively correlate with RTT phenotypic severity, reflecting the molecular
consequence of differentially impaired MeCP2 binding to methylated DNA. Moreover,
inhibitory neurons appear to be more sensitive to the transcriptional effects of such
mutations than excitatory neurons.

Transcriptional Features of T158M and R106W DEGs

The genetic removal of MeCP2 from different brain regions or cell types in mice is
associated with distinct, non-overlapping phenotypes that reflect the specific neural
circuit being impaired16,17. In a similar fashion, we investigated whether MeCP2dependent transcriptional changes are specific to each cell type. Indeed, we found only
20 T158M DEGs (6.2% of total) and 114 R106W DEGs (10.7% of total) that overlap
between excitatory and inhibitory neurons (Fig. 3f), similar to a study using Mecp2-null
mice39. This degree of overlap is unexpectedly low, given that 74.2% of expressed genes
are shared between excitatory and inhibitory neurons (data not shown). The finding that
MeCP2-dependent gene expression changes are specific to each cell type prompted us to
examine the association between MeCP2 DEGs and EXC/INH-enriched genes. We found
that cell type-enriched genes are significantly overrepresented and comprise 70-80% of
DEGs in each cell type (Fig. 3g). Moreover, EXC- and INH-enriched genes are
preferentially downregulated and upregulated, respectively, in each cell type (Figure 3h).
Furthermore, upon examination of relative expression levels of MeCP2 DEGs
using Fragments Per Kilobase of transcript per Million mapped reads (FPKM), we found
that T158M, R106W, and overlapping DEGs all displayed significantly lower median
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FPKM values than overall expressed genes in each cell type (Fig. 3i). To confirm whether
low-expressing genes are specifically enriched for MeCP2 DEGs, we divided actively
expressed genes from each cell type into four equally sized bins according to the FPKM
expression level. Among these bins, EXC- and INH-enriched genes display expected
distributions for each cell type (Supplementary Fig. 4b). In contrast, T158M and R106W
DEGs are preferentially enriched in Q1, the bottom 25th percentile of actively expressed
genes, in both excitatory and inhibitory neurons (Fisher Exact one-tailed P, T158M EXC
= 1.11e-07, T158M INH = 2.03e-04, R106W EXC = 4.04e-08, R106W INH = 1.50e-02;
Supplementary Fig. 4b). Between both mutations, we found that T158M DEGs are more
likely to be enriched in Q1 (Fisher Exact Odds Ratio (OR) for Q1, T158M EXC = 3.1,
T158M INH = 3.2) than R106W DEGs (Fisher OR for Q1, R106W EXC = 2.0, R106W
INH = 1.3). Accordingly, R106W DEGs consistently display significantly higher FPKM
values than T158M DEGs in both cell types, and these higher FPKM genes are
predominantly downregulated in R106W neurons (Fig. 3i and Supplementary Fig. 4c).
Thus, in excitatory and inhibitory neurons of mice at 6 weeks of age, lowexpressing cell type-enriched genes are particularly sensitive to MeCP2 dysfunction
regardless of mutation and cell type. However, when compared to the T158M mutation,
the increased severity of the R106W mutation is consequently associated with an
increased number of high-expressing genes that are preferentially downregulated in both
cell types.

Upregulated and Downregulated Genes Demarcate Distinct Cellular Functions
We noticed that DEGs are preferentially downregulated in excitatory neurons and
upregulated in inhibitory neurons, and this trend is preserved among the DEGs shared
between both mutations (Fig. 3c). The increased severity of the R106W mutation also
correlates with increased numbers of high-expressing DEGs that are preferentially
downregulated, whereas upregulated DEGs similarly comprise low-expressing genes in
both mutants (Supplementary Fig. 4c). Given these characteristics, we next performed a
pre-ranked Gene Set Enrichment Analysis (GSEA, FDR < 0.1) to determine whether
upregulated and downregulated DEGs represent functionally distinct categories. We
found that upregulated genes in T158M and R106W mice are both primarily associated
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with transcriptional regulation (Fig. 3j). These include DNA-binding transcriptional
activators, co-activators, repressors, and chromatin remodelers, most of which tend to be
INH-enriched genes (Fig. 3j and Supplementary Fig. 4d). Significant functional
categories associated with downregulated genes, however, are specifically detected in
R106W excitatory neurons and enriched for post-synaptic membrane proteins, including
Na2+, K+, Ca2+ and Cl- channels, synaptic scaffolding proteins, and ionotropic glutamate
receptors (Fig. 3j). The specific loss of these synaptic functions appears to be consistent
with the preferential downregulation of high-expressing genes in R106W excitatory
neurons and the development of more severe phenotypes in R106W than T158M mice.
Although significant gene functions were not identified among downregulated DEGs in
inhibitory neurons using our established GSEA FDR cutoff, gene functions associated
with upregulated DEGs in R106W inhibitory neurons are related to cellular metabolism
and signal transducer activity (Supplementary Fig. 4e).

Subcellular RNA Fractions Reveal Global Transcriptional and Post-transcriptional
Changes

Several recent reports implicate MeCP2 in the transcriptional regulation of long genes,
which are preferentially upregulated in the neurons of multiple RTT animal models23,39.
We therefore examined the possibility that genome-wide transcriptional changes may
correlate with T158M and R106W phenotypic and molecular severity. Similar to these
studies, we sorted and binned expressed protein-coding genes according to gene length
and measured the mean fold change in Mecp2 mutant neurons at 6 weeks of age.
Nuclear transcriptomes revealed a striking inversion of previously reported gene
expression changes whereby short (≤ 100kb in gene length) and long (> 100kb in gene
length) genes are upregulated and downregulated, respectively, in a length-dependent
manner (Supplementary Fig. 5a).
Although most nuclear RNAs comprise intron-containing pre-mRNA transcripts
on chromatin, the presence of processed mRNA transcripts awaiting nuclear export may
confound the assessment of transcriptional events using nuclear RNA alone40. We
therefore performed global nuclear run-on with high-throughput sequencing (GROseq41) to directly assess de novo transcriptional activity by RNA polymerase in cortical
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nuclei of TAVI and R106W mice. Similar to sorted nuclear RNA, the nascent
transcription of short and long genes in R106W neurons is predominantly increased and
decreased, respectively (Fig. 4a). LOESS local regression of DEGs that were identified in
R106W excitatory and inhibitory neurons, which are individually upregulated or
downregulated, also revealed a similar overall trend towards the preferential
downregulation of long genes (Fig. 4a). The genome-wide trend we observe in sorted
nuclear RNA thus represents a primary effect at the transcriptional level, prompting us
to further investigate if the length-dependent upregulation of long genes that was
previously reported may represent an indirect effect of MeCP2-dependent
transcriptional deregulation. To test this, we resected cortical tissue from TAVI and
R106W mice at 6 weeks of age. Each cortical half was used to isolate whole cell RNA or
nuclear RNA in parallel, followed by sequencing. Whole cell RNA from mutant cortices
display a length-dependent increase in the mean expression of long genes (Fig. 4b),
similar to what was previously described23,39. In contrast, cortical nuclear RNA isolated
from the same TAVI and R106W mice exhibited a length-dependent upregulation of
short genes and downregulation of long genes genome-wide (Fig. 4c), corroborating the
transcriptional changes we observed from nascent RNA (Fig. 4a) and sorted nuclear
RNA preparations (Supplementary Fig. 5a). Using the 10,390 expressed genes associated
with de novo transcription by GRO-seq (Fig. 4d), we observed that genes upregulated in
nascent and nuclear RNA fractions were cumulatively shorter in length relative to those
upregulated in whole cell RNA, and the inverse was observed among downregulated
genes (Fig. 4e). Together, these data demonstrate that gene expression changes in
Mecp2-mutant neurons are substantially different between subcellular RNA fractions.
To directly compare individual genes across subcellular fractions, we next
classified all 10,390 expressed genes into eight groups depending on the direction in
which genes are misregulated across fractions. Groups B and D comprise 38.4% of
expressed genes and represent expression changes that are misregulated in the same
direction across nascent, nuclear, and whole cell RNA fractions (Fig. 4f). Among these
groups of genes, log2 fold changes measured from the whole cell are significantly smaller
than fold changes in the nuclear compartment, suggesting that gene expression changes
in the nucleus are post-transcriptionally minimized in the cell (Fig. 4f and
Supplementary Fig. 5b). The majority of genes (48%), however, exhibit expression
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changes in nuclei that are significantly inverted in whole cell RNA (Groups A,C,G,H; Fig.
4f). Groups A and C consist of relatively long, EXC-enriched genes that are
transcriptionally downregulated in nascent RNA but post-transcriptionally upregulated
using whole cell RNA (Fig. 4f and Supplementary Fig. 5c-d). DAVID gene ontology
revealed that Group A genes are associated with synaptic functions and protein
phosphorylation signaling at the plasma membrane (Fig. 4g). Groups G and H consist of
considerably shorter, INH-enriched genes that are transcriptionally upregulated in
nascent RNA but post-transcriptionally downregulated in whole cell RNA (Fig. 4f and
Supplementary Fig. 5c-d). Notably, Group G genes are functionally associated with
cellular energy and metabolism in mitochondria (Fig. 4g). Finally, we used the GRO-seq
dataset to also filter for genes in age-matched T158M and R106W sorted neurons that
are associated with de novo transcriptional activity in cortical nuclei (Supplementary Fig.
5e). This revealed a trend towards long genes being more severely downregulated in both
excitatory and inhibitory neurons bearing the R106W mutation when compared to the
T158M mutation (Fig. 4h and Supplementary Fig. 5f-g).
Taken together, these data support that global gene expression changes in
Mecp2-mutant mice differ between subcellular RNA fractions, and that many long genes
are transcriptionally downregulated in the nucleus of Mecp2 mutant neurons.
Furthermore, the molecular severity of missense mutations correlates with the extent to
which these long genes are downregulated in both excitatory and inhibitory neurons at 6
weeks of age.

Female RTT Mouse Models Reveal Cell and Non-Cell Autonomous DEGs

RTT is an X-linked disorder that primarily affects heterozygous females. However, the
extent to which intermixed Mecp2 WT and mutant (MUT) neurons in cellular mosaic
RTT females affect each other at the level of gene expression remains unknown. The
reduced stability and expression of T158M and R106W mutant protein allowed us to use
our genetic tagging and sorting strategy to isolate and profile WT (denoted by subscript:
T158MWT, R106WWT) and MUT (denoted by subscript: T158MMUT, R106WMUT) excitatory
neurons from mosaic female mice. By comparing the gene expression profiles of WT or
MUT neurons from heterozygous mutant mice to those from control mice (TAVIWT), we
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could discern both cell and non-cell autonomous gene expression changes as a result of
MeCP2 mutations. We thus generated TAVI (Mecp2Tavi/+;R26cBirA/+;NEXCre/+), T158M
(Mecp2Tavi/T158M-Tavi;R26cBirA/+;NEXCre/+), and R106W (Mecp2Tavi/R106WTavi;R26cBirA/+;NEXCre/+)

mosaic females that each carry one copy of the Tavi-tagged WT

allele and one copy of the tagged T158M, tagged R106W, or untagged WT allele.
We first aged females to ~18 weeks, when T158M and R106W females both
display RTT-like phenotypes relative to TAVI females (Fig. 5a). We next subjected female
cortical nuclei for FACS isolation (Fig. 5b-c and Supplementary Fig. 6a). From the
number of females sampled, we did not detect skewed XCI (> 75%) among excitatory
neurons in TAVI, T158M, or R106W mice (Fig. 5d). When compared to TAVIWT neurons,
we identified a total of 526 and 678 unique protein-coding DEGs in T158MWT and MUT and
R106WWT and MUT neurons, respectively (Fig. 5e and Supplementary Fig. 6b). Most DEGs
represent cell autonomous gene expression changes that occur in mutant neurons alone
(Fig. 5e). However, R106W DEGs contain a larger proportion of indirect DEGs that are
found in both WT and MUT neurons (43.4%; Fig. 5e), revealing a mutation-specific
susceptibility of WT neurons to non-cell autonomous gene expression changes in
heterozygous females. We further visualized differences in transcriptomes using
principal component analysis (PCA) to plot the first two major axes of variation (PC1 vs.
PC2; Fig. 5f). PC2 separates neuronal populations by Mecp2 allele status (WT vs. MUT
neurons) irrespective of genotype, indicating that Mecp2 mutations induce cell
autonomous changes that are transcriptionally distinct from neighboring wild-type
neurons. However, PC1 accounts for twice the variation as PC2 and clusters R106Wderived populations away from other genotypes, revealing the additive extent to which
indirect DEGs associate with this mutation. Against PC1 and PC2, T158MWT neurons
closely resemble TAVIWT, suggesting that the mere presence of mutant neurons is not
sufficient to generate the indirect gene expression changes apparent in R106W mice (Fig.
5f). Thus, indirect DEGs are likely a result of the increased molecular severity associated
with the R106W mutation.
We found that 194 DEGs overlap between T158M and R106W female mice, most
of which are misregulated in the same direction (Fig. 5g). Among these genes, cell
autonomous transcriptional changes (149 genes, 76.8%) are more likely to be shared
across independent Mecp2 mutations than non-cell autonomous changes (9 genes, 4.6%;
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Fig. 5h). These overlapping DEGs also show higher fold changes in R106W than T158M
female mice, similar to observations from male mice (Fig. 5i). However, this difference is
mainly driven by indirect DEGs in R106W neurons (Fig. 5h).
Using the R106W female mice to further characterize features that distinguish
Mecp2-dependent DEGs in WT and MUT neurons, we noticed that non-cell autonomous
DEGs are predominantly upregulated (~60%) in contrast to cell autonomous DEGs
(~48%; Supplementary Fig. 6b). The absolute fold change among cell autonomous gene
expression changes is also significantly smaller than non-cell autonomous changes,
particularly among upregulated genes (Supplementary Fig. 6c). Furthermore, cell
autonomous DEGs are considerably longer in gene length, specifically among
upregulated genes (Supplementary Fig. 6d). To determine if cell and non-cell
autonomous DEGs represent distinct biological processes, we next performed preranked GSEA (FDR < 0.1) and found that non-cell autonomous gene expression changes
primarily affect cell-to-cell signaling and negative regulation of protein-kinases
(Supplementary Fig. 6e). Indeed, these DEGs include several immediate early and late
response genes that are induced by neuronal activity and modulate signaling pathways
associated with synaptic plasticity42. In contrast, cell autonomous DEGs are significantly
associated with transcriptional regulation (Supplementary Fig. 6f). These functional
categories demonstrate a marked resemblance to those observed in excitatory neurons of
male T158M and R106W mice (Fig. 5j). The striking consistency with which these
functional annotations characterize Mecp2-mutant neurons, despite apparent
differences in age and sex, supports the cell autonomous disruption of these functions as
a key, contributing factor to RTT pathogenesis.

Discussion
The complexity of MeCP2 molecular function, coupled with the cellular heterogeneity of
the brain, complicates the identification and interpretation of transcriptional changes in
RTT. To overcome these challenges, we developed a genetic strategy to biotinylate
MeCP2 and its mutant variants in different cell types of adult mice. This strategy couples
in vivo biotinylation with Cre-Lox technology and extends the use of the Tavi tag for cell
type-specific biochemical purification and molecular profiling studies43. Notably, the
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small size of the Tavi tag makes it ideal for targeted gene insertion using CRISPR-Cas9
technology. Our genetic approach can thus be expanded to any protein-coding gene of
interest for cell type-specific in vivo applications beyond those conveyed in this study.
By using an allelic series of mutations in mice to perform a transcriptome
analysis of cortical neurons that vary by cell type, subcellular compartment, and sex, we
discovered underlying transcriptional features that correlate with impairments in
MeCP2 binding to chromatin and have therapeutic implications for RTT. Our
characterization of T158M and R106W mice demonstrates that both mutations are
associated with a similar age-dependent onset and progression of RTT-like phenotypes.
We also found that both mutations exhibit similar molecular features among upregulated
genes, including those in male and female Mecp2-mutant neurons that encode INHenriched transcription factors and chromatin remodelers. Because T158M and R106W
mutations both impair MeCP2 binding to chromatin and lead to RTT-like phenotypes,
the misexpression of transcriptional regulators may contribute to shared etiology in
T158M and R106W mice. In support, both GRO-seq and nuclear RNA-seq show a trend
towards the increased transcription of short, INH-enriched genes across the genome in
T158M and R106W mice. Many of these genes are functionally associated with cellular
respiration and energy metabolism, which could provide a transcriptional basis for
several clinical features shared among RTT patients that notably resemble mitochondrial
and metabolic disorders44.
We also show that lowly-expressed, cell type-enriched genes are sensitive to the
effects of MeCP2 dysfunction, which likely contributes to the specificity of MeCP2mediated gene expression changes in different neuronal cell types. However, regardless
of cell type, the R106W mutation affects a larger number of genes that tend to be both
highly expressed and preferentially downregulated relative to the T158M mutation,
consistent with the greater impairment of MeCP2 R106W binding to methylated DNA32.
GRO-seq and nuclear RNA-seq further demonstrates that transcriptional differences
between these two mutations extend to most long genes throughout the genome, which
tend to be highly expressed in neurons45. Our data is thus in partial agreement with
global reductions of Ser5-phosphorylated RNA polymerase in Mecp2-null neuronal
nuclei46 and supports MeCP2 as a global modulator of gene transcription. Given that
transcription is impeded by chromatin-mediated physical constraints47, loss of MeCP2
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occupancy may induce alterations to chromatin structure or organization that decreases
the efficiency of transcriptional elongation at long genes. Alternatively, the loss of
MeCP2 binding may reduce HDAC3-mediated transcription factor de-acetylation that
could be required for long gene transcriptional activation48. Of note, downregulated
genes are associated with synaptic morphology and function, which is stereotypically
reduced in Mecp2-deficient neurons16. Because R106W mice also display reduced
lifespan compared to T158M mice, it is possible that reductions in long gene
transcription may act as a modifier in specific neuronal cell types, worsening subsets of
RTT-like phenotypes. RTT patients with mutations that preserve MeCP2 binding do
exhibit milder clinical features than patients for whom binding is disrupted12. Additional
transcriptional assessments of milder mutations that preserve MeCP2 binding to
chromatin, coupled with our biotin tagging and nuclei sorting approach, are necessary to
further standardize and refine genotype-phenotype correlations at the transcriptional
level.
RTT transcriptional changes in neuronal nuclei complement the reported
upregulation of long genes across multiple RTT mouse models23,39. By analyzing
subcellular distributions of RNA, we found that the upregulation of most long genes in
Mecp2 mutant neurons is absent in nuclear and nascent RNA but present in whole cell
RNA. Notably, whole cell RNA is enriched for cytoplasmic mRNAs whose steady-state
abundance and turnover is modulated by post-transcriptional regulatory mechanisms,
including RNA nuclear retention, miRNA-mediated decay, or sequestration into
cytoplasmic RNA granules40,49. Gene expression changes using whole cell RNA may thus
be compensatory and not fully reflective of transcriptional activity. This aptly questions
the therapeutic benefit surrounding the use of small molecules that decrease long gene
transcription for treating RTT patients. Rather, fold changes across subcellular RNA
fractions appear consistent with post-transcriptional mechanisms that could abate
cellular consequences arising from global alterations in synaptic, mitochondrial, and
metabolic gene transcription. Identifying molecular players that underlie a cellular
compensation of RTT-associated transcriptional changes may yield a novel class of
interventional therapies that can be administered prior to or during the initial regression
phase of RTT, minimizing its pathological impact during neurodevelopment.
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Importantly, our approach allows for the novel isolation and molecular
examination of Mecp2 WT and MUT neurons from cellular mosaic female mice, which
represent more accurate pre-clinical models of RTT. We demonstrate that WT neurons
are also susceptible to the effects of Mecp2 mutations in neighboring cells, and that these
non-cell autonomous gene expression changes are dependent on the molecular severity
of the MeCP2 mutation. Additionally, non-cell autonomous gene expression changes also
occur in Mecp2 MUT neurons, indicating that DEGs in RTT neurons arise from MeCP2dependent and independent molecular processes. Further investigation, encompassing a
wide range of X-inactivation ratios across multiple ages, cell types, and Mecp2
mutations, are thus required to elucidate direct and indirect contributions to RTT.
The non-cell autonomous gene expression changes we found in R106W females
markedly include genes whose expression is stereotypically induced by neuronal activity.
These genes are known to negatively modulate synaptic plasticity by reducing
responsiveness to excessive neuronal stimuli42. The selective upregulation of these
indirect genes in WT and MUT neurons of R106W, but not T158M, mice may be a
response to increased neuronal activity among severely affected mosaic neurons. This
would be strikingly consistent with morphological reductions in dendritic branching and
synaptic spine density exhibited by both WT and MUT neurons of heterozygous Mecp2null female mice50. Accordingly, electrophysiological abnormalities observed in
phenotypically severe Mecp2-null mice might not fully reflect the milder spectrum of
RTT-associated mutations. Furthermore, two of these late-response genes, Bdnf and
Igf1, are indirectly upregulated in both WT and MUT neurons of 18-week old females
and encode neuroprotective peptides that improve RTT synaptic, cellular, and behavioral
deficits16,51. Because these molecules are in active clinical trials52, pathways associated
with non-cell autonomous DEGs may act to ameliorate RTT-associated neuronal
phenotypes and could represent a novel source of therapeutic targets for treating RTT
patients.
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Materials and Methods

Generation of Mouse Lines

The targeting construct used for homologous recombination at the Mecp2 locus in
murine ES cells was cloned in two arms by PCR amplification of sv129 genomic DNA.
The 5′ arm was PCR amplified with 5′-AGGAGGTAGGTGGCATCCTT-3′ and 5′CGTTTGATCACCATGACCTG-3′ primers, whereas the 3′ arm was PCR amplified with 5′GAAATGGCTTCCCAAAAAGG-3′ and 5′-AAAACGGCACCCAAAGTG-3′ primers.
Restriction sites at the ends of each arm were created using nested primers for cloning
into a vector containing a loxP-flanked neomycin cassette (Neo) and a diphtheria toxin A
negative-selection cassette. QuikChange (Stratagene) insertional mutagenesis was used
to generate the Mecp2-Tavi targeting construct by inserting the Tavi tag immediately
upstream of the Mecp2 stop codon within the 5’ arm.
The portion of the Tavi tag containing the biotinylation consensus sequenced flanked by
5’ NaeI and 3’ BspHI restriction sites was inserted through two rounds of mutagenesis:
Round 1 Forward: 5’GACCGAGAGAGTTAGCGCCGGCCTGAACGACATCTTCGAGTCATGACTTTACATAGAG
CG-3’
Round 1 Reverse: 5’CGCTCTATGTAAAGTCATGACTCGAAGATGTCGTTCAGGCCGGCGCTAACTCTCTCGGT
C-3’
Round 2 Forward: 5’CTGAACGACATCTTCGAGGCTCAGAAAATCGAATGGCACGAATCATGACTTTACATAGA
G-3’
Round 2 Reverse: 5’CTCTATGTAAAGTCATGATTCGTGCCATTCGATTTTCTGAGCCTCGAAGATGTCGTTCA
G-3’
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The portion of the tag containing the TEV protease cleavage site was inserted upstream
of the NaeI restriction site with a third round of mutagenesis:
Round 3 Forward: 5’GACCGAGAGAGTTAGCGAAAACCTGTATTTTCAGGGCGCCGGCCTGAACGACATC-3’
Round 3 Reverse: 5’GATGTCGTTCAGGCCGGCGCCCTGAAAATACAGGTTTTCGCTAACTCTCTCGGTC-3’
To generate Mecp2-Tavi targeting constructs bearing independent RTTassociated point mutations, QuikChange site-directed mutagenesis was used to mutate
MeCP2 arginine 106 to tryptophan and MeCP2 threonine 158 to methionine within the
3’arm and 5’arm, respectively. A single nucleotide at codon T160 also underwent sitedirected mutagenesis for a silent mutation to introduce a BstEII restriction site to
correctly identify targeted ES cells.
To generate conditional BirA transgenic mice, PCR primers containing AscI
restriction sites and a Kozak consensus sequence were used to subclone the BirA coding
sequence and insert it downstream of both a CAG promoter and a floxed transcriptional
attenuator, Neo-STOP, within pROSA26-1, a transgenic targeting vector that has
previously been characterized53.
After confirmation by Sanger sequencing and linearization with NotI (Mecp2Tavi targeting construct and its mutant variants) or SgfI (BirA targeting construct), the
constructs were electroporated into sv129-derived murine ES cells. Correctly targeted ES
cells were independently injected into C57BL/6 blastocysts and subsequently implanted
into pseudopregnant females. Agouti offspring were screened by southern blot and PCR
genotyping to confirm germline transmission of the Mecp2-Tavi, Mecp2T158M-Tavi,
Mecp2R106W-Tavi, and R26cBirA alleles. In the case of the Mecp2-Tavi allele and its mutant
variants, the resulting offspring were mated with C57BL/6 EIIa-cre mice to ensure
germline deletion of the floxed Neo cassette between Mecp2 exons 3 and 4.

Additional Mouse lines
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Dlx5/6-Cre (Stock 008199) and EIIa-Cre (Stock 003724) mice were obtained from
Jackson Laboratories28,36. NeuroD6/NEX-Cre mice were obtained with permission from
the Nave Laboratory35.

Animal Husbandry

Experiments were conducted in accordance with the ethical guidelines of the US
National Institutes of Health and with the approval of the Institutional Animal Care and
Use Committee of the University of Pennsylvania. All of the experiments described were
performed using mice on a congenic sv129:C57BL/6J background with the knockin/transgenic alleles backcrossed to C57BL/6J mice (Charles River) for at least five
generations, unless otherwise stated. Mice were housed in a standard 12h light/12h dark
cycle with access to ample amounts of food and water. Mice bearing the Tavi tag were
genotyped using a bipartite primer PCR-based strategy to detect the Tavi tag at the 3’end of the endogenous Mecp2 gene (Forward: 5’-CACCCCGAAGCCACGAAACTC-3’,
Reverse: 5’-TAAGACTCAGCCTATGGTCGCC-3’) and give rise to a 318-bp product from
the wild-type allele and a 388-bp product from the tagged allele. Mice bearing the BirA
transgene were genotyped using a tripartite primer PCR-based strategy to detect the
presence or absence of the CAG promoter at the Rosa26 locus (Forward:5’TGCTGCCTCCTGGCTTCTGAG-3’, Reverse #1: 5’-GGCGTACTTGGCATATGATACAC-3’,
Reverse #2: 5’-CACCTGTTCAATTCCCCTGCAG-3’) and give rise to a 173-bp product
from the wild-type allele and a 477-bp product from the transgene-bearing allele. Mice
bearing Cre-recombinase (either NeuroD6/NEX-Cre or Dlx5/6-Cre) were genotyped
using PCR-based strategies as previously described35,36.

Phenotypic Assessment

For tagged Mecp2 knock-in mice, phenotypic scoring was performed on a weekly basis
for the presence or absence of RTT-like symptoms as previously described54. Investigator
was blinded to genotypes during phenotypic assessment of mice. For BirA transgenic
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mice, no formal scoring was performed. However, R26BirA heterozygous and homozygous
mice are viable, fertile, and devoid of any gross abnormalities, consistent with previously
engineered transgenic mice that express BirA either ubiquitously or within restricted
tissues using cell type-specific promoters55,56.

Immunofluorescence and Microscopy

Mice were anesthetized with 1.25% Avertin (wt/vol), transcardially perfused with 4%
paraformaldehyde (wt/vol) in 0.1M sodium-potassium phosphate buffered saline and
postfixed overnight at 4°C. Brains were coronally or sagittally sectioned at 20µm using a
Leica CM3050 S cryostat. Immunofluorescence on free-floating sections was performed
as previously described, except sections were permeabilized with 0.5% Triton without
methanol for 20 minutes, and sections were blocked overnight with 10% Normal Goat
Serum and 1:100 unconjugated goat anti-mouse IgG (Sigma M5899). The following
primary antibodies were incubated at 4°C overnight: rabbit anti-MeCP2 C-terminus
(1:1000, in house), rabbit anti-nucleolin (1:1000, Abcam ab22758), mouse antiparvalbumin (1:500, Millipore MAB1572), rabbit anti-calretinin (1:1000, Swant
7699/3H), mouse anti-GAD67 (1:500, Millipore MAB5406), mouse anti-NeuN (1:500,
Millipore MAB377). For rat anti-somatostatin (1:250, Millipore MAB354MI), primary
incubation was performed for 48 hours at 4°C. Fluorescence detection of primary
antibodies was performed using Alexa 488-conjugated goat anti-rabbit (1:1000,
Invitrogen A11008), Alexa 488-conjugated goat anti-mouse (1:1000, Invitrogen A11029),
and Alexa 488 goat anti-rat (1:1000, Invitrogen A11006). Fluorescence detection of
biotin was performed simultaneously with secondary antibody incubations, using
Streptavidin Dylight 650 (1:1000, Fisher 84547) for fluorescence microscopy and
Streptavidin Dylight 550 (1:1000, Fisher 84542) for confocal microscopy. Sections were
counterstained with DAPI (1:1000, Affymetrix 14564) to visualize DNA before mounting
with Fluoromount G (SouthernBiotech). Images were acquired using a Leica DM5500B
fluorescent microscope with a Leica DFC360 FX digital camera (region-specific
biotinylation, quantification of neuronal cell type-specific markers) or a Leica TCS SP8
Multiphoton confocal microscope (representative images of neuronal cell type specific
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markers, subcellular localization of MeCP2). Images were acquired using identical
settings for laser power, detector gain amplifier offset and pinhole diameter in each
channel. Image processing was performed using ImageJ and Adobe Photoshop,
including identical adjustments of brightness, contrast, and levels in individual color
channels and merged images across genotypes.

Quantitative western analysis

Quantitative western blot was performed using Odyssey Infrared Imaging System
(Licor). Primary antibodies include rabbit anti-MeCP2 C-terminus (1:4000, in house),
mouse anti-MeCP2 N-terminus (1:4000, Sigma M7433), mouse anti-NeuN (1:500,
Millipore MAB377), and rabbit anti-Histone H3 (1:1000, Abcam ab1791). Secondary
antibodies include anti-rabbit IRDye 680LT (1:10,000, Licor), anti-mouse IRDye
800CW (Licor), Streptavidin Dylight 650 (1:10,000, Fisher 84547) and Streptavidin
Dylight 800 (1:10,000, Fisher 21851). Quantification of protein expression levels was
carried out following Odyssey Infrared Imaging System protocols.

Co-immunoprecipitation using nuclear extracts

Tissues were mined on ice and homogenized in ice cold lysis buffer (10 mM HEPES pH
7.9, 1.5mM MgCl2, 10mM KCl, 0.5% NP-40, 0.2mM EDTA, protease inhibitors). Nuclei
were pelleted, washed and resuspended in nuclear extract (NE) buffer (20mM HEPES
pH 7.9, 1.5mM MgCl2, 500mM KCl, 0.2mM EDTA, 10% glycerol, protease inhibitors).
Nuclei were incubated in NE buffer at 4°C for two hours with rotation. Samples were
cleared by ultracentrifugation with a TLA 100.3 rotor (Beckman Optima TL) at 4°C for
30 minutes and the supernatant taken for nuclear extract. Protein concentration was
quantified using a modified Bradford assay (Bio-Rad). 1mg of nuclear extract was
adjusted to 300µl total volume with NE buffer to perform IP in duplicate. Protein G
Dynabeads or Streptavidin M-280 Dynabeads (Life Technologies) were washed three
times in PBS with 0.1% Tween-20 and 0.1% BSA. Nuclear extracts were cleared for 30
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minutes at 4°C with 25µl Protein G Dynabeads. For streptavidin pulldown, 50µl of
Streptavidin M-280 Dynabeads were added to the nuclear extract and incubated at 4°C
for two hours with rotation. To test if the Tavi tag was required for streptavidin
pulldown, nuclear extracts were split and incubated with or without 200U TEV protease
(Invitrogen) in the absence of a reducing agent and without agitation at 4°C for ≥ 4 hours
prior to IP. For antibody immunoprecipitation, 5µg of (rabbit anti-MeCP2, in house) was
added to the nuclear extract and incubated overnight at 4°C with rotation. Protein G
beads were blocked in wash buffer overnight at 4°C with rotation. Blocked beads were
then incubated with antibody-bound nuclear extract for two hours at 4°C with rotation.
Beads were washed four times in PBS with 0.1% Tween-20 and split into two equal
volumes. Each sample was resuspended in 25µl loading buffer with 50mM DTT and
boiled for 10 minutes at 95°C prior to loading on a 4-12% Bis-Tris NuPage gel (Life
Technologies).

Chromatin immunoprecipitation

Forebrain tissues from male mice at 8 weeks were homogenized in cross-linking buffer
(1% formaldehyde (wt/vol), 10mM HEPES (pH 7.5), 100mM NaCl, 1mM EDTA, 1mM
EGTA) and cross-linked for 5 minutes at RT. After quenching with 125mM glycine, crosslinked tissue was washed with ice-cold PBS and dounced with 16 strokes in lysis buffer
(50mM HEPES (pH 7.5), 140mM NaCl, 1mM EDTA, 1mM EGTA, 10% glycerol (vol/vol),
0.5% NP-40 (vol/vol), and 0.25% Triton X-100 (vol/vol) with protease inhibitors).
Nuclei were pelleted, washed and resuspended in chromatin buffer (10mM Tris-HCl (pH
8.0), 1mM EDTA, and 0.5mM EGTA with protease inhibitors). Chromatin was sonicated
using a Diagenode Bioruptor, and salt and detergent were added to adjust the chromatin
buffer to 0.5% Triton X-100, 150mM NaCl, 10mM EDTA, and 0.1% sodium deoxycholate
(DOC, vol/vol), and precleared at 4°C with Protein A Dynabeads (Invitrogen). For
immunoprecipitation, 3µg of purified rabbit anti-MeCP2 IgG (in house) or non-specific
rabbit IgG control (Millipore NI01) was incubated with 45µg of chromatin for 4 hours,
followed by an overnight incubation with pre-blocked Protein A Dynabeads, at 4°C with
rotation. Bead-bound chromatin was washed with low salt buffer (50mM HEPES pH 7.5,
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150mM NaCl, 1mM EDTA, 1% Triton X-100, 0.1% DOC), high salt buffer (50mM HEPES
pH 7.5, 500mM NaCl, 1mM EDTA, 1% Triton X-100, 0.1% DOC), LiCl buffer (50mM
Tris-HCl pH 8.0, 150mM NaCl, 1mM EDTA, 0.5% NP-40, 0.5% DOC) and TE buffer
(10mM Tris-HCl pH 8.0, 1mM EDTA). Chromatin was eluted with elution buffer (50mM
Tris-HCl pH 8.0, 10mM EDTA, and 1% SDS (wt/vol)), digested with proteinase K (0.5mg
ml-1), and reversed crosslinked at 65°C overnight. After RNase A treatment, DNA
fragments were extracted with phenol/chloroform and ethanol-precipitated.
Quantitative real-time PCR (qPCR) analysis was carried out using SYBR green
detection (Life Technologies) on an ABI Prism 7900HT Real-Time PCR System (Applied
Biosystems). The percent input for each amplicon was determined by comparing the
average threshold cycle of the immunoprecipitated DNA to a standard curve generated
using serial dilutions of the input DNA and interpolating the “fraction of input” value for
this sample.

FACS Isolation of Neuronal Nuclei for RT-PCR and RNA-seq

Nuclei were isolated from fresh cortical tissue for FACS as previously described under
ice-cold and nuclease-free conditions57. Mouse cortices were rapidly resected on ice and
subjected to dounce homogenization in homogenization buffer (0.32M sucrose, 5mM
CaCl2, 3mM MgAc2, 10mM Tris-HCl pH 8.0, 0.1% Triton, 0.1mM EDTA, Roche
Complete Protease Inhibitor without EDTA). Homogenates were layered onto a sucrose
cushion (1.8M sucrose, 10mM Tris-HCl pH 8.0, 3mM MgAc2 Roche Complete Protease
Inhibitor without EDTA) and centrifuged in a Beckman Coulter L7 Ultracentrifuge at
25,000 rpm at 4°C for 2.5 hours using a Beckman Coulter SW28 swinging bucket rotor.
Nuclei were resuspended & washed once in blocking buffer (1x PBS, 0.5% BSA (Sigma
A4503), RNasin Plus RNase Inhibitor (Promega)) and pelleted using a tabletop
centrifuge at 5000 RCF at 4°C for 10 minutes. Nuclei were resuspended in blocking
buffer to a concentration of ~6x106 nuclei/ml, blocked for 20 minutes at 4°C with
rotation, then incubated with Streptavidin Dylight 650 (1:1000, Fisher 84547) and Alexa
488-conjugated anti-NeuN antibody (1:1000, Millipore MAB377X) for 30 minutes at 4°C
with rotation. After a 5-minute incubation with 1:1000 DAPI to enable singlet detection
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during FACS, labeled nuclei were washed for an additional 30 minutes at 4°C with
blocking buffer, pelleted and resuspended in blocking buffer with 1% BSA. A BD
Biosciences Influx cell sorter at the University of Pennsylvania Flow Cytometry and Cell
Sorting Facility was used to identify cell type-specific populations of nuclei, and 1.2 – 2.5
x105 singlet nuclei from specified populations were directly sorted into Qiagen Buffer
RLT Plus for immediate lysis and stabilization of RNA transcripts. Total nuclear RNA
was processed using the Qiagen AllPrep DNA/RNA mini kit according to manufacturer
instructions, with exception to the on-column DNaseI treatment. RNA was eluted from
RNeasy mini spin columns and treated with DNaseI (Qiagen 79254) for 25 minutes at
room temperature, then precipitated with glycogen/NaOAc and stored in ethanol at 80°C. Ethanol precipitation of nuclear RNA was carried out to completion prior to
initiating RT-PCR or RNA-seq library construction.
For RT-PCR, total RNA was prepared from FACS-isolated cortical nuclei of TAVI
male mice at 6 weeks (2-3 mice pooled per biological replicate, 3 replicates each). To
validate cell type-specific cortical nuclei populations, total RNA from 120,000 sorted
nuclei was converted to cDNA with random hexamers using the SuperScript III FirstStrand Synthesis System (Invitrogen). RT-PCR was performed on a ABI Prism 7900HT
Real-Time PCR System (Applied Biosystems) using exon-spanning Taqman gene
expression assays to detect mRNA transcripts for the following genes: CRE
(Mr00635245_cn), Mecp2 (Mm01193537_g1), Rbfox3 (Mm01248771_m1), Gfap
(Mm01253033_m1), Aif1 (Mm00479862_g1), Mog (Mm00447824_m1), Slc17a7
(Mm00812886_m1), Tbr1 (Mm00493433_m1), Gad1 (Mm04207432_g1), Slc35a1
(Mm00494138_m1), Ht3ar (Mm00442874_m1), Pvalb (Mm00443100_m1), Sst
(Mm00436671_m1), Pgk1 (Mm00435617_m1), Actb (Mm00607939_s1), ß2m
(Mm00437762_m1). A geometric mean was calculated to normalize mRNA expression
levels to multiple housekeeping genes (Actb, ß2m, and Pgk1), and cell type-enrichment
for each sorted population was determined relative to the total mixed population of
DAPI+ nuclei.
For RNA-seq, total RNA was prepared from FACS-isolated cortical nuclei of male
mice at 6 weeks (TAVI, T158M, R106W, 2-3 mice pooled per biological replicate, 4
replicates each) and female mice at 18 weeks (TAVI, T158M, R106W, single mouse per
biological replicate, 2 replicates each). No method of randomization was used to
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determine how animals were allocated to experimental groups, which was determined by
genotype. The numbers of biological replicates used for differential gene expression
analysis are in compliance with ENCODE consortium long RNA-seq recommendations
(≥2 replicates). Furthermore, the total amount of RNA isolated from 120,000-250,000
sorted nuclei was used as input for library construction; hence differential gene
expression comparisons between FACS-isolated Mecp2 control and mutant neurons are
performed using RNA from equivalent numbers of neuronal nuclei. Total RNA was
depleted of ribosomal RNAs, subjected to 5 minutes of heat fragmentation, and
converted to strand-specific cDNA libraries using the TruSeq Total RNA library prep kit
with RiboZero depletion (Illumina). Multiplexed libraries were submitted for 100 pairedend sequencing on the Illumina HiSeq 2000/2500 platform at the University of
Pennsylvania Next Generation Sequencing Core facility, yielding approximately 30-40M
total reads per library. 90-95% of total reads were uniquely mapped to the mouse
Ensembl GRCm38/mm10 mouse genomic assembly.

GRO-seq

Nuclei were isolated from fresh cortical tissue under ice-cold and nuclease-free
conditions as described in the preceding section. After ultracentrifugation, nuclei were
resuspended & washed once in PBS (1x PBS, RNasin Plus RNase Inhibitor (Promega))
and pelleted using a tabletop centrifuge at 5000 RCF at 4°C for 10 minutes. Nuclei were
resuspended in PBS, pipetted through a 0.22µm filter and counted using a
hemocytometer. Nuclei were then pelleted, resuspended to a concentration of 5×106 10×106 nuclei/100µl in glycerol storage buffer (50mM Tris pH 8.3, 40% glycerol, 5mM
MgCl2, 0.1 mM), and flash frozen in liquid N2 for storage until needed.
For each nuclear run-on (NRO), 100µl of nuclei was mixed with 46.5µl NRO
Reaction Buffer (10mM Tris pH 8.0, 5mM MgCl2, 1 mM DTT, 300mM KCl), 3.5µl
Nucleoside Mix (50µM ATP, 50µM GTP, 2µM CTP, 50µM Br-UTP, 0.4U/µl RNasin), and
50µl 2% Sarkosyl
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Nuclear Run On Stop Solution (20mM Tris pH 7.4, 10mM EDTA, 2% SDS). The NRO
reaction was performed at 30°C for 5 minutes, then terminated by a 20 minute
incubation with DNAse I at 37°C, followed by a hour-long incubation with 225µl NRO
Stop Buffer (20mM Tris, pH 7.4, 10mM EDTA, 2% SDS) and Proteinase K at 55°C.
Phenol-extracted RNA was fragmented with 0.2N NaOH, and BrdU-RNA was isolated
three consecutive times with BrdU-antibody beads, with enzymatic TAP and PNK
treatments to remove the cap and 3’-phosphate and to add a 5’-phosphate, as well as
Illumina TruSeq small RNA sample prep kit adapter ligations between BrU-RNA
isolation steps as described41,58.

RNA-seq Mapping, Read Counting, and Differential Expression Analysis

The mouse mm10 genomic sequence
(Mus_musculus.GRCm38.75.dna.primary_assembly.fa.gz) and gene information
(Mus_musculus.GRCm38.75.gtf.gz) were downloaded from Ensembl release 75. The
genome files used for mapping were built by STAR using the parameters "STAR -runMode genomeGenerate --runThreadN 12
--genomeDir ./ --genomeFastaFiles
Mus_musculus.GRCm38.75.dna.primary_assembly.fa.gz --sjdbGTFfile
Mus_musculus.GRCm38.75.gtf --sjdbOverhang 100". The FASTQ files were mapped to
the mouse Ensembl GRCm38/mm10 genome assembly by STAR (version 2.3.0) 59 using
the parameters "--genomeDir ENSEMBL_75_mm10 --runThreadN 10 -outFilterMultimapNmax 1 --outFilterMismatchNmax 3". Perl scripts generated in-house
were used to count the number of read pairs that mapped to across the entire gene body
(exon + intron) for each gene. If one end of a read pair overlapped with the annotated
genomic region of a given gene and the other did not, the read pair was included in the
final count for that gene. Therefore, the total number of read pairs that overlapped
within a given gene represented the final read count for that gene. All intron and exonmapped reads were used for differentially expressed gene comparisons, which were all
performed using the edgeR (v3.10.0) and DEseq2 (v1.8.0) R packages60,61. Genes with a
total edgeR CPM ≥2 were included in the edgeR comparison. A false discovery rate <
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0.05 was set to identify differentially expressed genes. No fold change cutoff was applied.
For each comparison, the results of edgeR and DESeq2 analyses were merged to avoid
method-based biases. The mean fold change and the mean FDR generated from both
methods were used for generating plots and heatmaps.

Functional Enrichment of Differentially Expressed Genes

For DAVID gene ontology, a list of differentially expressed protein-coding genes was
compared to a background list of actively expressed protein-coding genes from their
respective cell type. Statistically significant terms (Benjamini P < 0.01, FDR < 0.05) were
plotted for Figures S3C-D. For Gene Set Enrichment Analysis (GSEA), we performed a
seeded, pre-ranked GSEA from lists of differentially expressed protein-coding genes
(ranked by fold change) using the September 2015 Mouse GO Gene Set Release
(http://download.baderlab.org/EM_Genesets/September_24_2015/Mouse/). GSEA
network associations (P-value < 0.1, Q-value < 0.1) were visualized using the
Enrichment Map application (v2.0.1) in Cytoscape (v3.2.1)62,63, and clustered using gene
set overlap coefficients.

Determination of Actively Expressed Genes

Actively expressed genes for excitatory and inhibitory neurons were determined by
calculating the normalized FPKM (zFPKM) and using ZFPKM ≥ 3 for the active gene
cutoff as previously described64.

Statistical Analyses

Statistical analyses were performed using Graphpad Prism version 6.0 for Mac
(GraphPad Software, La Jolla California USA, www.graphpad.com) and R65. No
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statistical method was used to estimate sample size, as pre-specified effect sizes were not
assumed. No animals or samples were excluded from analyses. Individual statistical tests
are fully stated in the main text or figure legends. Comparisons of normally distributed
data consisting of two groups with equal variances (F-test equality of variance P > 0.05)
were analyzed using Student’s T-test, and unequal variances (F-test equality of variance
P < 0.05) using Students T-test with Welch’s correction for unequal variance.
Comparisons of normally distributed data consisting of three or more groups were
analyzed using One-way ANOVA with the appropriate post-hoc test. Comparison of two
or more factors across multiple groups was analyzed using a Two-way ANOVA with
Sidak’s correction for multiple comparisons. Comparisons of non-normally distributed
data were analyzed using the Mann-Whitney/Wilcoxon test (two groups) or the KruskalWallis test (three or more groups) with the appropriate post-hoc test. For multiple
comparisons, all p-values are adjusted using the Holm-Bonferroni correction unless
otherwise indicated.

Main Figure Statistical Analyses

Figure 1 Utilization and characterization of Mecp2Tavi mice and associated RTT variants
(f) nreplicates = 4, One-way ANOVA [F = 25.55, P = 0.0012]; Tukey’s multiple comparisons
correction applied. (g) nWT = 20, nTAVI = 11, nKO = 6, nT158M = 6, nR106W = 12; One-way
ANOVA [F = 20.05, P < 0.0001]; Tukey’s multiple comparison correction applied. (h)
nWT = 31, nTAVI = 23, nKO = 17, nT158M = 39, nR106W = 26, Mantel-Cox [χ2 = 109.3, df = 4, P <
0.0001].

Figure 2 Cell type-specific transcriptional profiling of neuronal nuclei
(d) nreplicates = 3, Two-way ANOVA, Control [Cell Type-Gene Interaction, F = 42.68, P <
0.0001; Cell Type, F = 222.0, P < 0.0001; Gene, F =80.03, P < 0.0001], Non-Neuronal
[Cell Type-Gene Interaction, F = 12.47, P < 0.0001; Cell Type, F = 109.8, P < 0.0001;
Gene, F = 7.655, P = 0.0027], EXC-specific [Cell Type-Gene Interaction, F = 4.376, P =
0.0198; Cell Type, F = 1227, P < 0.0001; Gene, F = 0.3267, P = 0.5756], INH-spectific
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[Cell Type-Gene Interaction, F = 3.047, P = 0.0040; Cell Type, F = 646.5, P < 0.001;
Gene, F = 2.916, P = 0.033]; Dunnett’s multiple comparisons correction applied.

Figure 3 T158M and R106W differentially expressed genes at 6 weeks of age
(e) One-tailed Wilcoxon Signed Rank, Excitatory PUpregulated = 4.357e-3, Excitatory
PDownregulated = 7.345e-3, Inhibitory PUpregulated = 4.575e-09, Inhibitory PDownregulated =
1.684e-05. (e) One-tailed Two-sample Kolmogorov-Smirnov, Excitatory P = 0.1241
[D^+ = 0.17391], Inhibitory P = 2.032e-05 [D^+ = 0.31776]. (g) Chi-square Goodnessof-Fit, Excitatory PT158M < 2.2e-16 [χ2 = 182.2, df = 2], Excitatory PR106W < 2.2e-16 [χ2 =
401.11, df = 2], Inhibitory PT158M < 2.2e-16 [χ2 = 119.94, df = 2], Inhibitory PR106W < 2.2e16 [χ2 = 346.86, df = 2]. (i) Two-tailed Kruskal-Wallis Rank Sum, Excitatory P < 2.2e-16
[χ2 = 418.2, df = 3], Inhibitory P < 2.2e-16 [χ2 = 1026.9, df = 3]; Pairwise Wilcoxon Rank
Sum P displayed.

Figure 4 Genome-wide length-dependent transcriptional changes in RTT mutant mice
(e) Top, n = 10,390 genes, Kolmogorov-Smirnov P < 2.2e-16 for each nascent or nuclear
RNA versus whole cell RNA comparison, no correction for multiple comparisons. (f) n =
10, 390 genes, Kruskal-Wallis PGroup A < 2.2e-16 [χ2 = 2664.8, df = 2], PGroup B < 2.2e-16 [χ2
= 290.18, df = 2], PGroup C < 2.2e-16 [χ2 = 2403.3, df = 2], PGroup D < 2.2e-16 [χ2 = 319.36, df
= 2], PGroup E < 2.2e-16 [χ2 = 1483.8, df = 2], PGroup F < 2.2e-16 [χ2 = 1385.8, df = 2], PGroup G
< 2.2e-16 [χ2 = 2522.9, df = 2], PGroup H < 2.2e-16 [χ2 = 2442.7, df = 2]; Pairwise Wilcoxon
Rank Sum P displayed.

Figure 6 T158M and R106W differentially expressed genes in mosaic female mice
(a) Two-way ANOVA [Genotype-Time Interaction, F = 2.987, P = 0.0712; Genotype, F =
41.14, P < 0.0001; Time, F = 7.332, P = 0.0129; Subjects (matching), F = 1.873, P =
0.0744]. (b) FACS isolation of cortical mosaic excitatory neuronal nuclei from
heterozygous TAVI, T158M, or R106W female mice. (c) nT158M = 4, nR106W = 9, Two-way
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ANOVA [Population-Genotype Interaction, F = 0.3320, P = 0.5703; Population, F =
111.1, P < 0.0001; Genotype, F = 0.332, P = 0.5703]. (d) nTAVI = 12, nT158M = 4, nR106W = 9,
One-way ANOVA [F = 0.9376, P = 0.4067]. (h) One-tailed Fisher’s Exact Test [Odds
Ratio = 19.3, P = 2.43e-05]. (i) One-tailed Wilcoxon Signed Rank, PTotal Overlap = 0.0331,
PCell. Auto. = 0.5778, PNon-Cell Auto. = 8.825e-06.

Data availability

All sequencing data reported in this study has been deposited in the NCBI Gene
Expression Omnibus (GSE83474).
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Figures
Figure 1

Figure 1 Utilization and characterization of Mecp2Tavi mice and associated RTT variants
(a) Diagram of wild-type and tagged MeCP2 showing R106W or T158M missense
mutations. MBD, Methyl-CpG Binding Domain; TRD, Transcriptional Repression
Domain. (b) Breeding strategy to biotinylate the Tavi tag in a Cre-dependent manner.
(c) Representative western blot showing the conditions in which the Tavi tag is
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biotinylated using whole brain nuclear extracts. Blot is probed with streptavidin for
biotin detection and antibodies against MeCP2 N-terminus, Tavi tag, and NeuN. (d)
Representative images showing immunofluorescent detection of biotinylated MeCP2 and
mutant variants in hippocampal tissues of untagged (WT) and tagged (TAVI, T158M,
R106W) male mice at 6 weeks of age. Tissue is probed with streptavidin for biotin
detection and antibody against the MeCP2 C-terminus. Scale bars represent 10 µm. (e)
Representative western blot comparing MeCP2 protein expression levels between Tavitagged control (TAVI) and mutant (T158M, R106W) male mice at 6 weeks of age. Blot is
probed with antibodies against the MeCP2 C-terminus and TBP. (f) Quantification of
western blot in (e) (nreplicates = 4, One-way ANOVA). (g) Brain weights from untagged
(WT, KO) and tagged (TAVI, T158M, R106W) male mice at 6 weeks of age (nWT = 20,
nTAVI = 11, nKO = 6, nT158M = 6, nR106W = 12; One-way ANOVA). (h) Body weight over
postnatal age in untagged (WT, KO) and tagged (TAVI, T158M, R106W) male mice. Data
points consist of at least 6 observations each. Total number of mice assessed: nWT = 31,
nTAVI = 23, nKO = 15, nT158M = 14, nR106W = 28. (i) RTT-like phenotypic score across
postnatal development in untagged (WT, KO) and tagged (TAVI, T158M, R106W) male
mice. Data points over time consist of at least 6 observations each. Total number of mice
assessed: nWT = 31, nTAVI = 23, nKO = 15, nT158M = 14, nR106W = 28. (j) Kaplan-Meier
survival curve for untagged (WT, KO) and tagged (TAVI, T158M, R106W) male mice
(nWT = 31, nTAVI = 23, nKO = 17, nT158M = 39, nR106W = 26). *P < 0.5, **P < 0.01, ***P <
0.001, ****P < 0.0001, n.s. = not significant; all pooled data depicts mean ± SEM. See
also Supplementary Figure 1.
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Figure 2

Figure 2 Cell type-specific transcriptional profiling of neuronal nuclei (a)
Representative images showing immunofluorescent detection of biotinylated MeCP2Tavi protein in Cre-specified neuronal populations of the mouse hippocampus. Probed
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using streptavidin for biotin detection and antibody against the MeCP2 C-terminus.
Scale bars represent 100µm. (b) Schematic of cortical nuclei preparation and FACS
isolation. (c) FACS analysis of labeled cortical nuclei populations. Data shown is
representative of nine independent experiments using NEX-Cre mice. Percentages
indicate the mean distribution of neurons that are biotin+ (excitatory; 85.2% ± 0.35) or
biotin- (inhibitory; 14.8% ± 0.35). (d) RT-PCR validation of FACS-isolated populations
depicted in (c) (nreplicates = 3, Two-way ANOVA). (e) Pearson correlation of biological
replicate nuclear RNA-seq libraries from FACS-isolated populations depicted in (c).
Colors correspond to EXC-enriched (blue) and INH-enriched (red) genes identified
through differential expression analysis of excitatory and inhibitory neurons. (f) Pearson
correlation of excitatory and inhibitory RNA-seq libraries. Data shown is representative
of 4 biological replicates. Note lower Pearson correlation and clear dispersal of cell typeenriched genes. (g) IGV browser snapshot of Dlgap1 genomic locus in excitatory and
inhibitory neurons of TAVI male mice at 6 weeks of age. RefSeq and Ensembl gene
annotations are both shown. *P < 0.5, **P < 0.01, ***P < 0.001, ****P < 0.0001, n.s. =
not significant; all pooled data depicts mean ± SEM. See also Supplementary Figures
2 and 3.
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Figure 3

Figure 3 T158M and R106W differentially expressed genes at 6 weeks of age (a) FACS
isolation of cortical excitatory and inhibitory neuronal nuclei from TAVI, T158M, or
R106W male mice at 6 weeks of age. (b) Total number of protein coding and non-coding
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differentially expressed genes (DEGs) identified in excitatory or inhibitory neurons of
Mecp2-mutant mice. (c) Heatmap displaying log2 fold changes among protein-coding
DEGs in excitatory and inhibitory neurons of Mecp2-mutant mice, compared across
genotypes. Excitatory DEGs nshared = 69 genes, Hypergeometric P = 3.15e-77. Inhibitory
DEGs nshared = 107 genes, Hypergeometric P = 5.33e-134. (d) Boxplots comparing log2
median fold changes among overlapping DEGs between T158M and R106W neurons in
(c) (One-tailed Wilcoxon Signed Rank). (e) Cumulative distribution function of the
absolute log2 fold change among overlapping DEGs between T158M and R106W neurons
in (c) (One-tailed Two-sample Kolmogorov-Smirnov). (f) Heatmap displaying log2 fold
changes among protein-coding DEGs in excitatory and inhibitory neurons of Mecp2mutant mice, compared across cell types. (g) Distribution of constitutive, EXC- or INHenriched genes among T158M and R106W protein-coding DEGs, compared against
genomic distribution (Chi-square Goodness-of-Fit). (h) Bar plot summarizing R106W
DEGs, partitioned by cell type-enriched or constitutive genes, which are preferentially
upregulated or downregulated. Red indicates statistical significance (One-tailed Fisher’s
Exact Test). (i) Boxplots comparing the log2 FPKM distribution of actively expressed
genes against T158M, R106W, and shared DEGs for each cell type (Pairwise Wilcoxon
Rank Sum P displayed). (j) Enrichment map of pre-ranked Gene Set Enrichment
Analysis (GSEA) functional network associations. Data represents DEGs from R106W
(top) and T158M (bottom) excitatory neurons (P-value < 0.01, Q-value < 0.1). Nodes
denote functional categories, colored by Normalized Enrichment Score (NES). Line
weight denotes extent of gene overlap between connected nodes. *P < 0.5, **P < 0.01,
***P < 0.001, ****P < 0.0001, n.s. = not significant. See also Supplementary Figure
4.
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Figure 4

Figure 4 Genome-wide length-dependent transcriptional changes in RTT mutant mice
(a) Genome-wide log2 fold changes in R106W mice (n = 2) compared to TAVI mice (n =
2) at 6 weeks of age using GRO-seq. Top, Lines represent mean fold change in expression
for genes binned according to gene length (200 gene bins, 40 gene step) as described in
23.

Ribbon represents SEM of genes in each bin. Bottom, Smoothed scatterplot depicting

LOESS correlation between gene length and log2 fold change for all individual protein65

coding genes detected in GROseq. Genes in red highlight R106W DEGs identified from
sorted excitatory and inhibitory neuronal nuclei. (b,c) Same as in (a), but using total
RNA-seq analysis of whole cell (b) or nuclear (c) cortical RNA isolated from the same
biological samples. (d) Top, Diagram of RNA distribution across subcellular
compartments. Bottom, Area proportional Venn diagram comparing overlap in gene
expression changes between nuclear RNA, whole cell RNA, and nascent RNA. (e)
Cumulative distribution function of gene lengths for all upregulated and downregulated
protein-coding genes among nascent, nuclear, and whole cell RNA fractions (n = 10,390
genes, Kolmogorov-Smirnov). (f) Top, Boxplots depicting median log2 fold changes in
R106W mice between nascent, nuclear, and whole cell RNA fractions, classified by the
direction of gene misregulation (n = 10, 390 genes, Pairwise Wilcoxon Rank Sum P
displayed). Gene groups are sorted by median gene length. Arrows highlight gene groups
with similar changes (38.4% of genes), opposite changes (48%), or incongruent changes
(13.6%) across subcellular fractions. Bottom, Heatmap displaying statistical enrichment
of 6-week T158M and R106W DEGs in excitatory neurons among gene groups (Onetailed Fisher’s Exact Test). (g) DAVID Gene ontology terms (Benjamini P < 0.01, FDR <
0.05) for Group A and Group G sets of genes defined in (f). (h) Mean log2 fold change in
6-week R106W (red; n = 4) and T158M (orange, n = 4) sorted excitatory neurons (left)
and inhibitory neurons (right) using GRO-seq filtered genes. See also Supplementary
Figure 5.
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Figure 5

Fig. 5. T158M and R106W differentially expressed genes in mosaic female
mice (a) RTT-like phenotypic score in TAVI (n = 12), T158M (n = 4), and R106W (n =
9) female mice (Two-way ANOVA). Data depicts mean ± SEM. (b) FACS isolation of
cortical mosaic excitatory neuronal nuclei from heterozygous TAVI, T158M, or R106W
female mice. (c) Biotin signal intensity from FACS-isolated populations depicted in (a)
(nT158M = 4, nR106W = 9, Two-way ANOVA). Data depicts mean ± SEM. (d) X-inactivation
ratios among cortical excitatory neurons in female mice, displayed as a percentage of the
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FACS-sorted WT population (nTAVI = 12, nT158M = 4, nR106W = 9, One-way ANOVA). Data
points in red highlight samples used for RNA-seq. Data depicts mean ± SEM. (e) Bar
graph showing the cell and non-cell autonomous distribution of total protein-coding
DEGs identified from T158M and R106W female mice. (f) Principal component analysis
of WT and MUT cell populations isolated from TAVI, T158M, and R106W female mice.
(g) Heatmap displaying log2 fold changes among the total number of protein-coding
DEGs detected in both WT and MUT populations from T158M or R106W female mice.
Note genes that overlap across genotype (n = 194). (h) Proportion of cell autonomous
and non-cell autonomous genes that overlap between T158M and R106W female
excitatory neurons (One-tailed Fisher’s Exact Test). (i) Boxplots comparing absolute log2
fold change between cell autonomous and non-cell autonomous shared DEGs (n = 185)
between T158M and R106W female mice (One-tailed Wilcoxon Signed Rank). (j)
Enrichment map of pre-ranked GSEA functional network associations (P-value < 0.01,
Q-value < 0.1). Data represents DEGs that overlap between T158M and R106W mice (n
= 185). Nodes denote functional categories, colored by NES. Line weight denotes extent
of gene overlap between connected nodes. *P < 0.5, **P < 0.01, ***P < 0.001, ****P <
0.0001, n.s. = not significant. See also Supplementary Figure 6
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Supplementary Information
Supplementary Figure 1

Supplementary Figure 1. Design and characterization of MeCP2-Tavi and BirA mice (a)
Schematic of targeting strategy for generating Tavi-tagged knock-in mice at the
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endogenous Mecp2 gene locus. MBD, Methyl-CpG Binding Domain; TRD,
Transcriptional Repression Domain; NEO, Neomycin cassette. (b) Schematic of
targeting strategy for generating conditional BirA transgenic mice at the Rosa26 gene
locus. (c) Western blot showing the conditions in which the Tavi tag is biotinylated and
accessible for biochemical pulldown using whole brain nuclear extracts. Pulldowns were
performed using streptavidin or an antibody against MeCP2 C-terminus. Blot is probed
with antibodies against MeCP2 N-terminus and Tavi tag. (d) Relative MeCP2 mRNA
expression levels between wild-type untagged and tagged mice at 20 weeks of age,
normalized to GAPDH mRNA (n = 3, Two-tailed Unpaired Student t-test P = 0.7882).
(e) Relative MeCP2 protein expression levels between wild-type untagged and tagged
mice at 20 weeks of age, normalized to TBP (n = 3, Two-tailed Unpaired Student t-test P
= 0.0203). (f) Western blot comparing MeCP2 protein expression levels between wildtype untagged and tagged mice at 20 weeks of age. Blot is probed with antibodies against
MeCP2 C-terminus and TBP. (g) ChIP-PCR signal of MeCP2 binding at highly
methylated repetitive elements using antibodies against MeCP2 C-terminus or normal
rabbit IgG (nreplicates = 3, Two-way ANOVA, Major Sattelite [Antibody-Genotype
Interaction, F = 1.313, P = 0.2850; Antibody, F = 933.5, P < 0.0001; Genotype, F =
0.5824, P = 0.4673], IAP [Antibody-Genotype Interaction, F = 1.672, P = 0.2320;
Antibody, F = 262.6, P < 0.0001; Genotype, F = 0.9161, P = 0.3665]). (h) Streptavidinmediated pulldown of biotinylated MeCP2-Tavi and interacting NCoR co-repressor
components (HDAC3, TBLR1). Blot is probed with streptavidin for biotin detection and
antibodies against MeCP2 C-terminus, HDAC3, and TBLR1. (i) Brain weight from
untagged (WT) and tagged (TAVI) male mice at 20 weeks of age (nWT = 21, nTAVI = 23,
Two-tailed Unpaired Student t-test P = 0.1096). (j) Relative MeCP2 mRNA expression
levels between wild-type untagged and tagged mice at 6 weeks of age (n=3-4 per
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genotype, One-way ANOVA [F = 0.9238, P = 0.4721]). (k) Representative images
showing immunofluorescent detection of biotinylated mutant MeCP2 in hippocampal
tissues of untagged (WT) and tagged (T158M, R106W) male mice at 6 weeks of age.
Tissue is probed with streptavidin for biotin detection and an antibody against MeCP2 Cterminus. Scale bars represent 10µm. (l) Immunofluorescent spatial colocalization of
biotinylated mutant MeCP2 and nucleoli in hippocampal tissue of untagged (WT) and
tagged (T158M, R106W) male mice at 6 weeks of age. Tissue is probed with streptavidin
for biotin detection and an antibody against nucleolin. Scale bars represent 10µm. *P <
0.5, **P < 0.01, ***P < 0.001, ****P < 0.0001, n.s. = not significant; all pooled data
depicts mean ± SEM. See also Fig. 1.
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Supplementary Figure 2
Validation of NEX-Cre and Dlx5/6-Cre mouse lines (a,b) Representative images
showing immunofluorescent detection of biotinylated MeCP2-Tavi protein in Crespecified neuronal populations of the mouse cortex (a) and striatum (b). Probed using
streptavidin for biotin detection and an antibody against the MeCP2 C-terminus. Scale
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bars represent 100µm. (c,d,e,f,g) Representative confocal images depicting Cremediated biotinylation in NeuN+ (c), GAD67+ (d), Parvalbumin+ (e), Somatostatin+ (f),
and Calretinin+ (g) neurons. Scale bars represent 50µm. (h) Quantification of Cremediated biotinylation in NeuN+, Parvalbumin+, or Calretinin+ neurons (n = 3, Twotailed Unpaired Student t-test PNeuN < 0.0001, PCalretinin < 0.0001, PParvalbumin = 0.0023).
(i) FACS analysis of labeled cortical nuclei populations. Data shown is representative of
three independent experiments using Dlx5/6-Cre mice. Percentages indicate the mean
distribution of neurons that are biotin+ (inhibitory; 14.2% ± 0.4) or biotin- (excitatory;
85.8% ± 0.4). (j) RT-PCR validation of FACS-isolated populations depicted in (i)
(nreplicates = 3, Two-way ANOVA, Control [Cell Type-Gene Interaction, F = 353.8, P <
0.0001; Cell Type, F = 337.4, P < 0.0001; Gene, F = 203.2, P < 0.0001], Non-Neuronal
[Cell Type-Gene Interaction, F = 3.535, P = 0.0119; Cell Type, F = 20.98, P < 0.0001;
Gene, F = 2.973, P = 0.0702], EXC-specific [Cell Type-Gene Interaction, F = 0.9698, P =
0.4312; Cell Type, F = 351.1, P < 0.0001; Gene, F = 7.491, P = 0.0146], INH-spectific
[Cell Type-Gene Interaction, F = 2.251, P = 0.0274; Cell Type, F = 901.3, P < 0.0001;
Gene, F = 1.345, P = 0.2703]; Dunnett’s multiple comparisons correction applied). *P <
0.5, **P < 0.01, ***P < 0.001, ****P < 0.0001, n.s. = not significant; all pooled data
depicts mean ± SEM. See also Fig. 2.
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Supplementary Figure 3
Functional characterization of excitatory and inhibitory neurons (a) Unsupervised
hierarchical clustering and heatmap showing correlations between excitatory and
inhibitory neuronal nuclei from 6-week TAVI mice. (b) Distribution of protein coding
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and non-coding genes across genomic, actively expressed, or cell type-enriched genes in
each cell type. (c) DAVID gene ontology terms (Benjamini P < 0.01, FDR < 0.05) for
EXC-enriched genes and their median gene lengths, all sorted by degree of fold change
(low, moderate, high enrichment) relative to inhibitory neurons. Dotted line indicates
the null proportion of low (62.3%), moderate (33.6%), and high (4.1%) enrichment
among total EXC-enriched protein-coding genes (n = 3,968). (d) DAVID gene ontology
terms (Benjamini P < 0.01, FDR < 0.05) for INH-enriched genes and their median gene
lengths, all sorted by degree of fold change (low, moderate, high) relative to excitatory
neurons. Dotted line indicates the null proportion of low (70.0%), moderate (25%), and
high (5%) enrichment among total INH-enriched protein-coding genes (n = 4,194). See
also Fig. 2.
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Supplementary Figure 4
Transcriptional features characterize MeCP2 DEGs (a) Distribution of protein coding
and non-coding genes among T158M or R106W DEGs in each cell type. (b) Bar plot
showing significant enrichment of MeCP2 DEGs across binned actively expressed genes
(One-tailed Fisher’s Exact Test). Dotted line represents null distribution. Q4 represents
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top 25% of actively expressed genes (high expression), Q1 represents bottom 25% of
actively expressed genes (low expression). (c) Boxplots comparing log2 FPKM
distributions between T158M, R106W, and shared DEGs, partitioned by upregulated and
downregulated genes (Two-tailed Kruskal-Wallis Rank Sum, Excitatory PUpregulated =
0.4739 [χ2 = 1.4937, df = 2], Excitatory PDownregulated = 6.276e-10 [χ2 = 42.378, df = 2],
Inhibitory PUpregulated = 0.3037 [χ2 = 2.3831, df = 2], Inhibitory PDownregulated = 1.162e-08 [χ2
= 36.542, df = 2]; Pairwise Wilcoxon Rank Sum P displayed). Additional boxplot shows
log2 FPKM distribution of actively expressed genes for each cell type. (d) Left, Pie chart
depicting the proportion of leading edge genes that are upregulated and downregulated
among nodes related to transcriptional regulation (see Figure 3J). Right, Heat map
depicting the preference of cell type-enriched genes among leading edge genes (Onetailed Fisher’s Exact Test). (e) Enrichment map of pre-ranked GSEA functional network
associations (P-value < 0.01, Q-value < 0.1). Data represents DEGs from R106W
inhibitory neurons. Nodes denote functional categories, colored by NES. Line weight
denotes extent of gene overlap between connected nodes. *P < 0.5, **P < 0.01, ***P <
0.001, ****P < 0.0001, n.s. = not significant. See also Fig. 3.
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Supplementary Figure 5
Extended Data for Figures 4 (a) Mean log2 fold change in 6-week R106W (red; n = 4)
and T158M (orange, n = 4) sorted excitatory neurons (top) and inhibitory neurons
(bottom); not filtered for GRO-seq detected genes. (b) Smoothed scatterplot comparing
log2 fold changes between nascent and whole cell RNA fractions (left), nuclear and whole
cell RNA fractions (center), and nascent and nuclear RNA fractions (right) in R106W
mutant mice (n = 10,390 genes). (c) Boxplots depicting gene length for corresponding
gene groups in Figure 4F, sorted by median gene lengths. Dotted line depicts median
gene length for all 10,390 genes. (d) Barplot depicting fraction of protein-coding DEGs
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classified as constitutive, EXC- or INH-enriched genes within the gene groups defined in
Figure 4F. Dotted line represents null distribution among all 10,390 genes. (e) Top,
Diagram of RNA distribution across subcellular compartments. Bottom, Area
proportional Venn diagram comparing overlap in gene expression changes between
sorted excitatory nuclear RNA, whole cell RNA, and nascent RNA. (f) Left, Genomewide Kolmogorov-Smirnov maximum distance (D^+) between cumulative distributions
of log2 fold changes between 6-week T158M and R106W sorted excitatory neurons. D^+
is summarized in bar plots (right). (g) Same as in (f), but using log2 fold changes
between t-week T158M and R106W sorted inhibitory neurons. *P < 0.5, **P < 0.01, ***P
< 0.001, ****P < 0.0001, n.s. = not significant. See also Fig. 4.
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Supplementary Figure 6
Cell and non-cell autonomous gene expression changes in RTT are functionally distinct
(a) Left, Browser snapshot of X-inactivation control genomic locus in both WT and MUT
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neurons of TAVI, T158M, and R106W female mice at 18 weeks of age. Right, Percentage
of reads detected with knock-in wild-type or mutant allele for each sorted population.
(b) Heatmap displaying log2 fold changes among protein-coding DEGs in WT and MUT
populations of T158M or R106W female excitatory neurons. (c) Boxplots comparing
median log2 fold changes among cell and non-cell autonomous genes (Two-tailed
Kruskal-Wallis Rank Sum, PUpregulated = 3.483e-14 [χ2 = 61.976, df = 2], PDownregulated =
0.0015 [χ2 = 12.983, df = 2]; Pairwise Wilcoxon Rank Sum P displayed). (d) Cumulative
distribution function comparing gene lengths among cell and non-cell autonomous genes
(Two-tailed Kruskal-Wallis Rank Sum, PUpregulated = 1.246e-08 [χ2 = 36.401, df = 2],
PDownregulated = 0.015 [χ2 = 8.4161, df = 2]; Pairwise Wilcoxon Rank Sum P displayed). (e)
Enrichment map of pre-ranked GSEA functional network associations (P-value < 0.01,
Q-value < 0.1). Data represents non-cell autonomous DEGs in R106W female excitatory
neurons. Nodes denote functional categories, colored by NES. Line weight denotes
extent of gene overlap between connected nodes. (f) Same as in (e), but using data from
cell autonomous DEGs in R106W female excitatory neurons. *P < 0.5, **P < 0.01, ***P <
0.001, ****P < 0.0001, n.s. = not significant. See also Fig.
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CHAPTER 3

A Rett Syndrome-associated mutation in Mecp2 alters the epigenomic and
chromatin architectural landscape of excitatory neurons

One Sentence Summary
Given the transcriptomic changes we observed in Chapter 2, this chapter
evaluates epigenomic and chromatin architectural changes in Mecp2 mutant mice,
providing insight into why DEGs are differentially susceptible to dysregulation in RTT
and positing MeCP2 as a key player in global maintenance of the methylome and
chromatin architecture for the preservation of neuronal gene expression.

Results

DNA methylation changes associated with R106W Mice

Numerous studies investigating the genome-wide binding patterns of MeCP2 via
chromatin immunoprecipitation followed by sequencing (ChIP-seq) in various mouse
brain regions have found that MeCP2 binds broadly across the genome (Chen et al.,
2015; Cohen et al., 2011; Gabel et al., 2015; Skene et al., 2010). Although broadly found,
MeCP2 is preferentially enriched at methylated regions of the genome, correlating with
both 5mCG (Chen et al., 2015; Cohen et al., 2011; Gabel et al., 2015; Skene et al., 2010)
and 5mCH dinucleotide density (Chen et al., 2015; Gabel et al., 2015). Given that MeCP2
binds to methylated DNA and that DNA methylation patterns are cell type-specific, we
sought to profile MeCP2 binding in a neuronal cell type-specific manner. Therefore, we
investigated the cell type-specific binding pattern of MeCP2 with the use of a Mecp2WTTavi/y;R26cBirA/+;NEXCre/+

mouse line (subsequently referred to as WT), in which an

affinity tag (TEV protease cleavage site and a biotinylation consensus motif, termed Tavi
for TEV and Avidin-binding) on MeCP2 is biotinylated in a Cre-dependent manner in
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forebrain excitatory neurons. With the use of streptavidin conjugated magnetic beads,
we carried out MeCP2 ChIP-seq in cortical excitatory neurons of 6-week mice. We found
that MeCP2 binds globally across the genome (Figure 1a), which is in agreement with
previous reports (Chen et al., 2015; Cohen et al., 2011; Gabel et al., 2015; Skene et al.,
2010). Also in line with published work, we find that MeCP2 is highly enriched at major
satellite DNA and previously established high-affinity sites and lowly enriched at known
low-affinity sites (Chen et al., 2015) (Figure S1A).
Given this global binding pattern and the large body of literature supporting that
MeCP2 binds to methylated DNA, we next sought to determine the global effect of the
R106W mutation on DNA methylation since this mutation in the methyl-CpG-binding
domain (MBD) of MeCP2 is known to abolish its ability to bind to methylated DNA. A
very simplistic model would predict that MeCP2 perseveres the methylation status of the
cytosines to which it binds, and therefore, in the presence of a mutation like R106W that
abolishes MeCP2’s ability to bind to DNA, unbound cytosines could be subjected to
hydroxymethylation and/or demethylation. Studies on this subject are few in number,
with one group finding that levels of 5hmC anticorrelated with levels of MeCP2 in mouse
cerebellar tissue (loss of MeCP2 resulted in an increase in 5hmC and overexpression of
MeCP2 lead to an decrease in 5hmC) (Szulwach et al., 2011) and another group finding
correlation between MeCP2 presence and 5hmC, with the absence of MeCP2 correlating
with a reduction in 5hmC in mouse granule cells of the cerebellum (Mellén et al., 2012a).
In addition to the conflicting conclusions of these findings, neither of these studies
examined 5mC and 5hmC simultaneously, and therefore, it remains to be determined
whether 5mC levels are altered, as well as the interplay between 5mC and 5hmC, in RTT.
Therefore, with the use of streptavidin conjugated to a fluorophore, we applied a
fluorescence-activated cell sorting (FACS)-based approach to isolate cortical excitatory
nuclei in 6-week WT and Mecp2R106W-Tavi/y;R26cBirA/+;NEXCre/+ (subsequently referred to
as R106W) mice. Whole genome bisulfite sequencing (WGBS) and Tet-assisted bisulfite
sequencing (TAB-seq) was carried out on these nuclei to obtain genome-wide, base pair
resolution profiles of 5mC and 5hmC, as integration of these two approaches enables
distinction between the two. The average genomic sequencing coverage for WGBS and
TAB-seq were ~14-fold (average cytosine coverage ~10 fold) (Figure S1B) and our
methylation data is highly correlated (r = 0.94) with previously published WGBS in WT
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excitatory neurons (Figure S1C). We find that the majority of 5mC and 5hmC are in the
CG context in similar percentages to previously published work (Lister et al., 2013; Mo et
al., 2015) (Figure S1D).
We found significant DNA methylation changes in R106W, with a global decrease
in 5mC and increase in 5hmC in both the CG and CH contexts in R106W (Figure 1B-C &
Figure S1E). Additionally, a significantly higher fraction of cytosines in the CH context
are altered than those in the CG context for both 5mC and 5hmC (Figure S1F), suggesting
that methylation in the CH context is more susceptible to demethylation in RTT. Given
this global reduction in 5mC and increase in 5hmC, we next investigated whether the
same cytosines that are losing 5mC are gaining 5hmC. We found that while 18% of
cytosines with a decrease in 5mC are gaining 5hmC, the majority (55%) of cytosines with
a reduction in 5mC are completely unmethylated (neither 5mC nor 5hmC) (Figure 1D).
These findings support the simplistic model that loss of MeCP2 binding leads to a
reduction in methylation and suggest that MeCP2 binding at CH is particularly
important for the preservation of methylation in this context.
Next, we sought to determine whether the reduction in 5mC in R106W leads to
an alteration in genome wide methylation states. Therefore, we employed MethylSeekR
(Burger et al., 2013) to segment 5mC in the CG context into fully methylated regions
(FMRs; average methylation is greater than 50%; associated with gene repression), lowmethylated regions (LMRs; average methylation of 30%; which are associated with gene
regulatory regions), unmethylated regions (UMRs; average methylation of 5.7%; which
are associated with CpG islands), and partially methylated domains (PMDs; regions with
disordered methylation)(Burger et al., 2013; Lister et al., 2009). In agreement with
previous reports(Avrahami et al., 2015), FMRs comprise the majority of the genome,
with ~2.1 Gbp found in this state (Figure S1G). In contrast to previous reports(Lister et
al., 2013; Mo et al., 2015), PMDs are present in our data (~5.8Mbp), which is likely due
to the methylation states in this current study being demarcated based solely on 5mC,
rather than evaluating both 5mC and 5hmC simultaneously (Figure S1G). In R106W, in
comparison to WT, there is an increase in the number of basepairs in LMRs, UMRs, and
PMDs, and a decrease in the number of basepairs in FMRs (Figure S1G). This finding
suggests that methylated regions are shifting to a lower methylated state and/or a more
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disordered methylation state, and thus, implicates MeCP2 as necessary for the
maintenance of FMRs, which are associated with repression.
Following our observation of global hypomethylation at the single cytosine
resolution in R106W, we next sought to determine whether stretches of DNA have
different methylation patterns in RTT. To do so, we defined differentially methylated
regions (DMRs; consisting methylation changes in both CG and CH contexts combined)
between WT and R106W. We identified 35,962 5mC DMRs (3,207 hyper-5mC-DMRs
with a median length of 248 bp; and 32,755 hypo-5mC-DMRs with a median length of
319bp) and 8,925 5hmC DMRs (935 hyper-5hmC-DMRs with a median length of 246bp
and 7,990 hypo-5hmC-DMRs with a median length of 246bp) (Figure 1E), which is in
agreement with the genome wide changes we found at the single cytosine level. Next, we
investigated whether differentially expressed genes (DEGs) in excitatory cortical neurons
of R106W mice at 6 weeks of age are significantly associated with methylation changes.
In previous work, we employed our FACS-based approach to profile the transcriptome of
cortical excitatory nuclei of 6-week WT and R106W mice, leading to the identification of
425 DEGs. We found that the number of these DEGs that intragenically overlap with
hypo-5mC-DMRs, but not any of the other DMR states, is significantly greater than
chance (chance being 1,000 permutations of randomly selected intragenic regions that
are number and length matched to DEGs) (Figure 1F). Furthermore, similar percentages
of upregulated and downregulated DEGs are enriched for each of the DMR states (Figure
S1H), suggesting that a loss of methylation is not simply a reflection of the directionality
of gene expression changes in the mutant since loss of methylation is usually associated
with gene upregulation, but not downregulation.
Following the simplistic model that predicts loss of MeCP2 binding would lead to
demethylation of unbound cytosines, we reasoned that DEGs could preferentially be
subjected to hypomethylation if they are enriched with MeCP2 occupancy in the WT
setting. Therefore, we plotted the average MeCP2 read count in excitatory neurons in the
gene bodies, plus 100kb upstream and downstream, of upregulated DEGs,
downregulated DEGs, and all actively expressed genes in cortical excitatory neurons
(Figure 1G). We found that both upregulated and downregulated DEGs are intragenically
enriched for MeCP2 binding in comparison to all actively expressed genes. Additionally,
upregulated DEGs have more MeCP2 enrichment than downregulated DEGs (Figure 1G).
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Notably, these patterns are not observed when the average read count for the Input is
plotted in a similar manner (Figure S1I), supporting that this enrichment is specific to
MeCP2. These results suggest that MeCP2’s ability to bind to methylated DNA preserves
the methylation status of cytosines, and when MeCP2’s ability to bind to methylated
DNA is compromised, such as in the R106W mutant, methylated cytosines are subjected
to hydroxymethylation and/or demethylation. Furthermore, these data suggest that
DEGs are preferentially affected in RTT due to their enrichment of MeCP2 binding in the
WT setting.
Given the enrichment of MeCP2 occupancy at DEGs in the WT setting and the
reduction of methylation at DEGs in the mutant, we next sought to determine the
relationship between DEGs and 5mC levels in the WT setting. To do so, we plotted
average methylation levels intragenically, plus 1kb upstream and downstream, across
upregulated DEGs, downregulated DEGs, and all actively expressed genes in cortical
excitatory neurons (Figure 1H-I). While upregulated DEGs have higher levels of
intragenic 5mCG and 5mCH methylation than actively expressed genes in the WT
setting, downregulated DEGs do not. Additionally, upregulated DEGs have higher levels
of intragenic 5mCG and 5mCH than downregulated DEGs, which is in agreement with
upregulated DEGs having a greater enrichment of MeCP2 than downregulated DEGs
(Figure 1G). These findings suggest that high average levels of 5mC, either in the 5mCG
or 5mCH context, isn’t the sole feature in determining MeCP2 enrichment, since both
upregulated and downregulated DEGs are enriched with MeCP2 binding, but only
upregulated genes have higher average levels of 5mCH and 5mCG than actively
expressed genes in excitatory neurons.

Chromatin Features of Rett Syndrome-associated differentially expressed genes

Our finding that average intragenic levels of 5mCG and 5mCH are not the sole
determinant of MeCP2 binding led us to determine common chromatin features of DEGs
to gain insight into why these genes are enriched for MeCP2 binding in WT and
preferentially susceptible to misregulation in Rett Syndrome. With the use of a Hidden
Markov Model, ChromHMM (http://compbio.mit.edu/ChromHMM/) (Ernst and Kellis,
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2012), multiple chromatin datasets were integrated to define chromatin states in the
adult male mouse cortex. Chromatin immunoprecipitation sequencing (ChIP-seq)
datasets from six histone marks were used, three of which were generated from 6-15week mouse cortical tissue by our lab, H3K9me3 (associated with heterochromatin),
H3K4me3 (associated with promoter regions), and H3K79me2 (associated with gene
bodies), and three are publicly accessible datasets from 8-11-week mouse excitatory
neurons of the cortex, H3K27ac (associated with promoter and enhancer activation),
H3K4me1 (associated with enhancers), and H3K27me3 (associated with polycomb
regions)(Mo et al., 2015). Additionally, we used publicly accessible CCCTF-binding
factor (CTCF) ChIP-seq (Encode: ENCFF001LIJ) and Polr2a ChIP-seq (Encode:
ENCFF001LIV) data from 8-week mouse cortical tissue. We also assessed open
chromatin regions in excitatory neurons of the cortex from 6-week old mice (using our
Mecp2WT-Tavi/y;R26cBirA/+;NEXCre/+ mouse line) with the assay for transposase accessible
chromatin using sequencing (ATAC-seq), and we found that our ATAC-seq data highly
correlates with previously published ATAC-seq data in excitatory neurons (r = 0.88)
(Figure S2A) and that our biological replicates are well correlated (r = 0.986) (Figure
S2B). Finally, we incorporated our MeCP2 ChIP-seq data from excitatory cortical
neurons of 6-week with the use of our Mecp2WT-Tavi/y;R26cBirA/+;NEXCre/+ mouse line.
Therefore, these data sets allow for the demarcation of chromatin states in cortical
neurons, primarily excitatory neurons due to 85% of neurons in the cortex consisting of
excitatory neurons and the fact that some of these datasets specifically assessed
excitatory neurons, of 6-15-week male mice.
Using these various epigenomic datasets, ChromHMM identified 11 independent
chromatin states (Figure 2A). We found that the number of DEGs intragenically
enriched for heterochromatin, active enhancers, and CTCF chromatin states is
significantly greater than chance (chance being random sampling (1,000 times) of genes
that are number and length matched to DEGs) (Figure 2B). When the relative
enrichments are compared across upregulated and downregulated DEGs, it was found
that three states are differentially enriched: the polycomb and active enhancer chromatin
states are found in a significantly higher percentage of downregulated DEGs and the
active promoter state is found in a significantly higher percentage of upregulated DEGs
(Figure 2C). Given that DEGs display intragenic enrichment for heterochromatin states,
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we next sought to determine whether our DEGs are associated with lamin associated
domains (LADs) since H3K9me 2/3 is enriched along the entirety of LADs(Guelen et al.,
2008; Harr et al., 2015; Wen et al., 2009). To do so, we used publicly available data of
lamin B1 associated domains from mouse neural precursor cells (NPCs) since this is the
closest data available to mouse cortical tissue (Peric-Hupkes et al., 2010) and found that
DEGs are not associated with LADs (Figure S2C). These data suggest that DEGs are
associated with a unique chromatin environment, which may explain the susceptibility of
these genes to misregulation in RTT. Furthermore, the differential enrichment of
particular chromatin states at upregulated versus downregulated genes provides insight
into the directionality of gene misregulation in RTT.
Given that DEGs are significantly intragenically associated with hypo-5mCDMRs, we next sought to determine whether particular intragenic chromatin states are
enriched for this DMR state. To do so, we isolated all chromatin state regions that
overlap with DEGs and determined whether particular states significantly overlap with
5mC-hypo-DMRs. Heterochromatin, polycomb, and gene body states that are
intragenically located within DEGs are significantly associated with hypo-5mC-DMRs
(Figure 2D). We next determined which chromatin states are significantly associated
with hypo-5mC-DMRs genome-wide and found similar states to be enriched:
heterochromatin, polycomb, gene body, and low-signal 1 states (Figure S2D). Taken
together, these data suggest that repressive states (heterochromatin and polycomb) are
globally demethylated in the mutant and that the enrichment of heterochromatin within
DEGs can partially explain their differential vulnerability to misregulation. Additionally,
the enrichment of gene bodies with hypo-5mC-DMRs is suggestive of a potential global
effect on genes.
Given our finding that DEGs are associated with active enhancer and CTCF
chromatin states, we next sought to determine whether particular transcription factors
(TFs) bind in or near DEGs (intragenic region plus 100kb upstream and downstream).
To do so, we performed TF footprinting analysis (Piper et al., 2015; 2013) in our ATACseq peak regions of excitatory neurons and subsequently used HOMER(Heinz et al.,
2010) to identify TF motifs significantly associated with these footprints. Using this
approach, we identified 19 TFs that are associated with footprints in ATAC-seq peak
regions of WT cortical excitatory neurons (Figure S2E). When evaluating these TF
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footprints for significant enrichment with DEGs, we found that DEGs are significantly
associated with CTCF, NeuroD2, and POU2F2 (Figure S2E). Furthermore, when the
relative enrichments of these TFs are compared across upregulated and downregulated
DEGs, we found that the ATF1 footprint is associated with a significantly higher
percentage of upregulated DEGs than downregulated DEGs (Figure S2F). In addition to
enrichment intragenically plus 100kb upstream and downstream, CTCF was also
enriched intragenically plus 500kb upstream and downstream (Figure 2E). These
findings suggest that certain TFs and architectural proteins, such as CTCF, are important
in the regulation of DEGs, and furthermore, that particular TFs regulate upregulated
versus downregulated DEGs.

CTCF Binding Site Alterations in R106W Mice

Given our findings that DEGs are significantly enriched with particular TF and
architectural protein footprints, the CTCF chromatin state, and the active enhancer state,
we next sought to investigate whether open regulatory regions are altered in the R106W
mice compared to WT. To do so, we carried out ATAC-seq in cortical excitatory neurons
of 6-week R106W male mice and compared the ATAC-seq profiles between WT and
R106W. The ATAC-seq read coverage for WT and R106W were comparable (Figure S3A),
and similar to the WT biological replicates, the R106W ATAC-seq biological replicates
were highly correlated (r = 0.985) (Figure S3B). The number and genomic distribution of
ATAC-seq peak regions are similar across WT and R106W (Figure S3C). When the
genomic locations of ATAC-seq peak regions were statistically tested for differences in
Tn5 transposase integrations (the enzyme used in ATAC-seq to fragment and insert
adapters into open regions of the genome) between WT and R106W, only 5 regions were
found to be significantly different (0.005% of all ATAC-seq peak regions). These findings
suggest that the location of open regulatory regions does not change in R106W mice,
which is in agreement with the subtle gene expression changes observed in the R106W
mice.
Although the genomic location of open regulatory regions did not change in the
mutant, it is possible that the recruitment and/or binding affinity of TFs is subtly
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affected within these open regulatory regions, and that such a difference cannot be
detected by simply comparing Tn5 transposase integrations at ATAC-seq peak regions.
In order to assess this, we performed differential ATAC-seq footprinting with the use of
Wellington-bootstrap (Piper et al., 2013; 2015) and found thousands of differential
ATAC-seq footprints: 31,907 sites that are WT specific (sites that are lost in R106W;
referred to as “R106W lost footprint sites”) and 36,474 sites that are R106W specific
(sites that are gained in R106W; referred to as “R106W gained footprint sites”). To
increase the stringency of our differential footprints, we subsequently only evaluated
footprints with a differential footprint score of 2 or higher, which equated to 3,459
R106W gained footprint sites and 2,471 R106W lost footprint sites. Visualizing average
Tn5 transposase integrations across all R106W gained or lost footprint sites confirms
that these are differential footprint sites, given the large difference in average Tn5
transposase integrations across the differential sites in WT and R106W (Figures 3A and
Figure S3D). We then used HOMER(Heinz et al., 2010) to identify TF motifs
significantly associated with these differential footprints. We identified 15 TF motifs that
are significantly associated with R106W gained footprint sites and 10 TF motifs that are
significantly associated with R106W lost footprint sites (Figure S3E-F). Since CTCF was
the most significantly enriched TF motif, we focused subsequent analyses on R106W
CTCF gained footprint sites. Visualizing Tn5 transposase integrations at CTCF
differential footprint sites by either evaluating Tn5 transposase insertions at each of the
R106W CTCF gained footprint sites independently (Figure 3B) or by averaging
integrations across all R106W CTCF gained footprint sites (Figure 3C) confirmed that
these footprints are more enriched in R106W than WT.
To corroborate that the R106W CTCF gained sites are enriched for CTCF binding
in R106W in comparison to WT, we next performed CTCF ChIP-seq in cortical tissue
from WT and R106W male mice at 6 weeks of age. When the average CTCF ChIP-seq
read counts at the R106W CTCF gained footprint sites are compared between WT and
R106W, CTCF read count is greater at these sites in R106W than WT (Figure 3D). This
supports that these R106W CTCF gained footprint sites are enriched for CTCF binding in
R106W compared to WT. One plausible explanation for the gain of CTCF binding at
these regions in R106W could be that these sites are losing methylation in R106W, and
therefore, enabling the binding of the methylation-sensitive CTCF at these sites. To test
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this, we compared the average 5mC methylation levels at each cytosine from the center
of the R106W CTCF gained footprint sites plus 1kb upstream and downstream in WT and
R106W and found a significant reduction in average methylation levels (p=0.0002501,
Fisher’s exact test) in R106W. And following our simple model that predicts that MeCP2
binding preserves the methylation status of cytosines to which it binds, we next
investigated whether MeCP2 binding is enriched at these R106W CTCF gained footprint
sites in the WT setting. Therefore, we analyzed the average MeCP2 ChIP-seq read count
at the R106W CTCF gained footprint sites plus 2kb upstream and downstream and found
that MeCP2 is enriched at these sites (Figure3E). These findings suggest that the loss of
MeCP2 binding at these regions leads to demethylation and/or accessibility of these sites
to CTCF binding.
We next evaluated the genomic distribution of R106W CTCF gained sites and
found that they are located on every chromosome, in both intergenic and intragenic
regions (Figure 3F). We subsequently sought to determine whether DEGs are enriched
for R106W CTCF gained sites. We found that a higher percentage of DEGs are associated
with R106W CTCF gained sites than chance (Figure 3G). Additionally, DEGs overlap
with more R106W CTCF gained sites than chance (Figure 3G). However, when
upregulated and downregulated DEGs were evaluated independently, a significant
percentage of downregulated genes were associated with R106W CTCF gained sites than
chance, but not upregulated DEGs (Figure 3H and Figure S3G). These data suggest that
the R106W mutation leads to a loss of methylation at sites that are bound by MeCP2 in
the WT setting, which therefore leads to CTCF binding at a portion of these sites.
Furthermore, downregulated DEGs, but not upregulated DEGs, are enriched for CTCF
gained sites, providing insight into the directionality of gene misregulation in R106W
mice.

Nuclear Architectural Alterations in R106W mice

The observation of genome-wide R106W CTCF gained sites, along with the
known importance of CTCF in genome organization(Ong and Corces, 2014), led us to
next examine whether there are detectable nuclear architectural changes in RTT. To do
so, we isolated nuclei from WT and R106W mouse cortical tissue and visualized various
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genomic regions with the use of Oligopaint FISH probes, which allow for highly specific
and efficient genomic targeting (Beliveau et al., 2012). We began by investigating the
extent to which global alterations occur in the two large-scale chromatin organizational
components, heterochromatin and euchromatin. Heterochromatin is a compact
conformational state with low levels of transcription, and euchromatin is an open,
transcriptionally active conformational state (Becker et al., 2016).
We first investigated the euchromatic conformational state by designing primary
Oligopaint FISH probes that span the entire euchromatic region of chromosome 9
(Chr9) and subsequently using secondary oligo probes conjugated to a fluorophore for
visualization of euchromatic Chr9 (Figure 4A). Chr9 was chosen because of its
intermediary size (12th largest chromosome out of 21 chromosomes). We also used
streptavidin conjugated to a fluorophore to visualize and restrict analysis to one cortical
cell type, excitatory neurons (Figure 4A). We first measured the volume of the nucleus to
determine whether our FISH protocol preserves the known phenotype of reduced
nuclear volume in RTT (Mazumder et al., 2008b), and we found that the volume of
R106W nuclei is significant reduced compared to WT (Figure 4B). Chr9 volume is also
significantly reduced in R106W nuclei (Figure 4C), and when Chr9 volume is normalized
to nuclear volume, the effect is nullified (Figure 4D). This suggests that Chr9 is
condensing in R106W nuclei and that the reduction in Chr9 volume is proportional to
the reduction in nuclear volume. This general relationship between chromatin
condensation and nuclear size is supported by previous work (Linhoff et al., 2015;
Mazumder et al., 2008a; Shen et al., 1996). Additionally, we observed an elongation of
Chr9 (ratio of longest axis/shortest axis) in R106W (Figure S4A). Finally, we investigated
the nuclear location of Chr9 by segmenting the nucleus into 5 regions of equal volume
from the periphery to center (Figure S4B) and computing the fraction of Chr9 found in
each nuclear segment. There was found to be a small, but significant, shift of Chr9
towards the periphery of the nucleus (Figure S4C). Taken together, these data support
Chr9 condensation, as well as slight changes in Chr9 shape and nuclear positioning, in
RTT.
Given these euchromatic observations, we next investigated the extent of
heterochromatic changes in R106W nuclei. A major component of heterochromatin is
repetitive DNA sequences, existing primarily in two forms: pericentric major satellites
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and centromeric minor satellites. Therefore, we visualized heterochromatin by designing
primary Oligopaint FISH probes that specifically target mouse major or minor satellites,
as well as designing secondary oligo probes that uniquely bind to these two regions with
different conjugated fluorophores (Figure 4E). Similar to euchromatic Chr9 volume,
both major and minor satellite volume (both total and average volume per foci) was
significantly reduced in R106W (Figure 4F-G and S4D-E) However, differing from
euchromatin, when major and minor total volume was normalized to nuclear volume,
the reduction in volume remains significant (Figure 4H and S4). This suggests that the
reduction in volume for major and minor satellites is greater than the reduction in
nuclear volume. We also observed a significant reduction in major and minor satellite
number (Figure 4I and S4G), which might be explained by the significant reduction in
average distance between major and minor satellites (Figure 4J and S4H), suggesting
that similar organizational compartments are merging together. There is also an increase
in merging across major and minor satellites compartments, given the significant
increase in major and minor overlap (Figure 4K). Finally, there was found to be a slight,
but significant, shift in major and minor satellite positioning toward the center of the
nucleus (Figure S4I-J). Therefore, these findings support condensational and
organizational defects in heterochromatin in RTT.
Given these alterations in euchromatin and heterochromatin, we next sought to
determine whether we could detect organizational changes at the gene level, comparing a
DEG to a gene of similar length (referred to as Control) whose expression does not
significantly change in R106W excitatory neurons. We chose to examine two genes on
Chr9 given our prior findings of condensation of the euchromatin regions of this
chromosome: Bmper was chosen as the DEG (length: 262,127 bp and fold change (FC):
1.3) and Ncam1 was chosen as the Control (length: 294,562bp). Oligopaint probes were
designed to span the entire intragenic regions of these genes (Figure 5A). Differing from
what was observed for the euchromatic region of Chr9 or heterochromatin, both the
DEG (Bmper) and Control (Ncam1) volume increased in R106W (Figure S5A-B) and this
increase remained significant after normalizing for nuclear size (Figure 5B-C). Next,
given our bioinformatics findings that DEGs intragenically overlap with the
heterochromatic chromatin state, we next determined the distance from the center of
each gene to the center of the nearest major satellite. In agreement with our
93

bioinformatics data, we find that the DEG (Bmper) is closer to a major satellite than the
control gene (Ncam1) (Figure 5D and Figure S5C) in the WT setting; however, this
difference was not observed in the mutant setting (Figure S5D-E). Therefore, we
reasoned that the distance of at least one of the genes to its nearest major satellite is
perhaps changing in the RTT. When the distance of each gene to its nearest major
satellite was compared between WT and R106W, we found that although the raw
distance does not change for either gene (Figure S5F-G), the normalized distance of the
DEG (Bmper) to its nearest major satellite significantly increases (Figure 5E and S5H).
Taken together, these data suggest that gene bodies, for both DEGs and Controls alike,
are decondensing in RTT, and that the proximity of a DEG to major satellite could be a
contributing factor to misregulation in RTT. Additionally, we garnered insight into the
directionality of gene misregulation in RTT, since this upregulated DEG shifts
significantly away from repressive heterochromatin, which could contribute to
transcriptional upregulation.
Next, we sought to investigate another DEG and Control gene to determine
whether similar differences are observed. This time we chose a downregulated DEG,
Sgcd (length: 1,092,717bp, RPKM: 4.9, and FC: 0.79), and a Control gene of similar
length and expression levels, Gpc6 (length: 1,054,233 and RPKM: 6.8). This
downregulated DEG is also associated with a R106W CTCF gained footprint site. Similar
to what was observed above for the other DEG and Control pair, both genes increased in
volume in RTT (Figure S5I-J) and this remained significant after normalizing for nuclear
size (Figure 5F-G). Another characteristic similar to the other gene pair, the DEG (Sgcd)
is closer to a major satellite than the Control gene (Gpc6) in WT (Figure 5H and S5K),
and in R106W, the distances are similar between the DEG and Control (Figure S5L-M).
However, differing from what was observed previously, when measuring the distance of
a gene to its nearest major satellite across WT and R106W, the downregulated DEG
distance remains unchanged (Figure 5I and S5N) and the Control gene distance
increases (Figure S5O), although this effect is lost when normalized to nuclear volume
(Figure S5P). Collectively, this corroborates the gene body decondensation, for both
DEGs and Control genes alike, in RTT, and supports that DEGs are located in closer
proximity to major satellites than Controls. Moreover, the downregulated DEG stays in
similar proximity to its nearest major satellite, which is in opposition to the upregulated
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DEG shifting significantly away from its nearest major satellite, implicating this
proximity to a repressive state as a plausible explanation the directionality of gene
misregulation in RTT.
To further substantiate the observed increase in nuclear volume of gene bodies of
both DEGs and Controls in RTT, we used Oligopaint probes to intragenically labeled 11
DEGs of varying lengths, expression levels, and FC, as well as 11 matched Controls with
similar lengths and expression levels (Figure S6A). Using this approach, we again find an
increase in volume for both DEGs and Control genes in R106W nuclei (Figure 6A-B and
Figure S6B-C). We also evaluated the nuclear location of DEGs and Controls across WT
and R106W and found a slight, but significant, shift of both DEGS and Controls towards
the center of the nucleus (Figure S6D-E), suggestive of global organizational alterations
in RTT. When the nuclear location of DEGs was compared to that of Controls, it was
found that DEGs are significantly located more centrally than Controls in both WT and
R106W (Figure 6D and Figure S6F), which is in agreement with DEGs being in closer
proximity to major satellites than Controls since the majority of major satellites are
located centrally.
Finally, given our findings of decondensation of both DEGs and Controls by
visualizing the entire gene body, we next sought to determine whether this increase in
volume could also be found by measuring the distances between different regions of the
gene body, since an increase in volume should correlate with an increase in distance
between different regions of the gene. To do so, we designed Oligopaint probes that
target 100kb regions at the 5’ end, Middle (Mid), and 3’ end of a downregulated DEG
(Kcnip4; length: 1,135,403bp, RPKM: 33.7, FC: 0.76) and Control Gene (Tenm2; length:
1,229,39bp and RPKM: 29.5) (Figure 6E). This downregulated DEG is associated with a
R106W CTCF gained footprint site. To gain insight into the conformation of these genes,
we measured the distances across all combinations of intragenic locations (5’ to Mid,
Mid to 3’, and 5’ to 3’) and compared the 5’ to 3’ distance to that of the sum of 5’ to Mid
plus Mid to 3’ (referred to as 5’ to 3’ Summed) and found that the 5’ to 3’ distance is
shorter than the 5’ to 3’ Summed distance (Figure S6G), suggesting that both of these
genes are not in a linear conformation, but rather a loop-like conformation. First, we
compared the sum of all distances (5’ to Mid plus Mid to 3’ plus 5’ to 3’) across WT and
R016W and found that this summed distance is greater in R016W for both the DEG
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(Kcnip4) and Control (Tenm2) (Figure S6H), which confirms what we previously found
with the volume expansion of two pairs of genes. Next, we measured the distances
between each of the intragenic regions in both the DEG (Kcnip4) and Control (Tenm2)
across WT and R106W. The distance between 5’ to Mid remained unchanged for both
genes (Figure 6F) and both genes demonstrate a significant increase in 5’ to 3’ distance
(Figure 6G) across WT and R106W. However, the DEG (Kcnip4), but not Control
(Tenm2), displayed an increase Mid to 3’ distance (Figure 6H) across WT and R106W.
Given this DEG-specific increase in the Mid to 3’ region of the gene, we next evaluated
the distances between Mid to 3’ in the WT setting between the DEG (Kcnip4) and
Control (Tenm2) and found that the distance between the Mid to 3’ of the DEG is the
only distance significantly shorter in the DEG (Figure S6I), suggesting that perhaps this
is a unique feature of DEGs and that disruption of this tight chromatin unit might be
contributing to gene misregulation. This is particularly intriguing given that the R106W
CTCF gained site is located nearest to the 3’ end of DEG, suggesting that this gain in
CTCF binding could possibly be contributing to the alteration in chromatin compaction.

Materials and Methods

ChIP-seq library construction and mapping

MeCP2, H3K4me3, and CTCF ChIP-seq were generated from 3 cortices of 6-week
male mice (Mecp2WT-Tavi/y;R26cBirA/+;NEXCre/+ or Mecp2R106W-Tavi/y;R26cBirA/+;NEXCre/+).
H3K79me2 and H3K9me3 ChIP-seq were generated from 3 cortices of 15-week old male
mice. 50-200ug of chromatin was used per IP, which was performed as previously
described in Chapter 2 of this dissertation. Libraries were generated using NEB
enzymatic reagents (End Repair, 5' Adenylation, Adapter Ligation) with Illumina Truseq
adapters according to Illumina ChIP-seq prep kit manufacturer instructions. Libraries
were sequenced on a HiSeq 2500 (50SE). The ChIP-seq FASTQ files were mapped to the
mouse mm10 genome with bowtie using “-v 2 -m 1”. Only uniquely mapped reads were
included for further analysis.
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MeCP2 ChIP-RT-PCR

The following primers were used:
1) Major Satellite: forward 5′-catccacttgacgacttgaaaa-3′, reverse, 5′gaggtccttcagtgtgcattt-3′
2) high-affinity site 1: forward 5′-atgttccagggatgatgaactt-3′, reverse 5′-gctacgcagtagagacatgctg-3′
3) high-affinity site 2: forward 5′-atgtagacgtacacgcccttg-3′, reverse 5′agttctgactgtcctggaactg-3′
4) low-affinity site 1: forward 5′- ccagctactcgcggctttacgg-3′, reverse 5′cctcccgccctgcttatccagt-3′
5) low- affinity site 2: forward 5′-ggaagtgaggacagaaatggac-3′, reverse 5′attggctcataccaaaccagag-3′
TAB-seq and WGBS library construction, mapping, and analysis

Genomic DNA was isolated from nuclei of cortical excitatory neurons using an
AllPrep DNA/RNA Mini kit (Qiagen cat. #80204) and subsequently treated with RNase
(Roche cat. # 11119915001). TAB-seq and WGBS libraries were generated from 400ng
and 300ng of DNA, respectively, as previously reported (Yu et al., 2012a). Trim Galore
was used to remove the adaptor contamination from the raw sequencing reads using “stringency 2 --length 36”. The trimmed reads were mapped to mm10 genome by
Bismark41 using parameters “-n 2 -l 40”. Clonal reads were excluded to avoid PCR
artifacts. Methylation calling was performed by Binomial distribution followed by the
Benjamini-Hochberg correction. The mC level for a cytosine was calculated as the WGBS
methylation levels subtracted the hmC level in that cytosine.
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MethylSeekR

Identification of UMRs, LMRs, and PMDs was carried out as previously described
(Burger et al., 2013). Unique to our analysis was the demarcation of states based solely
on 5mC, rather than evaluating both 5mC and 5hmC combined given that we performed
both WGBS and TAB-seq, allowing for the distinction between the two methylation
marks. Our α distribution had a distinct long tail, and therefore, we identified and
masked PMDs genome-wide. To identify FMRs, all UMRs, LMRs, and PMDs were
excluded from the genome using bedtools subtract, and the remaining sequences were
taken to be FMRs.

ATAC-seq library construction

Five hundred thousand cell type-specific nuclei were sorted and subsequently
pelleted as previously described (Jiang et al., 2008). Briefly, 1.6 mL of nuclei in PBS were
mixed with 372 µL of pelleting buffer (360 µL of 2M Sucrose, 10 µL of 1M CaCl2, and 2 µL
of 3M Mg(Ac)2) by gentle inversion, incubated on ice for 15 min, and centrifuged for 15
min at 5,000 rpm at 4°C. Nuclei were resuspended in 60 µL of 1x TD Buffer (Illumina
Cat #FC-121-1030) and counted using a hemocytometer. 50,000 nuclei were brought up
to 47.5 µL with 1x TD buffer and transposed with 2.5 µL of transposase (Illumina Cat
#FC-121-1030) for 30 min at 37°C. ATAC-seq libraries were constructed exactly as laid
out previously (Buenrostro et al., 2013), with a few exceptions. First, only 2.0 µL of 25
µM customized Nextera PCR Primers were used during PCR amplification. Second, the
additional number of PCR cycles for each library was kept to 3-4 cycles (step 6 under III.
PCR Amplification). Third, the final amplified library was purified using AMPure XP
beads (Beckman A63881) to remove larger fragments (> 800 bp) by using 0.5X beads to
remove larger fragments, removing the supernatant, adding 1.6X beads to the
supernatant, and subsequently following the AMPure XP bead (Beckman A63881)
instructions for DNA isolation. Libraries were analyzed on a Bioanalyzer (Agilent) and
sequenced on an Illumina HiSeq (100 PE).
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ATAC-seq mapping

The mate1 and mate2 files of the paired-end sequencing were mapped separately to the
mm10 genome by bowtie38 using “-v 2 -m 1”. If both mates of a read pair were mapped to
the opposite strands of the same chromosome and the distance in-between was less than
2 kb, the read pair was included for further analysis.

Random Sampling for determining significant enrichment

Bedtoools shuffle with the –incl flag was used to select number- and lengthmatched regions that were then intersected with features of interest. Carrying this out
1,000 times led to the generation of a random distribution from which a population
mean and standard deviation was obtained for the generation of a z-score that was then
converted into a two-tailed p-value.

Footprint and differential footprint analysis

ATAC-seq Fastq files were merged across biological replicates and Epinomics’
ATAC-Seq platform (https://open.epigenomics.co/) was used for adapter trimming,
alignment, filtering (removal of duplicates and mitochondrial reads). Footprinting was
performed using the pyDNase (http://pythonhosted.org/pyDNase/) (Piper et al., 2013;
2015) script wellington_footprints.py with default parameters and the–A flag to indicate
that the data come from ATAC-seq. Footprints with a p-value cutoff of e-20 were
subsequently used for analysis. Footprints were extended 10bp upstream and
downstream, and Homer (Heinz et al., 2010) was used for de novo TF motif discovery
using findMotifsGenome.pl with the flag –size given. For differential footprint analysis,
the pyDNase script wellington_bootstrap.py was used to determine WT-specific
andR106W-specific footprints with default parameters and the –A flag. To create a
background file for motif enrichment, WT and R106W ATAC-seq peaks that did not
contain either a WT-specific or R106W-specific footprint were subjected to footprinting
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using the pyDNase script wellington_footprints.py, and footprints with a p-value cutoff
of e-20 were subsequently used for analysis. All footprints were extended 10bp upstream
and downstream prior to de novo TF motif discovery with Homer with the background
files specified using findMotifsGenome.pl with the flags –h, -size given, and -bg. To
determine the location of TFs of interest, Homer’s annotatePeaks.pl script was used with
the flag –size given. For the generation of plots that display the average Tn5 integrations
around a set of regions, the pyDNase script dnase_average_profile.py was used with the
–A flag. For the generation of the heatmaps displaying the raw data, the pyDNase script
dnase_to_javatreeview.py was used along with the –A flag and –o flag, which orders the
differential footprint from most differential at the top to least differential at the bottom.
JavaTreeView was used for heatmap visualization.

ChromHMM Modeling

Modeling was followed exactly as laid out in the ChromHMM manual
(http://compbio.mit.edu/ChromHMM/) (Ernst and Kellis, 2012), with the specification
of 11 states.

RP30M, RPKM, and FPKM

The number of sequencing reads or read-pairs mapped to the whole gene bodies
(GRO-seq, ChIP-seq, ATAC-seq, and total RNA-seq) or the exonic regions (mRNA-seq)
of each gene were counted by in house Perl programs. RP30M, read counts per 30
million uniquely mapped reads or read-pairs. For RPKM and FPKM, edgeR was used to
normalize the read counts to obtains the count per million (CPM) values, and then the
CPM values were further normalized by the length of whole gene (GRO-seq, ChIP-seq,
ATAC-seq, and total RNA-seq) or the total length of all exons (mRNA-seq) to obtain the
values of RPKM (reads per kilobase per million mapped reads, single-end sequencing
data) and FPKM (fragments per kilobase per million mapped read-pairs, paired-end
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sequencing data). A gene was defined as an expressed gene if its GRO-seq RPKM > 0.5
and as a non-expressed gene if its GRO-seq RPKM < 0.01.

Metagene analysis (heatmaps and line plots)

The total numbers of uniquely mapped reads or read-pairs for all sequencing data
were normalized to 30 million. The signal represents the RP30M per base pair or per
bin. For bin analysis, the gene body, upstream, and downstream regions were divided
into 1000 equal bins for each gene, respectively, and the number of sequencing reads for
each bin was calculated and normalized. For the heatmaps, the normalized bin signals
were used to generate the heatmaps. For the line plots, the median value of the
normalized bin signals of a given bin of that gene group was used to generate the plots.
Heatmaps were generated by heatmap.2 function in the gplots R package.

Oligopaint probe design and synthesis

Probes were designed as previously described (Beliveau et al., 2012), with one
exception: bowtie2 was used instead of OligoArray. CustomArray was used for
Oligopaint library synthesis as previously described (Beliveau et al., 2012). Oligopaint
probe synthesis was carried out as previously described (Beliveau et al., 2015).

Oligopaint FISH

A single cortex per biological sample was homogenized, and the homogenate was
treated with 1% formaldehyde for 5 minutes and subsequently quenched with glycine.
Nuclei were then isolated as previously described in Chapter 2 and resuspended in PBS.
Nuclei in PBS were then placed on Polysine slides (Thermo Scientific™, cat. #6776215)
for 30 minutes and subsequently fixed onto the slides with 4% PFA for 5 minutes,
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followed by rinsing with PBS for 10 minutes. Nuclei on slides were stored in PBS at 4oC
until use. FISH was carried out as previously described (Beliveau et al., 2015; 2012).
Briefly, slides in PBS were warmed to room temperature (RT). Slides were then
incubated in 2X SCCT for 5 min at RT, 50% formamide in 2X SCCT for 5 min at RT, 50%
formamide in 2X SCCT for 2.5 minutes at 92oC, and 50% formamide in 2X SSCT for 20
minutes at 60oC. Nuclei were then hybridized with 50pmol of Oligopaint probe in a
hybridization mixture consisting of 2X SSCT, 50% formamide, 10% (w/v) dextran
sulfate, and 10mg of RNase. A coverslip and rubber cement were used to seal the
hybridization mixture. Slides were then placed on a 92oC heat block for 2.5 min to enable
denaturation, followed by overnight hybridization in a humidified chamber at 42oC.
Slides were then washed in 2X SSCT for 15 minutes at 60oC followed by two 10 min 2X
SCCT RT washes. Nuclei were then hybridized with 10pmol of secondary oligos
conjugated to fluorophores in hybridization mixture, sealed with a coverslip and rubber
cement, and hybridized for 2 hours at RT. Slides were then washed in 2X SSCT for 15
minutes at 60oC followed by two 10 min 2X SCCT RT washes. Slides were then stained
with streptavidin conjugated to a fluorophore (1:1000) for 2 hr at RT in 2X SCCT. Slides
were then stained for 5 minutes with DAPI (1:5000) and washed for 10 min in 2X SCCT
at RT twice. Slides were then mounted and imaged.

Oligopaint analysis

Images were analyzed using TANGO (Tools for Analysis of Nuclear Genome
Organization) (Ollion et al., 2013). Downstream data analysis was performed only on
excitatory neurons, which was determined by measuring the intensity of streptavidin
staining.
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Figure 1. Global Hypomethylation is significantly association with DEGs in
R106W mice. (A) Browser representation of MeCP2 binding and the four major forms
of methylation in cortical excitatory neurons across a region of Chr9. For the DNA
methylation tracks, the height of each track represents % methylation (0-100%). (B)
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Top: Heat-scatterplot representation of 5mC differentially methylated cytosines in WT
and R106W mice. Bottom: Heat-scatterplot representation of 5hmC differentially
methylated cytosines in WT and R106W mice. Each dot represents a single differentially
methylated cytosine. (C) Comparison of the percentage of all cytosines in the CG (left) or
CH (right) context that are 5mC (top) or 5hmC (bottom) in WT versus R106W excitatory
cortical neurons (*****p < 2.2e-16, Fisher’s exact test). (D) Heatmap representation of
differentially methylated cytosines in R106W mice. Each line represents a single
differentially methylated cytosine. (E) Heatmaps of differentially methylated regions
(DMRs) in R106W. (F) Number of DEGs vs Random Genes (random sampling (1,000
times) of genes that are number and length matched to DEGs) that overlap with each of
the 4 types of DMRs. The mean, maximum, and minimum numbers of overlapping genes
are displayed for the Random Genes (###p <0.005, two-tailed test). (G) MeCP2 read
count from our MeCP2 ChIP-seq in excitatory neurons in the gene bodies, plus 100kb
upstream and downstream, of upregulated DEGs, downregulated DEGs, and all actively
expressed genes in cortical excitatory neurons. The gene body, upstream, and
downstream regions were divided into 1000 equal bins for each gene and the number of
sequencing reads for each bin was calculated and normalized. RP30M: read counts per
30 million. (H) 5mCG or (I) 5mCH gene body methylation levels across upregulated
DEGs, downregulated DEGs, and all actively expressed genes in WT cortical excitatory
neurons. The gene body region was segmented in 1000 equally sized bins for each gene
and the average cytosine methylation level for each bin was calculated and normalized.
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Figure
2. Differentially
expressed
Polycomb
Active
Strong
Promoter Enhancer

Chromatin States

genes in R106W are associated with

particular chromatin states. (A) Hidden Markov Modeling of 10 chromatin datasets
let to the demarcation of 11 re-occurring combinatorial patterns that were used to define
chromatin states. (B) Number of DEGs vs Random Genes (random sampling (1,000
times) of genes that are number and length matched to DEGs) that overlap with each of
the 11 states. The mean, maximum, and minimum numbers of overlapping genes are
displayed for the Random Genes (***p<0.00005 & ****p<0.00001, two-tailed test). (C)
The percentage of upregulated DEGs and downregulated DEGs associated with
chromatin states that significantly differed in enrichment between the two DEG states
(#p<0.05 & *p<0.0005, Fisher’s exact test). (E) Number of DEGs vs Random Genes
(random sampling (1,000 times) of genes that are number and length matched to DEGs)
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that overlap with the CTCF site either intragenically plus 100kB upstream and
downstream or intragenically plus 500kb upstream and downstream (#p<0.05 &
###p<0.005,

two-tailed test).
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Figure 3
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Figure 3. Alterations in CTCF Binding in R106W Mice (A) Average Tn5 insertion
profiles at R106W gained footprint sites plus 100bp upstream and downstream in
R106W vs WT (red: positive strand cuts; blue: negative strand cuts). (B) Heatmap of the
Tn5 insertions at R106W CTCF gained footprint sites in R106W and WT ordered from
most differential at the top to least differential at the bottom. Yellow indicates a greater
number of positive strand cuts compared to negative strand cuts per nucleotide position
and blue indicates a greater number of negative strand cuts. (C) Average Tn5 insertion
profiles at R106W CTCF gained footprint sites plus 100bp upstream and downstream in
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R106W vs WT (red: positive strand cuts; blue: negative strand cuts). (D) Mean
difference in CTCF ChIP-seq read count in R106W and WT at R106W CTCF gained
footprint sites plus 2kb upstream and downstream. RP30M: read counts per 30 million.
(E) MeCP2 mean read count at R106W CTCF gained footprint sites plus 2kb upstream
and downstream. RP30M: read counts per 30 million. (F) Genomic distribution of
R106W CTCF gained footprint sites. (G) Number of unique overlaps or total overlaps of
DEGs or (H) downregulated DEGs vs Random Genes (random sampling (1,000 times)
of genes that are number and length matched to DEGs) with R106W CTCF gained
footprint sites (gene bodies plus 500kb upstream and downstream). The mean,
maximum, and minimum numbers of overlapping genes are displayed for the Random
Genes (#p<0.05, ##p<0.01, & ###p <0.005, two-tailed test).
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Figure 4
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Figure 4. Heterochromatic and euchromatic condensation in R106W mice.
(A) Fluorescence images of DAPI, biotin (labeling biotinylated MeCP2 in excitatory
neurons), and Chr9 in WT and R106W nuclei. Cumulative frequency distribution and
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boxplot of (B) nuclear volume, (C) total Chr9 volume (per nucleus sum), (D) and the
percentage of the nucleus occupied by Chr9 ((Chr9 volume divided by nuclear volume) x
100) (n=3 WT animals and n=3 R106W animals with 126 nuclei per animal). (E)
Fluorescence images of DAPI, biotin, major satellites, and minor satellites in WT and
R106W nuclei. Cumulative frequency distribution and boxplot of (F) total major satellite
volume (per nucleus sum), (G) average major satellite volume (average volume of a
single major satellite foci), (H) percentage of the nucleus occupied by major satellites
((total major satellite volume divided by nuclear volume) x 100), (I) major satellite
number per nucleus, (J) average distance between major satellites, (K) fraction of major
satellite volume that overlaps with minor satellites (n=3 WT animals and n=3 R106W
animals with 118 nuclei per animal). Boxplots extend from the 25th to 75th percentiles
with a line at the median and whiskers range from the 10th to 90th percentiles.
###p<0.005, *p<0.0005, **p<0.0001.

Significance marks in the frequency distribution

area indicate significance via the Kolmogorov-Smirnov test and significance marks in the
boxplots indicate significance via the Mann-Whitney test.
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Figure 5. Gene body decondensation in R106W mice. (A) Fluorescence images
of DAPI, biotin (labeling biotinylated MeCP2 in excitatory neurons), DEG (Bmper), and
Control (Ncam1) in WT and R106W nuclei. Cumulative frequency distribution and
boxplot of (B) percentage of the nucleus occupied by Control (Ncam1) ((total Control
volume divided by nuclear volume) x 100), (C) percentage of the nucleus occupied by
DEG (Bmper) ((total DEG volume divided by nuclear volume) x 100), (D) distance of
DEG (Bmper) or Control (Ncam1) from nearest major satellite in WT, and (E) DEG
(Bmper) distance to nearest major satellite (n=3 WT animals and n=3 R106W animals
with 125 nuclei per animal; #p<0.05; ##p<0.01; ###p<0.005; **p<0.0001; significance
marks in the frequency distribution area indicate significance via the KolmogorovSmirnov test and significance marks in the boxplots indicate significance via the MannWhitney test). Cumulative frequency distribution and boxplot of (F) percentage of the
nucleus occupied by Control (Gpc6) ((total Control volume divided by nuclear volume) x
100), (G) percentage of the nucleus occupied by DEG (Sgcd) ((total DEG volume divided
by nuclear volume) x 100), (H) distance of DEG (Sgcd) or Control (Gpc6) from nearest
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major satellite in WT, and (I) DEG (Sgcd) distance to nearest major satellite (n=3 WT
animals and n=3 R106W animals with 100 nuclei per animal; ##p<0.01; *p<0.0005;
**p<0.0001;

significance marks in the frequency distribution area indicate significance

via the Kolmogorov-Smirnov test and significance marks in the boxplots indicate
significance via the Mann-Whitney test). Boxplots extend from the 25th to 75th percentiles
with a line at the median and whiskers range from the 10th to 90th percentiles.
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Figure 6
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Figure 6. Further confirmation of gene body decondensation in R106W. (A)
Fluorescence images of DAPI, biotin (labeling biotinylated MeCP2 in excitatory
neurons), DEGs, and Controls in WT and R106W nuclei. Cumulative frequency
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distribution and boxplot of (B) percentage of the nucleus occupied by Controls ((total
volume of Controls divided by nuclear volume) x 100), (C) percentage of the nucleus
occupied by DEGs ((total volume of DEGs divided by nuclear volume) x 100) (n=2 WT
animals and n=3 R106W animals with 125 nuclei per animal; ###p<0.005; *p<0.0005;
**p<0.0001;

significance marks in the frequency distribution area indicate significance

via the Kolmogorov-Smirnov test and significance marks in the boxplots indicate
significance via the Mann-Whitney test). (D) Comparison of the nuclear location of
Controls vs DEGs in WT across all 5 Shells (**p<0.0001; Mann-Whitney test). (E)
Fluorescence images of DAPI and biotin (labeling biotinylated MeCP2 in excitatory
neurons), along with the 5’ end, Middle, and 3’ end of a DEG (Kcnip4) or Control
(Tenm2) WT and R106W nuclei. Cumulative frequency distribution and boxplot of (F)
the normalized distance between the 5’ to Mid gene regions (distance divided by nuclear
radius) of a DEG (Kcnip4) or Control (Tenm2), (G) the normalized distance between the
5’ to 3’ gene regions (distance divided by nuclear radius) of a DEG (Kcnip4) or Control
(Tenm2), and (H) the normalized distance between the Mid’ to 3’ gene regions (distance
divided by nuclear radius) of a DEG (Kcnip4) or Control (Tenm2) (n=3 WT animals and
n=3 R106W animals with 100 nuclei per animal; ##p<0.01; *p<0.0005; **p<0.0001;
significance marks in the frequency distribution area indicate significance via the
Kolmogorov-Smirnov test and significance marks in the boxplots indicate significance
via the Mann-Whitney test). Boxplots extend from the 25th to 75th percentiles with a line
at the median and whiskers range from 10th to 90th percentiles.

114

Supplemental Figure 1
% ChIP / Input

A

B

8
6

WGBS

4

WT

2

TAB-seq

0

1
2
1
2
e
llit
y#
y#
y#
y#
ate ffinit ffinit ffinit ffinit
S
jor h A h A w A w A
M a Hig Hig
Lo
Lo
No biotinylated MeCP2-Tavi present
Loss of biotinylated MeCP2-Tavi tag
Biotinylated MeCP2-Tavi

*****

CG
CG

6

69,910,972

Paired end

355,482,726

Single end

90,399,255

Paired end

342,226,844

Single end

76,664,971

Paired end

362,161,658

Single end

82,948,394

Genomic
coverage

No. of
profiled
cytosines

Cytosine
coverage
(mean)

14.41

910,767,892

10.26

14.84

892,356,502

9.34

14.09

919,794,624

9.71

14.95

897,101,884

9.61

E
Number of cytosine
sites that
change in mutant
( é, Hypermethylation)

CH
CH
Genotype

CG
context

4

0

G

Number of
methylated
sites

89%

5mC

Methylation
State

WT

5hmC
5hmC

Number of
Basepairs

CG

25,097,058

CH

14,679,722

CG

24,937,160

5mC
R106W

FMR

2,114,052,792

LMR

WT

*****

8,366,590

FMR

2,095,492,757

LMR

25,894,156

55hhm
mC
C

I

DEG intragenic overlap
with DMRs
UpU
U
DD
D Downregulated
regulated
U
DEG
DEG

40 40
40
20 20
20

WT

CG

8,974,474

CH

1,134,378

CG

10,542,560

5hmC
R106W

8,376,457

121,394 (0.5%)

ê

538,459 (2.2%)

é

101,469 (0.7%)

ê

479,618 (3.4%)
N/A
N/A

CH

1,615,932

é

270,875 (2.6%)

ê

80,668 (0.8%)

é

74,582 (4.6%)

ê

34,172 (2.1%)

597,113,098

Input Average Read Count
Actively expressed genes
Upregulated DEGs
Downregulated DEGs

5.0
4.5

RP30M

60 60
60

13,945,529

N/A
é

580,648,498

PMD

Δ 5mC Δ 5hmC

CH

N/A

23,498,024

PMD

R106W

( ê, Hypomethylation)
(% , percentage of
cytosines with change)

2

UMR

55mm
CC

354,206,959

Single end

63%

UMR

00

Paired end

Methylation

5mC

CH
CH

22

80 80
80
% of DEGs
overlapping with DMR

CG
CG

Uniquely
mapped
reads

ConextContext
of all methylation

0
50
100
WGBS methylation level (%)

66

H

4.0
3.5
3.0

0 00
Hypo-

yp
o5m
H
HH ypo Cyyp D
poe 5m MR
-r5 C
5mC -D
H -m
M
HH ype
yyp r C-D-DM R
peo -5
r- m MRR
5
H
m
h CHH ypo mCC- DM
yyp D
poe 5h -DMMRR
-r5 m
C R
H -h5m
h
H ype mC -DM
yp r
C-D
er -5h -DMMR
-5 m RR
hm C
C -DM
-D R
M
R

Hyper- Hypo- Hyper5mC- 5mC- 5hmC- 5hmCDMR DMR DMR DMR

H

D

Low

0

44

TAB-seq

High

50

88

R106W

all cytsoines
% %of5mC
allof cytosines

r = 0.94

Context of methylation
changes in R106W

% of all cytosines with change
in that context

F

100

WGBS

Density

Mo et al.
WGBS methylation level (%)

C

Platform

Genotype

2.5
2.0
1kb
upstream

TSS

TTS

1kb
downstream

Figure S1. (A) RT-PCR of DNA pulled down by streptavidin in cortical tissue of mice
with no biotinylated (R26cBirA/+;NEXCre/+), with loss of the biotinylated MeCP2-Tavi tag
(Mecp2WT-Tavi/y;R26cBirA/+;NEXCre/+; lysates are treated with Tev protease prior to
streptavidin mediated pulldown, which leads to the cleavage of the biotinylated Tavi tag
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on MeCP2, or Biotinylated MeCP2-Tavi (Mecp2WT-Tavi/y;R26cBirA/+;NEXCre/+) using
primers for major satellite DNA and previously established high-affinity sites and lowly
enriched at known low-affinity sites (Chen et al., 2015). (B) WGBS and TAB-seq
sequencing information. (C) Density map comparing the methylation status of
individual cytosines between previously published data and our own data (MeCP2WT)
from glutamatergic cortical neurons. r, Pearson correlation. (D) Percentage of all
cytosines that are methylated in each of the 4 major contexts of DNA methylation in WT.
Percentages within the bars represent the percentage of 5mC or 5hmC in the CG context.
(E) Summary of the number of methylated cytosines and differentially methylated
cytosines in various contexts. (F) Context of methylation changes in R106W (*****p <
2.2e-16, Fisher’s exact test). (G) Summary of the number of basepairs in FMRs, LMRs,
UMRs, and PMDs. (H) The percentage of upregulated DEGs and downregulated DEGs
that overlap with each of the 4 types of DMRs. (I) Input read count in the gene bodies,
plus 100kb upstream and downstream, of upregulated DEGs, downregulated DEGs, and
all actively expressed genes in cortical excitatory neurons. The gene body, upstream, and
downstream regions were divided into 1000 equal bins for each gene and the number of
sequencing reads for each bin was calculated and normalized. RP30M, read counts per
30 million.
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Figure S2. (A) Density map comparing accessible genomic regions (via ATAC-seq)
between previously published data and our own data in glutamatergic neurons. r,
Pearson correlation; RPM, reads per million. (B) Density map comparing accessible
genomic regions between the two ATAC-seq biological replicates in excitatory neurons. r,
Pearson correlation; RPM, reads per million. (C) Number of DEGs vs Random Genes
(random sampling (1,000 times) of genes that are number and length matched to DEGs)
that overlap with the lamin associated domains (LADs) (****p<0.00001, two-tailed test).
117

(D) Number of 5mC-hypo-DMRs vs Random Regions (random sampling (1,000 times)
of regions throughout the genome that are number and length matched to 5mC-hypoDMRs) (****p<0.00001, two-tailed test). (E) Number of DEGs vs Random Genes
(random sampling (1,000 times) of genes that are number and length matched to DEGs)
that overlap with the each of the 19 TF footprint sites intragenically plus 100kB upstream
and downstream (****p<0.00001 & #p<0.05, two-tailed test). (F) The percentage of
upregulated DEGs and downregulated DEGs associated with the TF footprint sites that
significantly differed in enrichment between the two DEG states (#p<0.05).
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Figure S3. (A) ATAC-seq sequencing information. (B) Density map comparing
accessible genomic regions between the two ATAC-seq biological replicates in excitatory
neurons. r, Pearson correlation; RPM, reads per million. (C) Genomic distribution of
ATAC-seq peaks in WT and R106W. (D) Average Tn5 insertion profiles at R106W lost
footprint sites plus 100bp upstream and downstream in WT vs R106W (red: positive
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strand cuts; blue: negative strand cuts). (E-F) Summary tables of the TF motifs enriched
at R106W lost gained and lost footprint sites. (G) Number of unique overlaps or total
overlaps of upregulated DEGs vs Random Genes (random sampling (1,000 times) of
genes that are number and length matched to DEGs) with R106W CTCF gained footprint
sites (gene bodies plus 500kb upstream and downstream). The mean, maximum, and
minimum numbers of overlapping genes are displayed for the Random Genes.
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Figure S4. (A) Cumulative WT
frequency
R106W distribution and boxplot of Chr9 elongation (n=3
WT animals and n=3 R106W animals with 126 nuclei per animal; **p<0.0001;
significance marks in the frequency distribution area indicate significance via the
Kolmogorov-Smirnov test and significance marks in the boxplots indicate significance
via the Mann-Whitney test). (B) Schematic demonstrating shell designations for
nuclear location analysis. (C) Comparison of Chr9 nuclear location in WT vs R106W
across all 5 shells (n=3 WT animals and n=3 R106W animals with 126 nuclei per animal;
##p<0.01; **p<0.0001,

Mann-Whitney test). Cumulative frequency distribution and

boxplot of (D) total minor satellite volume (per nucleus sum), (E) average minor
satellite volume (average volume of a single major satellite foci), (F) percentage of the
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nucleus occupied by minor satellites ((total major satellite volume divided by nuclear
volume) x 100), (G) minor satellite number per nucleus, and (H) average distance
between minor satellites (n=3 WT animals and n=3 R106W animals with 118 nuclei per
animal; ###p<0.005; *p<0.0005; **p<0.0001; significance marks in the frequency
distribution area indicate significance via the Kolmogorov-Smirnov test and significance
marks in the boxplots indicate significance via the Mann-Whitney test). Comparison of
(I) major satellite or (J) minor satellite location in WT and R106W across all 5 shells
(n=3 WT animals and n=3 R106W animals with 118 nuclei per animal; ##p<0.01;
###p<0.005; *p<0.0005; **p<0.0001,

Mann-Whitney test). Boxplots extend from the 25th

to 75th percentiles with a line at the median and whiskers range from the 10th to 90th
percentiles.
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Figure S5. Cumulative frequency distribution and boxplot of (A) Control (Ncam1)
volume, (B) DEG (Bmper) volume, (C) distance of DEG (Bmper) or Control (Ncam1) to
nearest major satellite in WT, (D) raw distance of DEG (Bmper) or Control (Ncam1) to
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nearest major satellite in R106W, (E) normalized distance of DEG (Bmper) or Control
(Ncam1) to nearest major satellite in R106W, (F) Control (Ncam1) raw distance to
nearest major satellite, (G) DEG (Bmper) raw distance to nearest major satellite, (H)
Control (Ncam1) normalized distance to nearest major satellite (n=3 WT animals and
n=3 R106W animals with 125 nuclei per animal; ##p<0.01; ###p<0.005; **p<0.0001).
Cumulative frequency distribution and boxplot of (I) Control (Gpc6) volume, (J) DEG
(Sgcd) volume, (K) distance of DEG (Sgcd) or Control (Gpc6) to nearest major satellite
in WT, (L) raw distance of DEG (Sgcd) or Control (Gpc6) to nearest major satellite in
R106W, (M) normalized distance of DEG (Sgcd) or Control (Ncam1) to nearest major
satellite in R106W, (N) DEG (Sgcd) raw distance to nearest major satellite, (O) Control
(Gpc6) raw distance to nearest major satellite, (H) Control (Gpc6) normalized distance
to nearest major satellite (n=3 WT animals and n=3 R106W animals with 100 nuclei per
animal; ###p<0.005; ####p<0.001; *p<0.0005 **p<0.0001; significance marks in the
frequency distribution area indicate significance via the Kolmogorov-Smirnov test and
significance marks in the boxplots indicate significance via the Mann-Whitney test).
Boxplots extend from the 25th to 75th percentiles with a line at the median and whiskers
range from 10th to 90th percentiles.
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Figure S6. (A) Table summarizing the features of DEGs and Controls used. Cumulative
frequency distribution and boxplot of (B) Controls volume and (C) DEGs volume (n=2
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WT animals and n=3 R106W animals with 125 nuclei per animal; **p<0.0001;
significance marks in the frequency distribution area indicate significance via the
Kolmogorov-Smirnov test and significance marks in the boxplots indicate significance
via the Mann-Whitney test). Comparison of the nuclear location of (D) DEGs in WT vs
R106W across all 5 shells, (E) Controls in WT vs R106W across all 5 shells, (F) Controls
vs DEGs in WT across all 5 shells (###p<0.005; *p<0.0005; **p<0.0001; Mann-Whitney
test). (G) Distances between different locations of the genes. 5’ to 3’ summed is the sum
of the 5’ to Mid distance and the Mid to 3’ distance (n= 3 WT animals with 100 nuclei per
animal for both genes). (H) Sum of the normalized distances between all pairwise
combinations of locations (5’ to Mid, Mid to 3’, and 5’ to 3’) (n=3 WT animals and n=3
R106W animals with 100 nuclei per animal; #p<0.05; ##p<0.01; ###p<0.0005;
significance marks in the frequency distribution area indicate significance via the
Kolmogorov-Smirnov test and significance marks in the boxplots indicate significance
via the Mann-Whitney test). (I) Comparison of distances the WT setting. Boxplots
extend from the 25th to 75th percentiles with a line at the median and whiskers range
from 10th to 90th percentiles.
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CHAPTER 4
Summary / Discussion

Since the discovery of MeCP2, twenty-five years of research on this protein has
led to vast insight into the complex, multifaceted function of this protein, generating
numerous hypothesized molecular models, such as, a transcriptional repressor, a
transcriptional activator, a chromatin organizer, a regulator of alternative splicing, and a
miRNA processor (Lyst and Bird, 2015). Given that MeCP2 is a methyl-CpG-binding
protein and that DNA methylation patterns are cell type-specific (Mo et al., 2015), we
hypothesized that MeCP2 influences gene expression in a cell type-specific manner, and
that cellular heterogeneity must first be resolved in order to clearly delineate
transcriptional and epigenomic alterations for the understanding of how MeCP2 affects
transcription.
With the employment of our cell type-specific approach, we found that
differentially expressed genes (DEGs) in Mecp2 mutant mice are neuronal typedependent, given that the vast majority of misregulated genes in excitatory or inhibitory
neurons are exclusive to each cell type. In agreement with various studies (Ben-Shachar
et al., 2009; Chahrour et al., 2008; Tudor et al., 2002), gene expression differences in
R106W mice were found to be very subtle, with 70% of DEGs exhibiting less than a 50%
alteration in expression levels. Additionally, the numbers of DEGs that are upregulated
and downregulated are very similar, supporting neither an activator nor repressor model
for MeCP2. Furthermore, we find that DEGs are long and lowly expressed. Focusing on
one cell type, excitatory cortical neurons, we find that DEGs appear to be regulated by
MeCP2, rather than the DEGs being a byproduct of indirect effects, since cell typespecific ChIP-seq of MeCP2 demonstrates that DEGS are intragenically enriched with
MeCP2 when compared to genes that are not misregulated in RTT. Our finding that both
upregulated and downregulated DEGs are enriched with 5mC-hypomethylated
differentially methylated regions (DMRs) suggests that the loss of MeCP2 binding at
DEGs in Mecp2 mutant mice leads to the demethylation of unbound cytosines within
DEG gene bodies, and thus, contributes to the dysregulation of these genes. Given these
findings, we next sought to investigate whether DEGs are enriched with 5mC (in both the
CG or CH context) in order to gain an understanding of the epigenomic features that lead
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to the recruit of MeCP2. We found that gene bodies of upregulated, but not
downregulated, DEGs contain higher levels of 5mCG and 5mCH than genes that are not
misregulated in RTT. Notably, our findings on upregulated DEGs are in agreement with
recently published work that have found that MeCP2 enrichment at upregulated genes
correlates with high levels of 5mCH (Chen et al., 2015; Gabel et al., 2015). This implies
that the binding of MeCP2 at upregulated DEGs in the WT setting leads to gene
repression (given the upregulation in the mutant context), suggesting that MeCP2 is a
repressor. However, the regulatory role of MeCP2 at downregulated DEGs is currently
unclear, with our study finding that downregulated DEGs are associated with MeCP2
enrichment, but not with high levels of 5mCH; one previously published study finding
that downregulated DEGs are associated with both MeCP2 binding and high levels of
5mCH (Chen et al., 2015); and another study finding that downregulated DEGs are
neither associated with MeCP2 binding nor high levels of 5mCH (Gabel et al., 2015). One
plausible explanation for this discrepancy is that different brain regions/cell types were
assessed in each of these studies, with our study evaluating excitatory neurons of the
cortex, one study using whole cortical/cerebellar homogenate (Gabel et al., 2015), and
the other study using the hypothalamus (Chen et al., 2015). These findings also raise the
possibility that MeCP2 function is chromatin-feature dependent: the binding of MeCP2
at regions with high levels of methylation could lead to gene repression, whereas the
binding of MeCP2 at regions with low levels of methylation (and possibly in conjunction
with other chromatin features, like histone modifications or chromatin accessibility)
could lead to gene activation.
Since average intragenic levels of 5mCG and 5mCH cannot fully explain MeCP2
recruitment to DEGs, we next sought to determine common chromatin features of DEGs
in the WT context to gain insight into why these genes are enriched for MeCP2 binding
in WT and preferentially susceptible to dysregulation in RTT. The observation that DEGs
are lowly expressed is supported by our finding that DEGs are intragenically enriched for
the heterochromatic state (H3K9me3) based on ChIP-seq data and that DEGs are in
closer proximity to major satellites (a major component of heterochromatin) than
control genes via Oligopaint FISH. These findings are in line with the fact that MeCP2 is
highly concentrated at pericentromeric heterochromatin (Lewis et al., 1992), suggesting
that MeCP2 could play a role in the regulation of lowly expressed genes.
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Two other chromatin features were found to be significantly associated with the
gene bodies of DEGs in the WT context: CTCF and active enhancer chromatin states. As
a general feature, previous studies have found significant coenrichment of CTCF with
enhancers (Chepelev et al., 2012; Sanyal et al., 2012). CTCF enrichment at DEGs was
also corroborated via transcription factor footprinting analysis in open chromatin
regions. Given that CTCF is an architectural protein important for bridging together
regulatory sequences, it is possible that DEGs, especially given their length, require a
particular interconnected topology that aids in enhancer recruitment for the
maintenance of gene expression. And furthermore, it is possible that MeCP2 plays a role
in facilitating this specialized topology for the maintenance of appropriate gene
expression levels. Additionally, we found that certain chromatin features are
differentially enriched in upregulated versus downregulated DEGs, which aids in
understanding the directionality of gene dysregulation in RTT. A significantly higher
percentage of upregulated DEGs than downregulated DEGs are associated with the
active promoter state, suggesting that upregulated DEGs are in an environment that
facilitates gene expression. Contrastingly, a significantly higher percentage of
downregulated DEGs than upregulated DEGs are associated with the polycomb state,
suggesting that downregulated DEGs are in an environment associated with gene
repression. Taken together, these findings suggest that chromatin environment plays a
role in determining whether a gene will be upregulated or downregulated upon loss of
MeCP2 binding. Additionally, a significantly higher percentage of downregulated DEGs
are associated with active enhancers, which is in opposition to a model predicting that
chromatin state dictates gene expression changes observed upon loss of MeCP2 function,
however, an explanation for this apparent discrepancy will be offered below.
Given the finding that CTCF and active enhancer chromatin states are enriched at
DEGs, we next surveyed open chromatin regions via ATAC-seq and found that the gross
location and number of regulatory regions remain similar in R106W mice. However, a
more stringent analysis that evaluated the transcription factor (TF) footprint patterns
and location within open regulatory regions led to the discovery of thousands of
footprints (both lost and gained) in R106W mice. This suggests that the recruitment
and/or binding affinity of TFs is subtly affected within open regulatory regions, which is
in alignment with the subtlety of gene expression changes found in RTT (here, and (Ben129

Shachar et al., 2009; Chahrour et al., 2008; Tudor et al., 2002)). CTCF was found to be
the most significantly enriched TF motif within gained footprint sites (with gained
meaning more enriched in R106W than WT), and we subsequently confirmed that these
sites are enriched with CTCF binding in R106W compared to WT via CTCF ChIP-seq. We
found that these sites are enriched for MeCP2 binding in WT mice and that these sites
are significantly associated with a loss of methylation in R106W. Taken together, these
data suggest that the binding of MeCP2 in the WT context can prevent the recruitment of
CTCF, either by acting as a physical hindrance to CTCF binding and/or by preserving the
methylation status at these loci that would prevent methylation-sensitive CTCF from
binding (Maurano et al., 2015). CTCF gained sites are widespread across chromosomes,
occurring both intergenically and intragenically. We additionally found that CTCF sites
that are gained in R106W are significantly enriched in/around downregulated DEGs, but
not upregulated DEGs. This finding suggests that downregulated DEGs are potentially
more susceptible to changes in CTCF binding, and consequently, changes in chromatin
organization. And in light of our previous unexplained finding that in comparison to
upregulated DEGs, downregulated DEGs are enriched with active enhancers, these
findings implicate the gain of CTCF binding sites in/around downregulated DEGs as
potentially leading to alterations in the topology required for the preservation of active
enhancer interactions that are necessary for the maintenance of gene expression, and
thus, as a possible factor leading to transcriptional downregulation.
Given the widespread gain of CTCF binding in R106W, we next investigated
whether these changes in CTCF correlate with changes in chromatin architecture by
employing Oligopaint FISH. On the global scale, we observed that both euchromatin and
heterochromatin (major satellites) are reduced in volume in RTT, which is suggestive of
chromatin condensation and that heterochromatin (major satellites) are slightly more
affected than euchromatin, which is in align with the enrichment of MeCP2 at
pericentromeric heterochromatin in WT. In addition to a reduction in major satellite
volume, major satellites are located slightly more centrally and reduced in number,
which may be partially explained by the observed reduction in the average distance
between major satellites, suggesting that major satellites are clustering together in RTT.
This finding might also aid in understanding the molecular and cellular phenotypes
observed in RTT, given that pericentromeric heterochromatin undergo significant
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changes over neuronal development (Martou and De Boni, 2000; Solovei et al., 2004).
In neurons, heterochromatin number decreases from postnatal day 0 to 3 and then
increases to adult levels by postnatal day 15, and heterochromatin nuclear location is
predominately established by postnatal day 5-6 (Martou and De Boni, 2000; Solovei et
al., 2004). The timing of these heterochromatin alterations coincide with the period of
synaptogenesis in mice (2-4 weeks of age) (De Felipe, 1997), suggesting that this
reorganization is important for neuronal function and that the organizational alterations
observed in R106W mice could be a contributing factor in the neuroplasticity defects
observed in RTT (Chao et al., 2007; Dani and Nelson, 2009; Dani et al., 2005; Goffin et
al., 2012). In support of this, we find that DEGs are enriched with genes associated with
synaptic morphology and function (post-synaptic membrane proteins, including Na2+,
K+, Ca2+ and Cl- channels, synaptic scaffolding proteins, and inotropic glutamate
receptors).
Given these large-scale changes in nuclear architecture, we next investigated
whether DEGs are also susceptible to changes in chromatin organization. Therefore, we
employed Oligopaint FISH to label the entire intragenic regions of DEGs vs Control
genes (genes without expression changes in R106W mice). Two differences were
observed between DEGs and Controls: (1) DEGs are in closer proximity to major
satellites in the WT setting and (2) DEGs are located more centrally than controls in both
the WT and R106W setting, with the second finding possibly being linked to the first
finding since major satellites are predominately centrally located. Our finding that DEGs
are intragenically associated with the heterochromatin state based on ChIP data
corroborates this Oligopaint observation. However, the difference between DEG and
Control proximity to major satellites is lost in the Mecp2 mutant setting, suggesting that
heterochromatin proximity alone cannot account for gene misregulation in RTT.
Therefore, perhaps it’s a combination of all/some of the unique chromatin and gene
features of DEGs that render them differentially susceptible. Or perhaps proximity to
major satellites is only an effective repression mechanism for DEGs, but not Controls,
due to the genomic context in which DEGs are found (Jost et al., 2015). Interestingly, it
was found that upregulated DEGs slightly, but significantly, shift away from major
satellites in the R106W, while downregulated DEGs remain in similar proximity. This
shift away from the repressive, heterochromatic state may partly explain the
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upregulation of some DEGs. Given that downregulated DEGs are significantly associated
with CTCF gained sites, it is possible that this gain of binding creates a particular,
perhaps inflexible, conformational state that prevents DEGs from shifting away from
major satellites.
Differing from what was found for major satellites and euchromatin, we found
that DEGs (both upregulated and downregulated) and Control genes alike increase in
volume, which is suggestive of decondensation. To explore this more stringently, we
labeled the 5’ end, Middle (Mid), and 3’ end of a DEG or control gene and measured the
distances across all combinations. At this level of scrutiny, we found that although both
the DEG and Control expand from 5’ to 3’, the DEG preferentially expands from Mid to 3’
as well. This suggests that, although both DEGs and controls are decondensing, DEGs
are either decondensing to a greater extent and that particular regions of the genes are
expanding to a greater extent. It is possible that the condensation or the conformational
state of the Mid to 3’ region of DEGs is particularly important for gene regulation, with
circumstantial evidence coming from our observation that the Mid to 3’ distance of the
DEG is the only distance that is significantly shorter than the Control in the WT setting.
These findings complement recently published work in the RTT field that topoisomerase
(an enzyme that decondenses chromatin) inhibition leads to the rectification of the
expression of RTT-associated upregulated DEGs in cell culture (Gabel et al., 2015),
suggesting that upregulated DEGs are decondensed. The decondensation of DEGs is also
in agreement with our methylation data of 5mC-hypomethylation being enriched at
DEGs.
Taken together, this work implicates MeCP2 as a global, context-dependent
modulator of gene transcription, rather than a gene-specific activator or repressor, and is
supportive of MeCP2’s role as an architectural protein. Additionally, this work provides
insight into the chromatin features of DEGs that may account for their differential
susceptible to dysregulation in RTT and posits MeCP2 as a key player in global
maintenance of the methylome and chromatin architecture for the preservation of
neuronal gene expression. In support of this model, although we focused our analyses on
CTCF, we observed thousands of additional alterations in TF footprinting, which are
associated with various TFs, suggesting that the sum of all these subtle changes in TF
binding could be contributing to the subtle transcriptional alterations observed. And
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therefore, yet another model of MeCP2 function is emerging—a synergistic model that
treats many of the proposed molecular models as an integrative piece of MeCP2’s
function rather than treating them as mutually exclusive entities. It is possible that
MeCP2 is predominately an architectural protein important for regulating chromatin
structures that aid in the activation or repression of genes necessary for long-lasting
plasticity in response to neuronal activity. And therefore, in this model, the
transcriptional activator or repressor effects that have been attributed to MeCP2 would
be secondary to its architectural role.
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APPENDIX PART 1

Distinct cellular and molecular environments support aging-related DNA
methylation changes in the substantia nigra
One Sentence Summary
This story, which found that distinct cellular and molecular environments account for
aging-associated methylation changes in the SN, is published in Epigenomics.

Abstract
We aimed to investigate the relationship between brain region-specific changes in global
DNA methylation over aging and cellular and molecular environments. We measured
two major forms of DNA methylation and analyzed Dnmt, Tet, and metabolite levels in
the striatum and substantia nigra (SN) over aging in healthy male mice. The ratio of 5hydroxymethylcytosine to 5-methylcytosine increases over aging in the SN, and 5hydroxymethylcytosine increases preferentially in dopaminergic neurons. Additionally,
this age-dependent alteration in methylation correlates with a reduction in the ratio of αketoglutarate to succinate in the SN. Distinct cellular and molecular environments
account for aging-associated methylation changes in the SN, implicating this epigenetic
mechanism in the susceptibility of this brain region to age-related cell loss.

Introduction
Neurons live longer than nearly all other cell types in the body. In the absence of a
degenerative disease, the lifespan of most neurons is only limited by the longevity of the
organism. However, some brain regions and neuronal types are more vulnerable to agerelated cell death and degenerative diseases. One susceptible neuronal population is
dopaminergic neurons of the substantia nigra, with a 5-8% loss per decade of life in
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humans during normal aging (FEARNLEY and LEES, 1991; Jagust, 2013). This neuronal
population is also susceptible to the age-related neurodegeneration in Parkinson’s
disease (Goedert et al., 2013). The molecular mechanisms underlying the enhanced
vulnerability of dopaminergic neurons of the SN to age-related cell loss and degenerative
disease remains unclear.
Currently, the leading molecular predictor of chronological age is the pattern of
DNA methylation of the C5 position of cytosine at CpG dinucleotide sites, which
outperforms all other biomarkers, such as cell cycle inhibitor p16INK4A expression and
telomere length attrition rate (Benayoun et al., 2015; Sanders and Newman, 2013;
Tsygankov et al., 2009). Quantitative models based solely on methylation patterns are
able to predict an individual’s age with an average error of only 5.2 years (Benayoun et
al., 2015; Bocklandt et al., 2011; Day et al., 2013; Hannum et al., 2013; Maegawa et al.,
2010). DNA methylation is an epigenetic mechanism catalyzed by DNA
methyltransferases (DNMTs) that allows for the adaptability of gene expression in
response to developmental or environmental factors; it plays an essential role in various
biological functions such as regulation of gene transcription and establishment and
maintenance of cellular identity (Jaenisch and Bird, 2003). Historically, DNA
methylation was thought to be a stable, repressive covalent modification in mammalian
cells, existing predominantly as 5-methylcytosine (5mC). However, in 2009, two seminal
papers confirmed the existence of another cytosine modification, 5hydroxymethylcytosine (5hmC), which is formed from the oxidation of 5mC by the teneleven translocation (TET) family of proteins and is generally thought to correlate with
gene activation (Kriaucionis and Heintz, 2009; Tahiliani et al., 2009). It has since been
discovered that 5hmC can be converted to unmodified cytosine (He et al., 2011; Ito et al.,
2011). Thus, environmental influences can lead to changes in DNA methylation levels
and patterns.
Age-associated alterations in DNA methylation vary in absolute number and
genomic loci depending on organ type (Day et al., 2013; Maegawa et al., 2010),
suggesting that different tissues have different rates of changes in DNA methylation over
aging. However, it is unclear whether brain regions vary in the degree of DNA
methylation changes over aging, given the limited studies examining age-related changes
in only a few brain regions. Early chromatography studies found that global 5mC levels
in the whole brain of mice decrease with aging (Sanders and Newman, 2013; Tsygankov
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et al., 2009; Wilson et al., 1987). Recent studies employing bisulfite treatment of DNA,
which allows for genome-wide profiling of DNA methylation (both 5mC and 5hmC,
indistinguishably), from the cortex of human and mouse over aging have generated
different results, with Day and colleagues (Day et al., 2013) finding an increase in DNA
methylation in human cortex using Illumina bead chips that evaluate 26,486 CpG sites
and Lister et al. (Lister et al., 2013) observing stable DNA methylation levels in both the
mouse or human by employing whole-genome sequencing to assess all C sites in the
frontal cortex. Studies focusing on age-related changes in 5mC in the hippocampus of
mice using immunohistochemistry or enzyme-linked immunosorbent assays (ELISAs)
have also produced conflicting results, with one reporting an increase (Chouliaras et al.,
2012b) and another finding no change (Chen et al., 2012), respectively. There are also
contradictory results regarding 5hmC in the hippocampus over aging, with one study
finding no change using a chemical labeling, affinity enrichment approach followed by
sequencing (hMe-Seal) (Szulwach et al., 2011), while two other studies reported an
increase in 5hmC via ELISA (Chen et al., 2012) and immunohistochemistry (Chouliaras
et al., 2012a).
There are various factors contributing to the lack of congruity among studies.
First, different methods have vastly different levels of sensitivity. Second, methods
employing bisulfite treatment cannot distinguish between 5mC and 5hmC (Nestor et al.,
2010), which is a necessary distinction to make given the biological difference between
the two, and therefore, cannot be compared to methods that evaluate 5mC or 5hmC
independently. Lastly, the underlying cellular heterogeneity might account for the
discrepancies observed across brain regions. Given these incongruous findings,
additional research is necessary to determine the extent to which DNA methylation and
hydroxymethylation change with aging in the brain, and whether these changes are brain
region-specific. It is especially important to assess age-associated changes in DNA
methylation in the SN, an area hitherto unexplored, given this region’s enhanced
vulnerability to aging.
Since DNA methylation integrates environmental and developmental signals for
the modulation of transcriptional output, we set out to determine the degree to which
global levels of 5mC and 5hmC differ across two brain regions. We compare the DNA
methylation status of the SN to the dorsal striatum, the region to which dopaminergic
neurons of the SN project (Goedert et al., 2013), to gain insight into the susceptibility of
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the SN to age-related cell death. To address whether changes observed in the SN are
specific to dopaminergic neurons, we performed semiquantitative
immunohistochemistry of 5hmC in tyrosine hydroxylase (TH)-positive, dopaminergic
and parvalbumin (PV)-positive neurons of the SN. Finally, we focused on the regulation
of 5mC and 5hmC to gain insight into the underlying mechanism contributing to the
differences in DNA methylation status over aging between the striatum and SN. First, we
measured the expression levels of enzymes responsible for regulating 5mC and 5hmC,
and secondly, we assessed metabolites that regulate TET function. Our findings suggest
that distinct cellular and molecular environments account for the different DNA
methylation states observed between the striatum and SN over aging, and therefore,
implicate this epigenetic mechanism in the enhanced, age-related vulnerability of this
neuronal population.
Results
Age-related changes in DNA methylation are brain region-specific
We employed reversed-phase HPLC coupled with tandem mass spectrometry
(LC-MS/MS and LC-MS/MS/MS), along with the inclusion of stable isotope-labeled
standards, and carried out accurate measurement of 5mC and 5hmC across aging (P90,
young, and P545, old) from the striatum and SN of male mice. We found that there is no
statistically significant, age-dependent effect on total methylated cytosine (5mC plus
5hmC), total 5mC, or total 5hmC (Figure 1A-C). However, the ratio of 5hmC to 5mC
(5hmC/5mC) shows an age-dependent change, with an effect of age (F1,36=8.358,
p=0.0065) and an interaction effect (F1,36=4.197, p=0.0478), as well as a significant
increase over aging in the SN (~2% increase, p=0.0077), but not the striatum (Figure
1D). 5mC percentage of total methylated cytosine also shows an age-related change, with
an effect of age (F1,36=8.283, p=0.0067) and an interaction effect (F1,36=4.166,
p=0.0486), along with a significant decrease over aging exclusively in the SN (~2%
decrease, p=0.008) (Figure 1E). Additionally, 5hmC percentage of total methylated
cytosine changes over aging, with an effect of age (F1,36=8.283, p=0.0067) and an
interaction effect (F1,36=4.166, p=0.0486), together with an aging-related increase only in
the SN (~2% increase, p=0.008) (Figure 1F).
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Cell type-specific changes in 5hmC across aging in the substantia nigra
Given the brain region-specific changes in DNA methylation observed in the SN
over aging, we subsequently examined the extent to which changes in DNA methylation
are specific to nigral dopaminergic neurons, the cell population that is susceptible to
degeneration with advanced aging. Parvalbumin (PV)-positive neurons of the SN were
used as the comparison group since they are located adjacent to the dopaminergic
neurons, allowing for the control of microenvironmental effects (González-Hernández
and Rodríguez, 2000). Using 5hmC immunostaining, we evaluated the levels of this
epigenetic mark in dopaminergic neurons via co-staining for tyrosine hydroxylase (TH,
an enzyme required for dopamine synthesis) or in PV-positive neurons via costaining for
PV in the SN of young and old mice (Figure 2A-B). Semiquantitative analyses revealed an
increase in 5hmC immunoreactivity in nigral TH-positive, dopaminergic neurons over
aging (p=0.0003), but not in nigral PV-positive neurons (Figure 2C).

Dnmt and Tet expression over aging in the striatum and substantia nigra
Since DNA methylation status is mediated by two families of enzymes, DNMTs
and TETs, we measured mRNA levels of the family members that are highly expressed in
the brain: Dnmt1 and Dnmt3a, which methylate cytosine to 5mC, and Tet2 and Tet3,
which oxidize 5mC to 5hmC. Dnmt1 (p=0.0432) and Dnmt3a (p = 0.0185) expression
significantly increased in the striatum, but not in the SN, over aging (Figure 3A-B). Tet2
and Tet3 expression levels, on the other hand, did not change in either brain region over
aging (Figure 3C-D).

Metabolites in the striatum and substantia nigra across aging
We next investigated the potential contribution of metabolites to the observed
differences in global DNA methylation status between the striatum and SN over aging.
The metabolite α-ketoglutarate (α-KG) is an obligatory cofactor for TET function
(Tahiliani et al., 2009). TETs use molecular oxygen to catalyze oxidative decarboxylation
of α-KG, creating a highly reactive intermediate that converts 5mC to 5hmC, as well as
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generating carbon dioxide and succinate as byproducts (Kohli and Zhang, 2013).
Recently, it was discovered that the intracellular ratio of α-KG to succinate (αKG/succinate) regulates TET activity, which in turn alters DNA methylation levels
(Carey et al., 2015). Therefore, we evaluated the ratio of α-KG/succinate over aging in
both brain regions by using a highly quantitative method that employs gas
chromatography mass spectrometry (GC-MS) and isotope-labeled standards. In addition
to α-KG and succinate, we measured lactate, citrate, and fumarate to ensure that any
differences observed in the α-KG/succinate ratio were not due to changes in metabolite
flux through the mitochondrial tricarboxylic acid cycle. We found that the levels of all
metabolites measured did not statistically differ across aging in either brain region
(Figure 4A-E & G-K). However, we found that although the α-KG/succinate ratio
remained unchanged across aging in the striatum (Figure 4F), it significantly decreased
in the SN (Figure 4L).

Discussion

Although few in number, previous studies suggest that changes in global 5mC
and 5hmC occur in the brain over the aging process (Chen et al., 2012; Chouliaras et al.,
2012a; Day et al., 2013; Lister et al., 2013; Szulwach et al., 2011; Wilson et al., 1987);
however, the findings have been inconsistent, likely due to the inherent differences in
methods detecting 5mC and 5hmC and the brain regions assessed. Given the different
biological functions of 5mC and 5hmC, and the discrepancies regarding age-associated
changes of these two major forms of DNA epigenetic modifications in the brain, we used
a highly sensitive LC-MS/MS and LC-MS/MS/MS method to measure 5mC and 5hmC
levels from the striatum and SN at two different ages (P90, young and P545, old). We
specifically chose the SN given its enhanced vulnerability to aging, and the striatum was
selected as the brain region for comparison since this is the area to which dopaminergic
neurons of the SN project (Goedert et al., 2013).
We found selective changes in these two epigenetic marks over aging in the SN,
but not striatum. Specifically, we observed an increase in the ratio of 5hmC/5mC, which
correlated with a 2% decrease in the 5mC percentage of total methylated cytosine and a
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2% increase in the 5hmC percentage of total methylated cytosine. This suggests that
although the absolute levels of 5mC and 5hmC do not significantly change, the
percentage of sites that are converted from 5mC to 5hmC increases in the SN over aging.
Although a 2% change in DNA methylation seems marginal, this could account for a
change at ~1 million cytosines, given that there are ~50 million cytosines that are
methylated in the mouse genome (Lister et al., 2013), and therefore, the changes
observed are substantial and potentially biologically relevant. When we examined two
neuronal types in the SN, we found a significant increase in 5hmC in the TH-positive,
dopaminergic population, but not in neighboring PV-positive neurons. Despite the
limitation of a small sample size (n=4 per group), these findings suggest that changes in
global levels of 5hmC during aging are both brain region- and cell type-specific. Since
95% of the striatum is composed of GABAergic medium spiny neurons (Tepper and
Bolam, 2004) and since PV-positive neurons of the SN are GABAergic, our findings
suggest that GABAergic neurons maintain their DNA methylation status across aging,
independent of the brain region. This study elucidates a novel age-associated molecular
change in the vulnerable dopaminergic population and indicates that changes in 5hmC
are contingent upon the intracellular molecular environment, rather than extracellular
environment (i.e. brain region).
Therefore, we subsequently examined the molecular environment that could
underlie the difference in DNA methylation status between the striatum and SN over
aging and made two discoveries. First, we found an age-associated increase in both
Dnmts that are highly expressed in the brain, Dnmt1 and Dnmt3a, in the striatum, but
not the SN. It’s plausible that the increase in Dnmts over aging in the striatum
contributes to the stability of the ratio of 5hmC/5mC, unlike the SN. Our second finding
was the decrease in the α-KG/succinate ratio in the SN, but not striatum, albeit with a
small sample size (n=4 for the young group and n=6 for the old group). This suggests
that brain region-specific metabolic changes over aging could contribute to regionspecific changes in DNA methylation. Since we are measuring steady-state levels of the
metabolites, this finding supports a model in which TETs are more active in the SN of
old animals given the relative depletion of the α-KG pool, which is used by TETs to
oxidize 5mC to 5hmC, and an increase in succinate, which is a byproduct of TET activity.
Importantly, this result is consistent with our finding of an increase in the 5hmC/5mC
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ratio over aging in the SN, but not striatum.
Additional research is necessary to define a potentially causative role of the
enzymatic expression and/or metabolic ratio alterations with the age-related differences
in DNA methylation status between the striatum and SN. There are other regulators of
TETs that were not assessed in this work that could also contribute to the brain regionspecific DNA methylation differences across aging, such as iron levels, ascorbic acid
levels, and calpain activity (Blaschke et al., 2013; Tahiliani et al., 2009; Wang and Zhang,
2014; Yin et al., 2013). Additionally, determining the genomic locations of these
methylation changes, and consequential alterations in gene expression (Mellén et al.,
2012a), will aid in elucidating how normal aging predisposes nigral dopaminergic
neurons to cell death.

Conclusions
This work suggests that an increase in TET activity, as indicated by the alteration
in the α-KG/succinate ratio, underlies the selective, age-dependent increase in the ratio
of 5hmC/5mC in the SN. This work also supports that a brain region less susceptible to
aging, like the striatum, is able to employ protective mechanisms, such as increasing
Dnmt expression, to stabilize DNA methylation profiles over aging. Taken together, our
findings suggest that distinct cellular and molecular environments support the different
DNA methylation states observed between the striatum and SN over aging, and
specifically within dopaminergic neurons, implicating this epigenetic mechanism in the
enhanced vulnerability of this neuronal population in aging.

Summary Points

•

There are age-associated changes in DNA methylation in the substantia nigra, but
not striatum.
o

Aging did not significantly affect any of the DNA methylation parameters
assessed in the striatum.
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o

In the substantia nigra, on the other hand, the ratio of 5hmC/5mC
significantly increases over aging, suggesting that although the absolute
levels of 5mC and 5hmC do not significantly change, the percentage of
sites that are converted from 5mC to 5hmC increases.

•

There is a selective increase in 5hmC over aging in tyrosine hydroxylase-positive
dopaminergic neurons, but not parvalbumin-positive neurons, of the substantia
nigra.
o

Our results indicate that changes in 5hmC over aging are cell typedependent and contingent upon the intracellular molecular environment,
rather than the extracellular environment (i.e. brain region).

•

There is an age-dependent increase in Dnmt expression in the striatum, but not
substantia nigra.
o

In the substantia nigra over aging, Tet2, Tet3, Dnmt1, and Dnmt3a mRNA
levels remain unchanged.

o

In the striatum, although Tet2 and Tet3 mRNA levels are stable across
aging, Dnmt1 and Dnmt3a levels increase, suggesting that an increase in
Dnmts contributes to the stability of the ratio of 5hmC/5mC over aging,
unlike the substantia nigra.

•

We found a substantia nigra-selective reduction in the α-KG to succinate ratio
over aging.
o

Although the α-KG/succinate ratio remains unchanged across aging in the
striatum, it significantly decreases in the substantia nigra.

o

Since we are measuring steady-state levels of the metabolites, this finding
supports a model in which TETs are more active in the substantia nigra of
old animals given the relative depletion of the α-KG pool, which is used by
TETs to oxidize 5mC to 5hmC, and an increase in succinate, which is a
byproduct of TET activity.

•

Conclusion
o

Our findings suggest that distinct cellular and molecular environments
account for the different DNA methylation states observed between the
striatum and substantia nigra over aging, and therefore, implicate this
epigenetic mechanism in the enhanced vulnerability of this neuronal
population over aging.
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Materials and Methods
Animal tissue
All experiments were performed according to protocols approved by the
Institutional Animal Care and Use Committee of the University of Pennsylvania. All mice
were on the C57BL/6 genetic background. Tissues from healthy young male animals
were collected at postnatal day 90 (P90), and tissues from healthy old male animals were
collected at P545. Bilateral dorsal striatum and substantia nigra samples were collected
as previously described (Salvatore et al., 2012; Spijker, 2011). Briefly, a mouse brain
matrix (ASI-instruments) was used to coronally section the brain. Bilateral dorsal
striatum collection started rostrally when the anterior portion of the anterior
commissure crosses the midline (Bregma 0.20mm) and ended caudally with the loss of
the connection between the dorsal 3rd ventricle and the lateral ventricles (Bregma 0.58mm). Bilateral SN collection started rostrally when the hippocampus completely
wraps around the midbrain (Bregma -2.92mm) and ended caudally with the
disappearance of distinct blades of the dentate gyrus (Bregma -3.64mm).
Reverse-phase HPLC coupled with tandem mass spectrometry
LC-MS/MS and MS/MS/MS measurements of 5mC and 5hmC were performed
blind to age and brain region. DNA was isolated using an AllPrep DNA/RNA Micro Kit
(Qiagen) and treated with RNase (Roche). DNA (1 µg) was then treated with nuclease P1
(0.5 U) and phosphodiesterase 2 (0.00025 U) at 37°C for 48 hr in a digestion buffer (30
mM sodium acetate, 1.0 mM zinc acetate, 1 mM EHNA, pH 5.6), followed by the addition
of alkaline phosphatase (0.05 U) and phosphodiesterase 1 (0.0005 U) in another buffer
(50 mM Tris-HCl, pH 8.9) for 2 hr. For MS quantification of 5-hydroxymethyl-2ʹdeoxycytidine (5hmC) and 5-methyl-2ʹ-deoxycytidine (5mC), 50 fmol of [1,3-15N2-2ʹ-D]5hmC and 600 fmol of [1ʹ,2ʹ,3ʹ,4ʹ,5ʹ-D5]-5mC were added to the digestion mixture of 50
ng genomic DNA. Enzymes were removed by chloroform extraction. The resulting
aqueous layer was subjected to LC-MS/MS and MS/MS/MS analyses on an LTQ linear
ion-trap mass spectrometer (Thermo Fisher Scientific, San Jose, CA) that was equipped
with an electrospray ionization interface and coupled to an Agilent 1200 capillary HPLC
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(Agilent Technologies, Santa Clara, CA). Separation was carried out on a 0.5 × 250 mm
Zorbax SB-C18 column (5 µm in particle size, Agilent Technologies, Santa Clara, CA)
with a flow rate of 8.0 µL/min. A solution of 2 mM sodium bicarbonate (pH 7.0, solution
A) and methanol (solution B) were used as mobile phases and a gradient of 5 min 0-20%
B and 25 min 20-70% B was employed for the separation. MS settings were as follows:
electrospray voltage, 5 kV; capillary temperature, 275°C; capillary voltages, 38 V; tube
lens voltages, 60 V; sheath gas flow rate, 15 arbitrary units. Selected-ion chromatograms
were plotted for monitoring the transitions of m/z 258à142à124 for 5hmC, m/z
261à144à126 for [1,3-15N2, 2ʹ-D]-5hmC, m/z 242à126 for 5mC, and m/z 247à126 for
[1ʹ,2ʹ,3ʹ,4ʹ,5ʹ-D5]-5mC. The calibration curve for 5hmC and 5mC was constructed
previously (Liu et al., 2015; 2013). The numbers of moles of 2ʹ-deoxyguanosine (dG),
5mdC, and 5hmC in each sample were calculated from the peak area ratios, the
calibration curves, and the amounts of stable isotope-labeled standards added. 5mC and
5hmC were then calculated as the percentage of dG (% dG) by dividing the moles of 5mC
or 5hmC, respectively, by the moles of dG. Total methylated cytosine was calculated by
adding 5mC (% dG) and 5hmC (% dG) per sample, the ratio of 5hmC to 5mC was
calculated by dividing 5hmC (% dG) by 5mC (% dG), 5mC percentage of total methylated
cytosine was calculated by dividing 5mC (% dG) by total methylated cytosine, and 5hmC
percentage of total methylated cytosine was calculated by dividing 5hmC (% dG) by total
methylated cytosine. The sample size is 10 animals per group (n=10 bilateral young
striatum samples, n=10 bilateral old striatum samples, n=10 bilateral young SN samples,
and n=10 bilateral old SN samples). To reduce biological variation, the striatum and SN
samples were taken from the same animal. Additionally, RNA was taken from these same
tissue samples for the quantitative RT-PCR, and therefore, a total of 10 old and 10 young
animals (20 animals total) were used for the reverse-phase HPLC coupled with tandem
mass spectrometry and quantitative RT-PCR experiments.
Semiquantitative Immunohistochemistry
Mice were anesthetized with 1.25% Avertin, transcardially perfused with 4%
paraformaldehyde in PBS, and postfixed with 4% paraformaldehyde in PBS overnight at
4°C. Immunohistochemistry was carried out on 20 µm free-floating sections as
previously described (Liao et al., 2008).Tissue sections from the SN (see animal tissue
section above for the Bregma coordinates of the SN) were incubated with a 5hmC
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antibody (1:1000, Active Motif (39791)) in blocking solution overnight at 4°C. The next
day, the tissues were removed from the 5hmC antibody solution and incubated with
either a tyrosine hydroxylase (TH) antibody (1:1000, Abcam (ab76442)) or a
parvalbumin (PV) antibody (1:1000, Millipore (mab1572)) for 1 hr at 22-24°C.
Fluorescence detection of 5hmC was performed using Alexa Fluor 488 (1:1000,
Invitrogen) and of TH or PV using Alexa Fluor 594 for 1 hr at 22-24°C. Images were
captured and subsequently analyzed blind to age (the marked differences in neuronal
morphology prevent blinding of neuronal cell types). Images were captured using a Leica
confocal microscope with identical settings for laser power, detector gain amplifier
offset, and pinhole diameter for each channel for TH-positive neurons across both ages,
and the same for PV-positive neurons. TH-positive and PV-positive neurons were
analyzed from the same biological samples, with 4 animals in the young group and 4
animals in the old group. 38 bilateral TH-positive neurons and 15 bilateral PV-positive
neurons were analyzed per animal, giving a total of 152 TH-positive and 60 PV-positive
neurons that were analyzed at each age. 5hmC fluorescence was measured using ImageJ
as previously described (Burgess et al., 2010). Briefly, the free form tool was used to
calculate the area and integrated density of 5hmC for each TH-positive or PV-positive
neuron with a nucleus in focus. The freeform tool was then used to measure the mean
fluorescence of three background regions in close proximity to the 5hmC measured
(three regions were selected to improve accuracy). Each of the three background
readings was multiplied by the area of the 5hmC tracing to give an integrated density of
each of the three background readings dependent upon the size of the 5hmC tracing.
These calculated integrated densities were then averaged and subtracted from the
integrated density of the 5hmC tracing to get the corrected 5hmC fluorescence.
Quantitative RT-PCR
Total RNA was isolated using an AllPrep DNA/RNA Micro Kit (Qiagen) and
treated with DNase (Qiagen). Total RNA (400 ng) was reverse transcribed by oligo-dT
priming using SuperScriptIII reverse transcriptase (Invitrogen). Quantitative real-time
PCR was performed on the resulting cDNA using Taqman Probes with primer pairs that
are exon-spanning. All mRNA levels of genes of interest were normalized to Hprt mRNA
levels. The sample size was 10 animals per group (see LC-MS/MS and MS/MS/MS
methods section above for more details).
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Mass spectrometry for the measurement of metabolites
Concentrations of metabolites were determined blind to age and brain region by
the Metabolomics Core at The Children’s Hospital of Philadelphia, using a previously
described isotope dilution approach (Nissim et al., 1996; Weinberg et al., 2000). Briefly,
an aliquot of the sample was spiked with a mixture of 13C-labeled organic acids. GC-MS
measurement of 13C isotopic abundance in each sample was then performed.
Concentrations of metabolites in the sample were calculated as previously described
(Nissim et al., 1996). 4 animals are in the young striatum group, 4 animals are in the
young SN group, 6 animals are in the old striatum group, and 6 animals are in the old SN
group. The striatum and SN samples were taken from the same animal, and therefore, 10
animals in total were used for this analysis.
Statistics
Statistics were performed using Prism 6.0 (GraphPad Software) and RStudio.
The D’Agostino & Pearson omnibus normality test was used to test normality (p > 0.05),
and the F-test was used to test for equal variances (p > 0.05). The individual statistical
tests performed for each experiment can be found in the figure legends
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Figures
Figure 1

Figure 1: Age-associated changes in global DNA methylation levels over
aging in the substantia nigra, but not striatum. Measurement of global total
methylated cytosine (5mC plus 5hmC; Kruskal-Wallis rank sum test) (A), 5mC (KruskalWallis rank sum test) (B), 5hmC (Kruskal-Wallis rank sum test) (C), the ratio of 5hmC to
5mC (two-way ANOVA with pairwise comparisons with Bonferroni correction, **p<0.01)
(D), 5mC percentage of total methylated cytosine (two-way ANOVA with pairwise
comparisons with Bonferroni correction, **p<0.01) (E), and 5hmC percentage of total
methylated cytosine (two-way ANOVA with pairwise comparisons with Bonferroni
correction, **p<0.01) (F) by LC-MS/MS and LC-MS/MS/MS across aging in the two
brain regions. Solid bars indicated the young cohort and dotted bars indicate the old
cohort (mean ± SEM; n = 10 per group; dG, 2ʹ-deoxyguanosine; 5mC, 5-methylcytosine;
5hmC, 5-hydroxymethylcytosine)
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Figure 2

Figure 2: Selective increase in 5hmC over aging in tyrosine hydroxylasepositive dopaminergic neurons, but not parvalbumin-positive neurons, of
the substantia nigra. Immunohistochemistry in substantia nigral sections of young
and old mice showing 5hmC (green) in tyrosine hydroxylase (TH)-positive,
dopaminergic neurons (red) (A) and 5hmC in parvalbumin (PV)-positive neurons (red)
(B). Cells that were analyzed are marked with an arrow. (C) Quantification of 5hmC
fluorescence intensity in young and old PV-positive and TH-positive, dopaminergic
neurons. Solid bars indicated the young cohort and dotted bars indicate the old cohort
(mean ± SEM; n=152 neurons from 4 animals (38 neurons per animal) for TH-positive,
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dopaminergic neurons per age group; n=60 neurons from 4 animals (15 neurons per
animal) for PV-positive neurons per age group; ***p = 0.0003; Dunn’s multiple
comparisons test; TH, tyrosine hydroxylase; PV, parvalbumin; 5hmC, 5hydroxymethylcytosine).
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Figure 3

Figure 3: An age-dependent increase of Dnmt expression is specific to the
striatum. Relative changes in mRNA levels of Dnmt1 (striatum, two-tailed t-test with
Welch’s correction; SN, two-tailed t-test) (A), Dnmt3a (striatum, Mann-Whitney test;
SN, two-tailed t-test with Welch’s correction) (B), Tet2 (two-tailed t-test) (C), and Tet3
(striatum, two-tailed t-test; SN, two-tailed t-test with Welch’s correction) (D) as
measured by quantitative RT-PCR with the young group serving as the reference for each
brain region. Solid bars indicated the young cohort and dotted bars indicate the old
cohort (mean ± SEM; n = 10 per group; *p < 0.05).
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Figure 4

Figure 4: Decrease in the α-KG to succinate ratio in the substantia nigra, but
not striatum, over aging. Quantification of lactate (two-tailed t-test) (A & G), citrate
(two-tailed t-test) (B & H), fumarate (two-tailed t-test with Welch’s correction) (C & I),
α-KG (two-tailed t-test) (D & J), succinate (two-tailed t-test) (E & K), and α-KG to
succinate ratio (two-tailed t-test) (F & L) as measured by mass spectrometry with
isotope-labeled standards. Solid bars indicated the young cohort and dotted bars
indicate the old cohort (mean ± SEM; n = 4 for young group and n = 6 for old group; *p
< 0.05; α-KG, α-ketoglutarate)
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APPENDIX PART 2

Tet and 5hmC in Neurodevelopment and the Adult Brain

One Sentence Summary
This review, which summarizes the importance of 5hmC and TETs in neuronal function,
is a book chapter published in “DNA Modifications in the Brain: Neuroepigenetic
Regulation of Gene Expression.”

Keywords
5-hydroxymethylcytosine, 5hmC, Tet, Tet1, Tet2, Tet3, neurodevelopment, adult,
methylation, brain

Abstract
Since the discovery in 2009 that 5-hydroxymethylcytosine (5hmC) is remarkably
high in the brain, much effort has been put into understanding the role of this epigenetic
mark in neuronal function. With the advent of various approaches for the detection of
5hmC, in less than a decade, the field has gained invaluable insight into the role of 5hmC
in gene regulation, neurodevelopment, neurogenesis, differentiation, and
electrophysiological and circuit properties. Parallel to these advances has been the
substantial gain of knowledge for the functional role of the enzymes that convert 5methylcytosine (5mC) to 5hmC, the ten-eleven translocation family of enzymes (Tet1,
Tet2, and Tet3; Tets), in neuronal processes. Various knockout/knockdown and
overexpression techniques have been employed against Tets, implicating these enzymes
in maintaining and establishing 5hmC patterns, hippocampal function, differentiation,
and electrophysiological properties. Here we summarize the current understanding of
5hmC and Tets in the developing and adult brain.
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Introduction
DNA methylation at the 5-carbon of cytosine (C) is widely distributed throughout
the mammalian genome, with 5% of all C and 85% of all cytosine-phosphate-guanine
dinucleotides (CpGs) being methylated (Lister et al., 2013). Such methylation plays an
essential role in various biological functions such as the regulation of gene transcription,
establishment and maintenance of cellular identity, imprinting, silencing of transposons
and repetitive elements, and X-chromosome inactivation (Jaenisch and Bird, 2003).
Historically, DNA methylation of C was thought to be a stable covalent modification,
existing exclusively as 5-methylcytosine (5mC). However, this view was challenged in
2009 when two seminal papers published in parallel described another C modification,
5-hydroxymethylcytosine (5hmC), which is formed from the oxidation of 5mC
(Kriaucionis and Heintz, 2009; Tahiliani et al., 2009). Tahiliani et al. also described
enzymes that were able to convert 5mC to 5hmC, the ten-eleven translocation family of
enzymes, or Tet enzymes. These enzymes were found to be paralogues of the base J
binding proteins (JBP) from the parasite Trypanosoma brucei. However, instead of
converting the base thymine to 5-hydroxymethyl-uracil, as JBP enzymes do, Tet enzymes
convert modified cytosines to 5hmC (Tahiliani et al., 2009).
Since its rediscovery in 2009, 5hmC has added an important dimension in
understanding the epigenetic regulation of neuronal function (Kriaucionis and Heintz,
2009; Penn et al., 1972; WYATT and COHEN, 1953). The particular importance of 5hmC
in the brain is highlighted by the fact that while global 5mC levels are similar across
different tissue types, levels of 5hmC are highly variable with the highest concentration
in the central nervous system (CNS) (Globisch et al., 2010; Kriaucionis and Heintz,
2009; Münzel et al., 2010). Notably, all mature neurons in the central nervous system
are post-mitotic, meaning that they no longer divide. While it was previously known that
5mC could be passively removed through cell division, the discovery of Tet enzymes
meant that 5mC could be actively removed via oxidation of Tets to 5hmC, and this could
occur in post-mitotic cells. Further, 5hmC can also be removed, completely reverting the
base back to unmodified C. Removal of 5hmC occurs first via iterative oxidation by the
Ten-eleven translocation family of proteins (Tet1, Tet2, and Tet3, collectively referred to
as Tets) which convert 5hmC to 5-formylcytosine (5fC), and subsequently to 5carboxylcytosine (5caC) (Ito et al., 2011). Finally, 5caC is converted to C by thymine
153

DNA-glycosylase (TDG)-mediated base excision repair (BER) (He et al., 2011) (Figure
1). Therefore, it has been called into question whether 5hmC is a mere transient,
uninformative byproduct of DNA demethylation or a stable, purposeful epigenetic mark
with biological functional significance. Throughout this chapter, we will highlight recent
findings that have greatly advanced our understanding of the role of 5hmC in brain.

Global 5hmC and Tet expression throughout the adult brain
To gain a better understanding of the biological function of 5hmC, initial studies
interrogated the levels of 5hmC in various tissues using isotope-based liquid
chromatography-mass spectrometry (LC-MS). It has been unanimously found that
although this mark is present throughout the body, 5hmC levels are markedly higher in
the nervous system than other tissues. 5hmC concentrations in the central nervous
system are brain region-specific: 5hmC constitutes 0.7% of cytosine (C) bases in the
cortex and hypothalamus; 0.6% in the brainstem, olfactory bulb, and hippocampus;
0.5% in the spinal cord; 0.4% in the midbrain; and 0.3% in the cerebellum (Globisch et
al., 2010; Kriaucionis and Heintz, 2009; Münzel et al., 2010). For comparison, tissues
with the next closest levels of 5hmC, ranging from 0.15-0.17%, are the kidney, nasal
epithelium, bladder, heart, muscle, and lung. In the pituitary gland, a non-neuronal
structure at the base of the brain, 5hmC constitutes only 0.06% of total C, which
supports that high concentrations of 5hmC are specific to neural tissues, rather than
topographic location (Globisch et al., 2010). Further support of high levels of 5hmC
being specific to neurons comes from a comprehensive genome-wide study that found
5hmC levels are higher in neuronal than in non-neuronal cell types within the frontal
cortex (Lister et al., 2013).
It remains unknown what accounts for the high levels of global 5hmC within the
brain as compared to other tissues. Since Tets are expressed at similar levels in other
tissue with much lower 5hmC levels, overall expression levels of this family of proteins
cannot account for the difference. It also remains to be determined what accounts for the
differences in 5hmC levels across brain regions. Although the cortex, hippocampus, and
cerebellum have vastly different 5hmC levels that range from 0.7-0.3% of total C, the
regions have similar Tet expression levels (Szwagierczak et al., 2010). It’s possible that
brain region-specific levels of 5hmC are dependent upon the relative levels of Tet154

dependent cofactors, iron and alpha-ketoglutarate (a-KG) (Tahiliani et al., 2009), or
other potential regulators, such as ascorbic acid, calpain, succinate, and fumarate. In
embryonic stem cell (ESC) culture, supplementation of ascorbic acid decreased the levels
of 5mC and increased levels of 5hmC (Blaschke et al., 2013; Wang and Zhang, 2014; Yin
et al., 2013). This has unique implications for Tet activity in the brain, since the brain has
the highest levels of ascorbic acid in the body, mostly due to high expression of the
ascorbic acid-specific transporter SVCT2 (Lin JACS 135 2013). More research is this area
is warranted to elucidate what controls the levels of 5hmC.
In addition to brain region-specificity, global 5hmC levels are also cell typespecific and developmentally dependent. The cell type-specificity of 5hmC was noted in
the paper that rediscovered it in 2009 with the description that 5hmC constitutes 0.6%
of total CpGs in Purkinje neurons, but only 0.2% of granule cells (Kriaucionis and
Heintz, 2009). This has been confirmed by an independent group that found that the
levels and genomic distribution of 5hmC vary across Purkinje cells, granule cells, and
Bergmann glia of the cerebellum (Mellén et al., 2012b). The establishment of these cell
type differences in 5hmC levels in the brain occurs between embryonic day 12.5 and 13.5,
which is the time at which active specification of neurons and glial cells commences,
supporting that the 5hmC is important for neuronal identity (Wheldon et al., 2014). The
rapid increase in global 5hmC during neuronal differentiation and synaptogenesis also
highlights the developmental importance of this epigenetic mark in the brain (Hahn et
al., 2013; Song et al., 2011; Szulwach et al., 2011).
In the adult mouse (10-12 wk) brain, neuronal activity can also lead to changes in
global 5hmC. When neuronal activity is increased via flurothyl induced seizures, there is
a significant reduction in 5mC and 5hmC in area CA1 of adult mice at 24 hours after the
occurrence of seizures (Kaas et al., 2013). This differs from the dentate granule cells in
that synchronous activation of dentate granule cells in the adult mice by
electroconvulsive stimulation or voluntary running does not lead to a global change in
methylation, as there are similar number of CpGs that become methylated and
demethylated under these conditions as assessed by methyl-sensitive cut counting
(MSCC) method (Guo et al., 2011a).
These findings on the global 5hmC patterns throughout the brain and other
tissues suggest that 5hmC might be especially important in neuronal function and
identity. However, to truly unravel the biology of 5hmC, determining the genomic
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location of this epigenetic mark and its effect on gene expression is necessary, which will
be discussed in the following section.

The Genomic Distribution of 5hmC
Recent advances in sequencing have allowed for the mapping of the genomic
distribution of 5hmC in the brain, providing invaluable insight into the biological
function of this epigenetic mark. Various affinity- and enzyme-based methods have been
developed for profiling 5hmC genome wide, with the three most commonly used
approaches. First is 5-hmC selective chemical labeling (5hmC-Seal) in which 5hmC is
converted to biotin-N3-5-hydroxymethyl-cytosine (Biotin-N3-5-gmC) for affinity
enrichment through a two step synthesis (Song et al., 2011). Second is
hydroxymethylated DNA immunoprecipitation in which 5hmC is enriched via antibodies
that specifically bind to 5hmC (Jin et al., 2011). The third is Tet-assisted bisulfite
sequencing (TAB-Seq) in which 5hmC is exclusively protected via glycosylation and Tetmediated oxidation before bisulfite treatment (Yu et al., 2012b).
With the employment of these approaches, general features have emerged.
Quantitatively, intragenic and global 5hmC levels are equivalent across chromosomes in
both human and mouse, except for the male ChrX, which has 22% lower enrichment
(Lister et al., 2013; Mellén et al., 2012b; Szulwach et al., 2011). 5hmC is predominantly
found in CpGs in both the human and mouse across development (Lister et al., 2013;
Wen et al., 2014). In the fetal mouse brain, 5% of CpGs and 0% of non-CpGs (CH, where
H = A, C, or T) are hydroxymethylated, whereas in the adult mouse frontal cortex (6 wk),
hydroxymethylation occurs at 19% of CpGs and 0.02% of CHs. This epigenetic mark is
found across transcriptional end sites, intragenic regions, DNaseI-hypersensitive sites
(DHSs), and enhancers (Lister et al., 2013). It is present at both poised enhancers (solely
marked by distal H3K4me1) and active enhancers (marked by distal H3K4me1 and
H3K27ac), with poised enhancers constituting 32.6% of all 5hmC sites and active
enhancers constituting 28.6%. Major satellite and promoter regions, on the other hand,
are relatively devoid of 5hmC (Wen et al., 2014). Most 5hmC (71%) is found
intragenically, with a much higher concentration at exons than introns (Szulwach et al.,
2011). These findings on the genomic distribution of 5hmC implicate that it may play a
role in gene regulation.
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Given the relatively high enrichment of 5hmC across exons, and the proposed
hypothesis that methylation modulates alternative splicing (Maunakea et al., 2013),
studies have evaluated the role of this epigenetic mark in splicing. 5hmC appears to play
an important role in alternative exon usage in the mammalian brain, as there is a distinct
pattern of methylation at exon-intron boundaries. Firstly, there is a sharp decrease in
5hmC at the 5’ end of the intron at the exon-intron boundary. Secondly, across exons
from 5’ to 3’, there is a substantial increase in 5mC levels and a less pronounced decrease
in 5hmC (Khare et al., 2012b; Wen et al., 2014). Thirdly, 5hmC levels, but not 5mC
levels, within 20 basepairs of the exon-intron boundary correlate with constitutively
used exons relative to alternatively spliced exons. The importance of these features in
alternative exon usage rather than general transcription is highlighted by the fact that
first exons have much lower 5mC and 5hmC than internal exons and that exons of
intron-less or single-exon genes have lower 5hmC than multiple-exon genes (Khare et
al., 2012b). This feature seems to be specific to brain tissue since neither 5mC nor 5hmC
correlate with exon usage in the liver. Thirdly, flanking the highly conserved “GT” splice
site sequence at the 5’ splicing sites (5’ ss) of internal exons, at the -1 and -2 positions on
the exon side and +4 and +5 positions of the intron side of the exon-intron boundary, are
two prominent 5hmC peaks. 5mC, on the other hand, does not exhibit this type of
pattern in the brain (Khare et al., 2012b; Wen et al., 2014). This patterning of 5hmC at
the 5’ ss seems to brain-specific as 5mC, rather than 5hmC, marks exon-intron
boundaries in the liver (Khare et al., 2012b). Further examination of alternatively spliced
(AS) exons by RNA-seq, it was found that low or no methylation flanking the 5’ ss is
associated with significantly more exon skipping than methylated or hydroxymethylated
boundaries. This suggests that demethylation is associated with alternative splicing
events, which is consistent with the idea that DNA 5hmC aids in exon recognition and
inclusion (Khare et al., 2012b; Maunakea et al., 2013; Wen et al., 2014).
In addition to the correlation of 5hmC in exon usage, there is also a stronger
correlation between intragenic 5hmC levels and gene expression in both main cell types
of the brain, neurons and glia (Lister et al., 2013; Mellén et al., 2012b; Song et al., 2011).
5mC levels across the gene body, on the other hand, negatively correlate with gene
expression (Lister et al., 2013; Mellén et al., 2012b; Wen et al., 2014). The best correlate
with gene expression is the intragenic ratio of 5hmC to 5mC (5hmC/5mC). This
correlation extends to the tissue-specific and cell subtype-specific level, with a relatively
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high 5hmC/5mC ratio correlating with brain region-specific and cell type-specific
differentially expressed transcripts (Lister et al., 2013; Mellén et al., 2012b). When the
5hmC genomic distribution and expression profiles of three different cell types of the
cerebellum (Purkinje cells, granule cells, and Bergmann glia) were compared, it was
found that cell type-specific transcripts have higher intragenic 5hmC/5mC levels than
the other cell types (Mellén et al., 2012b). This cell-type specific patterning also hold true
across neuronal differentiation as cell type-specific genes that are developmentally
regulated gain intragenic 5hmC and lose intragenic 5mC across differentiation (Colquitt
et al., 2013).
There is also a significant difference between 5hmC and 5mC for strand bias of
expressed genes in both glia and neurons. When comparing the lowest to the highest
expressed genes, there is a seven-fold bias in 5hmC enrichment on the sense strand and
a five-fold bias in 5mC enrichment on the antisense strand. These findings suggest that
5hmC enrichment on the sense strand is correlated with activation. In agreement with
this is the finding that 5hmC is inversely related to two repressive histone modifications,
H3K27me3 and H3K9me3. On the other hand, these two histone modifications correlate
with 5mC (Wen et al., 2014). Genes enriched for 5hmC in the mammalian brain relative
to other tissues are synapse-related (Khare et al., 2012b). These findings highlight the
importance of 5hmC in the activation of genes specific to the brain, neuronal subtypes,
and neuronal function.
While 5hmC levels correlate highly with gene expression, it is unknown how this
is accomplished. In other words, what are the mechanisms that allow 5hmC to influence
or be influenced by gene expression? It is hypothesized that there are specific proteins
that are able to bind 5hmC and influence gene expression through binding to additional
protein complexes or initiating a signaling cascade(s). The first paper to inquire into
what proteins can bind 5hmC used quantitative mass spectrometry (MS)-based
proteomics. They used fragments of DNA that contained 5hmC to isolate interacting
proteins from mouse ESCs and analyzed the resulting proteins using LC-MS/MS. They
identified a large number of potential 5hmC interacting proteins, most notably Mpg and
Neil3, DNA glycosylases that, like TDG, may participate in the active DNA demethylation
pathway to convert 5hmC to unmodified C via BER. Interestingly, they found proteins
that had previously been uncharacterized, such as Wdr76. By purifying Wdr76 they
identified Wdr76-interacting proteins, including a DNA helicase that is thought to
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regulate DNA methylation levels (Hells, or Lsh) and a protein that binds H3K4me3
(OCR, or Spindlin-1). Looking at adult mouse brain cells, they confirmed the interaction
of 5hmC with Wdr76 and Thy28. A brain-specific 5hmC interaction was found with
Thap11 or Ronin, which is highly expressed in Purkinje cells. Additionally, they found
that the proteins thymocyte nuclear protein 1 (Thy28), ubiquitin-like with PHD and Ring
finger domains (Uhrf1), and methyl-CpG- binding protein 2 (MeCP2) bind to both 5mC
and 5hmC, although MeCP2 binds to 5mC with much higher affinity. The authors
conclude that 5hmC is an active intermediate in DNA demethylation and may be
involved in global epigenetic regulation (Spruijt et al., 2013).
However, the binding of MeCP2 to 5hmC is a contentious finding. Previous in
vitro studies found that conversion of 5mC to 5hmC abolished binding of MeCP2 to
oligonucleotide sequences (Valinluck et al., 2004). Another study compared the affinity
of Uhrf1 and MeCP2 to modified DNA in vitro, and found that Uhrf1 had a similar
affinity for 5mC and 5hmC, while MeCP2 had a greater affinity for 5mC, as Spruijt et al.
showed (Frauer et al., 2011; Spruijt et al., 2013). Similarly, yet another independent
group found that although MeCP2 is able to bind 5hmC, the affinity is 20 fold less than
that of 5mC (Khrapunov et al., 2014). On the other hand, Mellén et al. reported that
MeCP2 binds 5mC and 5hmC with similar affinity and that a Rett-associated mutation in
MeCP2 causes the disruption of its binding preferentially to 5hmC in vitro (Mellén et al.,
2012a). Additionally, Baubec et al. found that MeCP2 localization correlates with 5hmC
in embryonic stem cells (Baubec et al., 2013). Further confounding results come from
two studies addressing the affects of MeCP2 on levels of 5hmC in vivo (Mellén et al.,
2012a; Szulwach et al., 2011). Szulwach et al. showed that decreased levels of MeCP2
correlated with higher levels of 5hmC, and overexpression of MeCP2 revealed a decrease
in 5hmC in the cerebellum (Szulwach et al., 2011). On the other hand, Mellén et al.
reported that loss of MeCP2 results in a small, but significant, decrease in 5hmC levels
(Mellén et al., 2012a). Together, these findings suggest that further research is warranted
to determine whether MeCP2 is a bona fide binding partner of 5hmC in vivo.
The Role of 5hmC in brain development
Across brain development in both the human and mouse, 5hmC levels increase,
with the adult human prefrontal cortex containing tenfold more 5hmC than the fetal
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brain (Lister et al., 2013; Wen et al., 2014). In the adult (6 wk mouse), high levels of
5hmC are found across enhancer, transcriptional end sites, intragenic, and DNaseIhypersensitive (DHS) regions. In the fetus, on the other hand, enrichment of 5hmC is
primarily in DHS regions and enhancer regions that are unique to fetal development
(Lister et al., 2013). Many of the gene bodies that gain 5hmC enrichment in the adult
stage also have 5hmC present at the fetal stage, albeit at much lower levels. This implies
that the cell type-specific increase in 5hmC observed over development occurs at
intragenic regions that were partially established at the fetal stage. Although 5hmC levels
of the fetal brain are much lower than those of the adult brain across all genomic
features, there are numerous CpGs in which hydroxymethylation is higher in the fetal
brain. These Fetal > Adult hydroxymethylated CpGs are enriched at enhancers (Lister et
al., 2013; Wen et al., 2014). Developmentally downregulated genes have high levels of
gene body 5hmC at the fetal stage, but not at the adult stage (Lister et al., 2013). Regions
that have significantly higher hydroxymethylation in the fetal frontal cortex than the
adult are dormant regions poised for demethylation and activation over development in
both the mouse and human (Lister et al., 2013; Wen et al., 2014). Analysis of these
developmentally-dependent, differentially hydroxymethylated regions in adult Tet2-/mice revealed that these 5hmC-poised loci are dependent upon Tet2 activity (Lister et al.,
2013). These findings suggest a key role of 5hmC in brain development that is conserved
across mammals.
5hmC marks both developmentally dependent (P7, 6 wk, and 1 year mice) and
brain region-specific (hippocampus compared to cerebellum) loci. When brain regionspecific differentially hydroxymethylated loci were evaluated across development, it was
found that 5hmC marks region-specific genes during early development (at P7 or earlier)
to facilitate in region-specific transcriptional programs. These tissue-specific
differentially hydroxymethylated regions are enriched for a 21-nucleotide motif that
might be critical for regulating specific gene expression programs. 5hmC regulated
regions across development within mouse cerebellum and hippocampus revealed that
some loci are stable (5hmC acquired during P7 and maintained through 1 year of age),
whereas others are dynamic (5hmC is not present at all time points). When repeat
elements were assessed across development, it was found that, in both mouse
hippocampus and cerebellum, 5hmC enrichment increases at short interspersed nuclear
elements (SINEs) and long tandem repeats (LTRs) and decreases in long interspersed
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nuclear elements (LINEs) and satellites. In P7 cerebellum, but not adult, 5-hmC is
associated with the transcriptional start site (TSS) of genes with low expression. This can
be explained by the fact that at this stage, a significant amount of progenitors cells are
present, which is in line with the finding in mouse and human ES cells in which 5hmC is
enriched at the TSS of repressed, but developmentally poised, genes. At developmentally
activated genes, there is an increase in intragenic 5hmC, while at developmentally
repressed genes, there is only a small decrease in 5hmC across the gene body (Szulwach
et al., 2011). These findings highlight the importance of 5hmC in brain development.
5hmC changes associated with neuronal differentiation
In addition to developmentally-dependent changes in 5hmC, alterations in this
epigenetic mark also occur across neuronal differentiation as assessed by comparing the
genomic distribution of 5hmC in neural progenitor cells (NPCs) in the subventricular
zone to that of maturing neurons of the cortical plate in E15.5 mice. In NPCs and
maturing neurons alike, there is an absence of 5hmC at enhancers and enrichment at
promoters and gene bodies. Over differentiation there is an increase in 5hmC (but not
5mC), which is primarily intragenic. As typically found, intragenic 5hmC correlate
transcription in both progenitors and mature neurons, however this association is more
pronounced in maturing neurons. Genes that gain intragenic 5hmC are associated with
neuronal differentiation and axonogenesis. Genes with the highest increase in 5hmC
over differentiation did not show an increase in demethylation, indicating the stability of
this epigenetic mark. Concomitant with the increase in intragenic 5hmC during neuronal
differentiation at activated genes, is a gain of H3K4me3 at the promoter and a loss of
H3K27me3 in gene bodies and promoters. Tet2 or Tet3 may play a role in neurogenesis
since knockdown of their expression via electroporation of shRNAs lead to defects in the
progression of differentiation (Hahn et al., 2013).
Similar changes in 5hmC over neuronal differentiation also occurs in the
olfactory sensory neuron (OSN) differentiation as there is an increase in 5hmC from the
horizontal basal cell (HBC) stage to the globose cell basal cell (GBC) to mature olfactory
sensory neurons (mOSNs). Similar to neuronal differentiation in the ventricular zone,
the increase in 5hmC across OSN differentiation is primarily intragenic and associated
with developmentally regulated genes. When Tet3 is overexpressed in mOSNs via a
transgenic mouse model approach, genes with modest levels of 5hmC in the wild type
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(WT) mice exhibit an increase in 5hmC levels, and subsequent increase in expression,
whereas gene with high levels of 5hmC exhibit a loss of 5hmC, and subsequent decrease
in expression. The downregulation of the most highly expressed mOSN-specific genes,
such as olfactory receptors and guidance molecules, affects glomerular formation
(Colquitt et al., 2013). These findings from two neurogenic regions of the brain support
the role of 5hmC in neuronal differentiation.
The Role of 5hmC in aging and neurodegeneration
In light of the importance of 5hmC in neurodevelopment, researchers have
investigated the role of 5hmC in aging and neurodegenerative diseases. The two studies
conducted on aging (from 6 wk to 2 yr) have found that global 5hmC levels increase in
the hippocampus as aging occurs (Chen, Dzitoyeva, & Manev, 2012; Chouliaras et al.,
2012). Given this finding, more research is warranted to determine whether 5hmC also
increases in other brain regions, as well as the specific loci with 5hmC enrichment across
aging. While there are not an expansive number of studies on neurodegeneration, several
correlations have been found with 5hmC for both Huntington’s disease (HD) and
Alzheimer’s disease (AD). In a mouse model of HD, a genome-wide decrease in 5hmC
levels was found, correlating with decreases in gene expression (Wang et al., 2013). The
differentially hydroxymethylated regions contained genes involved in neuronal
development and survival, which could have an important affect on the
neurodegeneration seen in this disease (Wang et al., 2013). Additionally, studies in AD
patients have seen a decrease in 5hmC in the hippocampus, and 5hmC levels were
negatively correlated with amyloid plaque load, a common marker of AD pathogenesis
(Chouliaras et al., 2013; Condliffe et al., 2014). However, another study looking at
preclinical stages of AD saw an increase in 5hmC in hippocampal regions of the brain
(Coppieters, Dieriks, Lill, Faull, Curtis, & Dragunow, 2013; Sun et al., 2013). While
preliminary, these studies point to a potential role of 5hmC in neurodegeneration
through deregulation of gene expression. Additionally, 5hmC may act as a biomarker for
diagnosing and determining the stage of the disease. Further research is required to
understand the role 5hmC plays in neurodegeneration.
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The Role of Tet enzymes in brain function
The three Tet proteins, Tet1, Tet2, and Tet3, are members of the Fe(II)/αketoglutarate (α-KG)-dependent dioxygenase family of enzymes. It has been proposed
that the enzymes use molecular oxygen to catalyze oxidative decarboxylation of α-KG,
creating a highly reactive intermediate that converts 5mC to 5hmC (Figure 2). This
proposed mechanism is based off of other Fe(II)/α-KG-dependent dioxygenase family
proteins, since a structure of mammalian Tet enzymes has not been solved. Each of the
Tets contain a conserved catalytic domain (double-stranded β-helix fold (DSβH)) that
contains the metal-binding residues required for the oxidation reaction (Figure 3)
(Kohli and Zhang, 2013). Additionally, a cysteine-rich (Cys-rich) domain is found in all
Tet proteins upstream of the catalytic domain and is thought to be required for activity
(Iyer et al., 2009; Tahiliani et al., 2009). Tet1 and Tet3 contain a CXXC domain near the
N-terminal end of the protein, which is known to bind to CpG sites (Kohli and Zhang,
2013). While each of the human Tet enzymes only share ~18-24% sequence identity
(UniProt Consortium, 2015), the catalytic and Cys-rich domains are highly conserved
between the three enzymes (Figure 4). It is hypothesized that the remaining nonconserved portions of the protein may serve as regulatory domains and convey different
functionality between the three Tets.
All three Tet family members, Tet1, Tet2, and Tet3, are expressed in the brain,
with Tet3 having the highest expression, followed by Tet2, and Tet1 having much lower
expression levels than the other two family member (Szwagierczak et al., 2010).
Knockout, loss of function, and overexpression studies have revealed diverse functions of
these enzymes, and the importance of 5hmC, in neuronal function.
Tet1

Currently, Tet1 is the most well-studied Tet family member in the brain, most
likely due to the fact that Tet1 was the first enzyme discovered to convert 5mC to 5hmC
(Tahiliani et al., 2009). Although Tet1 expression is markedly lower than Tet2 and Tet3
in the brain, various studies have demonstrated the importance of Tet1 in neuronal
function.
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Tet1 whole-body knockout (KO) mice are viable and fertile without apparent
health deficits, albeit a smaller body weight and litter size than WT animals (Dawlaty et
al., 2011; Rudenko et al., 2013; Zhang et al., 2013). Additionally, there are no obvious
brain morphological or developmental brain abnormalities (Rudenko et al., 2013; Zhang
et al., 2013). In agreement with the importance of Tet1 in the generation of 5hmC, there
is a small, but significant reduction of 5hmC in the brains of Tet1 KO mice, but no change
in 5mC. The fact that the change is small is likely due to presence of Tet2 and Tet3, the
other members of the Tet family that are endogenous expressed much higher than Tet1
in the brain. There also are no apparent deficits in synaptic connectivity as measured by
Synapsin I, a marker of synaptic abundance (Rudenko et al., 2013). This compensation
effect is supported by the deficits and abnormalities observed in Tet1 and Tet2 double
KO (DKO) mice. DKO die perinatally, although a small percentage survive without gross
abnormalities. When compared to WT mice, DKO adult mice (2.5 mo) have reduced
5hmC levels (34%) and increased 5mC levels (~5%) in the cerebrum and cerebellum.
Although these are appreciable changes in methylation, a large portion of 5hmC remains
intact, suggesting that Tet3 plays a critical role in its maintenance (Dawlaty et al., 2013).
Behaviorally, adult Tet1 single KO mice (4 mo) do not show deficits in
locomotion, anxiety, fear memory acquisition, or depression-related behaviors. Multiple
groups have observed memory deficits, however, there is not a consensus as to the
specific type of memory deficit. According to one group, Tet1 KO mice have impairments
in short-term memory and spatial learning, but normal long-term memory, as assessed
by Morris water maze (MWM) (Zhang et al., 2013). Another group reported normal
short-term memory and spatial learning, but impaired spatial memory extinction, in the
MWM and classical Pavlovian fear conditioning (Rudenko et al., 2013). When Tet1 is
overexpressed in the CA1 region of the hippocampus, long-term memory was affected
(fear conditioning), but not locomotion, anxiety, or short-term memory. This deficit in
long-term memory formation was observed for both catalytically active and inactive
forms of TET1, suggesting that TET1’s role in memory formation is independent of its
catalytic activity. Tet1 expression, but not Tet2, Tet3, or other proteins involved in the
demethylation pathway, is significantly downregulated in the dorsal CA1 of mice after
fear learning (Kaas et al., 2013). These findings support that Tet1 contributes to basal
neuronal 5hmC levels that are potentially important for neuronal function. The
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behavioral effects of Tet1 in the brain still warrant further investigation seeing as though
there are confounding results.
At the cellular and molecular level, evidence suggests that Tet1 is important in
neurogenesis and hippocampal function. When Tet1 KO mice were bred with Nestin-GFP
transgenic mice, the number of GFP-positive cells in the subgranular zone (SGZ) in adult
mice was dramatically reduced by 45% when compared to WT animals (Zhang et al.,
2013). This is different from two other non-neurogenic brain regions examined, the
cingulate cortex and hippocampus CA1 (Rudenko et al., 2013). The reduction in
proliferation potential of neural progenitor cells (NPCs) is likely to underlie this deficit as
evidenced by a reduction in neurospheres isolated from Tet1 KO mice, the decrease in
bromodeoxyuridine (BrdU, which marks dividing cells) positive neurons in Tet1-dentate
gyrus-knockdown in adult mice, and the 35% decrease in BrdU positive neurons in
animals in which Tet1 is specifically deleted in neural progenitors at 2 mo of age.
Examination of the gene expression and methylation changes in Tet1 KO mice revealed
that the decreased expression of a cohort of genes involved in neurogenesis was
associated with an increase in 5mC at their promoters, suggesting that Tet1 positively
regulates adult neurogenesis through the oxidation of 5mC to 5hmC at these genes
(Zhang et al., 2013).
Tet1 overexpression in the dentate gryus (DG) or cornus ammonis 1 (CA1) region
of the hippocampus of mice results in a dramatic increase in 5hmC and decrease in 5mC,
providing evidence that Tet1 in vivo oxidizes 5mC to 5hmC (Guo et al., 2011b; Kaas et al.,
2013). The overexpression of Tet1 in the DG led to a significant decrease in methylation
at promoter IX of Bdnf (Bdnf IX) and the brain specific promoter of Fgf1 (Fgf1B), and a
concomitant increase in the expression of these two genes, supporting the role of Tet1 in
the demethylation pathway, and subsequent gene activation (Guo et al., 2011b). Tet1
overexpression in area CA1 or DG of the hippocampus leads to the increased expression
of various activity dependent genes (Fos, Arc, Egr1, Homer1, and Nf4a2), as well as
genes downstream of the Tet mediated oxidation (Tdg, Apobec1, Smug1, and Mbd4)
(Kaas et al., 2013). In the DG, the increased expression of these genes is dependent upon
the catalytic domain TET1, as evidence by the fact that only the expression of human
TET1 catalytic domain, but not expression of the catalytically inactive version of TET1;
however, in the CA1 region, either the catalytic active or inactive TET1 leads to increase
in expression of majority of these genes. This implies that TET1 acts via region165

dependent mechanisms (Guo et al., 2011b; Kaas et al., 2013). Furthermore, Tet1 is
required for neuronal activity-induced active DNA demethylation and gene expression
since short-hairpin mediated knockdown of endogenous Tet1 in the DG completely
abolished electroconvulsive stimulation (ECS)-induced demethylation of Bdnf IX and
Fgf1B promoters. These in vivo findings are in agreement with in vitro work that has
shown that Tet1 knockdown in hippocampal neuron leads the hypermethylation of
promoter IV of Bdnf and subsequent decreased expression from this promoter (Yu et al.,
2015). Given that demethylation at these promoters is similar completely abolished after
ECS with knockdown of Apobec1, this suggests that Tet1 and Apobec1 work together
through oxidation-deamination to achieve active demethylation in the adult mouse brain
(Guo et al., 2011b).
Loss of Tet1 causes electrophysiological deficits in the hippocampus. Tet1 KO
mice have normal basal synaptic transmission and intrinsic neuronal properties, as
measured by paired-pulse facilitation and presynaptic excitability, respectively.
However, long-term potentiation (LTP), assessed in the Schaffer collateral-CA1 pathway,
is attenuated, and long-term depression (LTD) is amplified. These in vivo
electrophysiological findings confirm what is found in vitro. Overexpression of the
catalytically active form of Tet1 prevents TTX-induced scaling-up, and knockdown of
Tet1 leads to synaptic scaling-down that is unaltered by bicuculline treatment (Yu et al.,
2015). Further analysis in vivo has demonstrated that alterations in metabotropic
glutamate receptor (mGluR)-dependent form of LTD is not affected, therefore suggesting
that a deficit in NMDAR-dependent LTD. Neuronal activity-regulated genes, including cFos, Egr2, Egr4, Arc, and Npas4, are affected in Tet1 KO mice. Analysis of the Npas4
promoter-exon 1 region confirmed a decrease of 5hmC and an increase in 5mC, which
could explain the downregulation of this group of genes. After memory extinction in Tet1
KO mice (but not after fear memory acquisition), the Npas4 and c-Fos genes exhibit a
decrease in 5hmC and an increase in 5mC, concomitant with a decrease in mRNA and
protein expression levels in both brain regions assessed, the cortex and hippocampus.
Since Tet1/Tet2/Tet3 expression does not increase during either fear memory extinction
or acquisition, the activity of these proteins change, rather than absolute levels (Rudenko
et al., 2013).
This body of work on Tet1 function in the brain suggests that Tet1, although
expressed at much lower levels in the mammalian brain than the other Tet family
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members, plays an important role in maintaining 5hmC levels, and subsequent geneexpression levels, at basal and activity-induced conditions.
Tet2

Despite it’s high level of expression, Tet2 is presently the least well-studied Tet
family member in the brain, but the limited studies conducted thus far have
demonstrated the importance of Tet2 in brain function. There are no reported brain
abnormalities or dysfunction in Tet2 knockout mice (Ko et al., 2011; Li et al., 2011).
However, when Tet2 is knocked down in hippocampal neurons in vitro, there is an
increase in miniature glutamatergic excitatory postsynaptic currents (mEPSC)
amplitudes compared to controls (Yu et al., 2015). This implies that neuronal function
may be impaired in the absence of Tet2.
Tet2 is also thought to play a role in the demethylation of developmentally
dependent genomic loci. With the use of Tet2 knockout mice, it was found that this
member of the Tet family is responsible for the oxidation of large fraction (19.7%) of CpG
genomic regions that gain hydroxymethylation status over development. On the other
hand, CpG regions with higher 5hmC in the adult than fetal stage are largely unaffected
in Tet2 knockout mice. Across development and aging (6 wk, 10 wk, and 22 mo) in Tet2
knockout mice, there are over fourfold more hypermethylated CpG regions (14,000 CpG
regions in total) than hypomethylated region, suggesting that Tet2 plays a role in the
demethylation over development and aging (Lister et al., 2013). Tet2 may also play a role
in neurogenesis since the knockdown of Tet2 and Tet3 via electroporation of shRNAs
into the cortex lead to defects in the progression of differentiation from the
subventricular zone (Hahn et al., 2013). These Tet2 findings suggest that Tet2 plays an
important role in regulating developmentally dependent, differentially
hydroxymethylated regions.
Tet3

Various studies on Tet3 function in the brain have confirmed that this most
highly expressed brain Tet family member is essential in regulating neuronal activity.
When mice undergo extinction training, there is a significant increase in Tet3 mRNA in
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the cortex. Tet3 knockdown via lentiviral plasmids in the infralimbic prefrontal cortex
(ILPFC) have normal fear memory acquisition but impaired fear memory extinction.
Furthermore, inhibiting NMDAR activity blocked the increase in Tet3 expression
associated with fear memory extinction, suggesting that the rise in Tet3 occurs via an
NMDAR-mediated pathway. Fear acquisition and fear extinction result in genome-wide
differences of 5hmC at locations that contain CA or CT dinucleotide repeats instead of
CpGs. Additionally, there is a reduction in 5hmC at intronic and intergenic sites and an
increase in 5hmC enrichment at distal promoters, 5’-UTR, 3’-UTR, exonic sequences,
and DNaseI-hypersensitive regions. Gene ontology analysis revealed that 16% genes
enriched for 5hmC after extinction learning are involved in synaptic signaling. When one
of these genes, gephyrin, was evaluated, it was found that there was enrichment for
5hmC, co-occurring with decrease in 5mC, within one intron. Moreover, in response to
extinction, there was an increase Tet3 occupancy at the gephyrin gene, as well as an
increase in specificity protein 1 (Sp1), a transcription factor that activates gene
expression by preventing the active loci from becoming methylated. The observed
reduction in transient H3K9me3 and increase in H3K27ac, p300, H3K4me1, and
dimethyl H3 arginine 2 (H3R2me2s), which is crucial for maintaining a euchromatic
state, all support the role of Tet3 in extinction-induced gene expression changes. These
changes are specific to fear extinction, and do not occur during fear acquisition. All of
these changes at the gephyrin gene are blocked with the use of a Tet3 shRNA (Li et al.,
2014).
Tet3 expression levels correlate with neuronal activity in vitro as well; an
increase in synaptic transmission correlates with an increase in Tet3, but not Tet1 or
Tet2. When Tet3 is knocked down from hippocampal neurons in culture, mEPSC
amplitudes are significantly larger than controls, and the reciprocal effect occurs when
Tet3 is overexpressed. Notably, knockdown of either Tet1 or Tet2 also increases mEPSC
amplitudes, but not as drastically as Tet3 knockdown. Tet3 is also essential for the
maintenance of homeostatic synaptic plasticity since knockdown of Tet3 leads to
synaptic scaling-up that is unaltered by tetrodotoxin (TTX) or retinoic acid (RA)
treatment; knockdown of Tet3 leads to synaptic scaling-down that occludes further
alterations with bicuculline treatment; and Tet3 overexpression prevents TTX-induced
synaptic scaling-up or bicuculline-induced scaling-down. Given that a similar effect on
mEPSC amplitudes and synaptic scaling occurs when poly (ADP-ribose) polymerase
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(PARP) or the apurinic/apyrimidinic endonuclease is inhibited, two major components
of the BER pathway, these data suggest that excitatory synaptic transmission is regulated
by the oxidation of DNA through Tet, followed by BER (Yu et al., 2015).
The molecular mechanism through which Tet3 causes these effects is likely
through the regulation of surface GluR1 receptors. Knockdown of Tet3 leads to an
increase in surface GluR1 receptors that is resistant to a further increase or decrease in
surface GluR1 receptors, which occurs in control neurons treated with TTX or
bicuculline. When gene expression changes were assessed in Tet3 knockdown neurons,
GO term enrichment revealed expression changes of genes involved in synapse and
synaptic transmission. Genes with differential expression due to TTX or bicuculline
treatment in control neurons lost responsiveness in Tet3 knockdown neurons. A very
similar effect was observed for bicuculline in Tet3 knockdown neurons. In Tet3
knockdown neurons, promoter IV of the brain-derived neurotrophic factor (Bdnf) is
hypermethylated, and there is a decrease in expression from this promoter. The
bicuculline-induced hypomethylation, as well as the TTX-induced hypermethylation, of
Bdnf promoter IV are occluded in Tet3 knockdown neurons. ChIP-PCR revealed that
Tet3 binds to the Bdnf promoter IV (Yu et al., 2015).
The importance of Tet3 in neural function is conserved across vertebrates, as
knockdown of Tet3 in Xenopus by morpholino antisense oligonucleotide leads to marked
developmental abnormalities, including malformation of the eye, small head, and early
death. At the molecular level, Tet3 depletion causes a reduction in expression of master
eye developmental genes (pax6, rx, and six3), primary neuronal markers (ngn2 and
tubb2b), neural crest markers (sox9 and snail), and major shh signaling components
(shh and ptc-1). Additionally, Tet3 chromatin immunoprecipitation (ChIP) assays
confirm the binding of Tet3 to the promoters of pax6, rx, six3, ptc-1, ptc-2, sox9, and
ngn2. Furthermore, at the promoters of some of these target genes, there was found to
be a developmental increase in 5hmC and decrease in 5mC from stage 10 to 19 in
Xenopus development, which is perturbed when Tet3 is knockdown. These findings
suggest that Tet3 acts as an upstream activator of key neural developmental genes (Xu et
al., 2012). Furthermore, these studies suggest that Tet3 plays an important role in brain
function that is conserved across animals.
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Conclusion
Despite it’s recent rediscovery in 2009, major advances have been made
regarding our understanding of the DNA modification 5hmC. 5hmC is now known to be
an intermediate of active DNA demethylation in neurons. However, the biological role of
5hmC in the brain is still up for debate. It is known that even within defined brain
regions, such as the cerebellum, there are a multitude of cell types that have vastly
different functions, gene expression patterns, and 5mC and 5hmC levels. While studies
have shown 5hmC distribution in different brain regions throughout development, it is
still not understood what happens to 5hmC in specific cell types as an animal ages.
Investigating 5hmC distribution in a heterogeneous brain region is likely to mask
important cell-type specific features and reveal false patterns due to the multitude of cell
types in the sample. Looking at 5hmC and Tet enzymes in specific cell types is crucial for
our understanding of how DNA demethylation and 5hmC affect neural functions.
In the search for the biological role of 5hmC, it is also imperative to know what
proteins bind to the modified base, and the cellular consequences of the interactions.
While a variety of putative 5hmC binding partners have been identified, the potential
interactions have not been confirmed in vivo, and the functions of 5hmC-protein
interactions have not been established. Studies addressing the binding partners of 5hmC
will greatly advance our understanding of 5hmC not just as a demethylation
intermediate, but also as an essential epigenetic mark.
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Figures
Figure 1

Figure 1. Cytosine modification cycle. Unmodified cytosine (C) is converted to 5methylcytosine (5mC) by DNA methyltransferase enzymes (DNMTs) DNMT1, DNMT3a,
or DNMT3b. 5mC can then be iteratively oxidized by Tet enzymes Tet1, Tet2, or Tet3, to
become 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC) and 5carboxylcytosine (5caC). Thymine DNA glycosylase (TDG) can recognize the bases 5fC
and 5caC and excise them from the DNA, leaving an abasic site. An abasic site triggers
the base excision repair pathway (BER) which restores the base to cytosine.
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Figure 2

Figure 2. 5mC to 5hmC conversion by Tet enzymes. Tet enzymes oxidize the 5methyl group of 5mC. With cofactors alpha-ketoglutarate (α-KG) and molecular oxygen,
Tet oxidizes the 5-methyl carbon, adding a hydroxyl group, yielding 5hydroxymethylcytosine (5hmC). Other byproducts of the enzymatic reaction include
carbon dioxide and succinate.
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Figure 3

Figure 3. Schematic of Tet enzymes. Tet1, Tet2, and Tet3 all share a conserved
catalytic double-stranded β-helix fold (DSβH) domain at the C-terminal end of the
protein. Additionally, a conserved cysteine-rich (Cys-rich) domain is found at the Nterminal portion of the catalytic domain. Tet1 and Tet3 contain an additional CpGbinding CXXC domain at the N-terminal end of the protein.
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Figure 4

Figure 4. Sequence conservation of Tet domains. (a) The cysteine-rich (Cys-rich)
domain is almost fully conserved between the Tet enzymes. (b) The catalytic doublestranded β-helix fold (DSβH) domain is also highly conserved between the three Tet
enzymes, even though the proteins only share 18-24% sequence identity. The remaining
non-conserved domains are hypothesized to serve as regulatory domains.
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APPENDIX PART 3

Locus- and cell type-specific epigenetic switching during cellular
differentiation in mammals

One Sentence Summary

This story, which found that the loss of DNA methylation is accompanied by the gain of
different histone modifications in a locus- and cell type-specific manner over cellular
differentiation, is published in Frontiers in Biology.

Abstract

BACKGROUND: Epigenomic reconfiguration, including changes in DNA methylation
and histone modifications, is crucial for the differentiation of embryonic stem cells
(ESCs) into somatic cells. However, the extent to which the epigenome is reconfigured
and the interplay between components of the epigenome during cellular differentiation
remain poorly defined. METHODS: We systematically analyzed and compared DNA
methylation, various histone modification, and transcriptome profiles in ESCs with those
of two distinct types of somatic cells from human and mouse. RESULTS: We found that
global DNA methylation levels are lower in somatic cells compared to ESCs in both
species. We also found that 80% of regions with histone modification occupancy differ
between human ESCs and the two human somatic cell types. Approximately 70% of the
reconfigurations in DNA methylation and histone modifications are locus- and cell typespecific. Intriguingly, the loss of DNA methylation is accompanied by the gain of
different histone modifications in a locus- and cell type-specific manner. Further
examination of transcriptional changes associated with epigenetic reconfiguration at
promoter regions revealed an epigenetic switching for gene regulation—a transition from
stable gene silencing mediated by DNA methylation in ESCs to flexible gene repression
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facilitated by repressive histone modifications in somatic cells. CONCLUSIONS: Our
findings demonstrate that the epigenome is reconfigured in a locus- and cell typespecific manner and epigenetic switching is common during cellular differentiation in
both human and mouse.

Introduction

Cellular differentiation is a precisely regulated process by which hundreds of
morphologically and functionally distinct cell lineages are derived from the same origin,
embryonic stem cells (ESCs). Given that ESCs and somatic cell types share an identical
genome, a fundamental question is how lineage-specific gene expression patterns are
established and maintained. Accumulating evidence supports that two epigenetic
mechanisms, DNA methylation and histone modifications, are crucial in this process
(Reik, 2007).
DNA methylation at the fifth carbon position of cytosine is an abundant covalent
modification that primarily occurs in CpG dinucleotides (mCpGs), with 80% of CpGs
being methylated in mammals. DNA methylation affects DNA-protein interactions and
therefore influences transcription in various physiological processes, such as imprinting,
X-inactivation, tumorigenesis, and embryogenesis (Jaenisch and Bird, 2003). In cellular
differentiation, DNA methylation plays a critical role as the loss of enzymes responsible
for establishing or removing methylation in embryos or ESCs results in skewed lineage
specification and transdifferentiation (Jackson et al., 2004; Koh et al., 2011; Tsumura et
al., 2006). Similar to DNA methylation, covalent modifications on histone tails play an
imperative role in cellular differentiation and modulate transcription by altering DNA
accessibility. Altering the activity of histone modifying enzymes, such as
methyltransferases and acetyltransferases, diminishes the differentiation potential of
ESCs (Margueron and Reinberg, 2011). Therefore, although histone modifications and
DNA methylation are required for successful differentiation, the precise function of each
in determining cell fate decisions is unknown.
Investigating the role of these epigenetic mechanisms has recently become possible
with the construction of single base-pair resolution profiles of DNA methylation
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(methylomes) and genome-wide histone modification profiles in multiple cell types,
tissues, and organisms (Lister and Ecker, 2009; Rivera and Ren, 2013). Comparison of
methylomes across cellular differentiation has revealed both de novo methylation (Reik,
2007; Smith and Meissner, 2013) and de novo demethylation (Hon et al., 2012; Lister et
al., 2009; Xie et al., 2013; Ziller et al., 2013). These findings raise the possibility that
mCpG is more dynamic than previously thought. Indeed, literature supports that mCpG
undergoes a demethylation process mediated by the TET family of proteins that oxidize
mCpG to hydroxymethyl-CpG (Tahiliani et al., 2009). The acquisition of methylomes
and histone modification profiles from multiple cell types also provides an opportunity
to examine the interplay between these two epigenetic mechanisms. Increasing evidence
supports that the loss of DNA methylation is coupled to the gain of histone
modifications, such as H3K27me3 and H3K9me3 in tumorigenesis (Hon et al., 2012);
H3K27me3, H3K9me3, and H3K4me1 in differentiation (Gifford et al., 2013; Hawkins et
al., 2010); and H3K27ac and H3K4me1 in development (Lister et al., 2013). However,
the interplay between these two epigenetic mechanisms has only been observed for a
limited number of histone modifications, leaving the large scope of DNA-histone
modification interactions to be explored.
In this study, we systematically integrated DNA CpG methylation, various histone
modification, and transcriptome profiles in ESCs and two somatic cell types in both
human and mouse. With the use of our novel unbiased, enrichment based statistical
approach, we found that both DNA methylation and histone modifications are
considerably altered during cellular differentiation. Approximately 70% of the
reconfigurations in DNA methylation and histone modifications are cell type-dependent
and locus-specific. Additionally, integrative analyses of these epigenomic
reconfigurations revealed a widespread locus-specific switching from DNA methylation
to histone modifications during cellular differentiation in both species. Furthermore,
when these epigenetic changes at promoter regions were correlated with gene
transcription, we found that the switching at promoter regions implicates a transition
from stable gene silencing mediated by DNA methylation to flexible gene repression
facilitated by histone modifications. Our study provides a comprehensive insight into the
role of epigenomic reconfiguration in cellular differentiation.
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Materials and methods

Bioinformatics analyses

All analyses in this study were processed in the MAC terminal window. Perl was used to
do in-house programming. R (http://www.r-project.org/) and Bioconductor libraries
(http://www.bioconductor.org) were used to do all statistical analyses. Integrative
Genomics Viewer (IGV, version 2.2.4) (Robinson et al., 2011; Thorvaldsdottir et al.,
2013) was used as the local genome browser in this study. The first replicate of each
histone modification (ChIP-seq) and gene expression (mRNA-seq) data set was used in
the browser representation for all the figures (Table S1). Samtools version 0.1.18 (Li et
al., 2009) was used to convert sam files to bam files and to sort the bam files by name.
Sorted bam files were converted to tdf files by igvtools version 2.2.1 using parameters “-z
5 -w 25 -e 250” for ChIP-seq files and “-z 5 -w 25 -e 250 --strands read” for strandspecific mRNA-seq files. The track scales for ChIP-seq and mRNA-seq were normalized
to the total number of uniquely mapped reads.
ChIP-seq_scale = (TDF_scale / Total_number_uniquely_mapped_reads) * 10,000,000
mRNA-seq_scale = (TDF_scale / Total_number_uniquely_mapped_reads) *
20,000,000

Obtaining the raw data and FASTQ files

The SRA raw data files for whole-genome bisulfite sequencing (WGBS), ChIP-seq, and
mRNA-seq were downloaded from NCBI Sequence Read Archive database
(http://www.ncbi.nlm.nih.gov/Traces/sra) under the accession numbers listed in Table
S1. The SRA Toolkit version 2.1.7 (http://www.ncbi.nlm.nih.gov/Traces/sra/sra.cgi?view
=software) was used to obtain the FASTQ files from the SRA files. The command used
was “fastq-dump”.
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Genomic sequences and annotations

The reference genomic sequences used in this study were hg19 for the human and mm9
for the mouse. The genomic annotations, human GRCh37 and mouse NCBIM37 that
were based on Ensembl release 66, were downloaded from Illumina iGenome database
(http://cufflinks.cbcb.umd.edu/igenomes.html). The distal 5ʹ end of a gene was defined
as the transcription start site (TSS). The exonic region was defined as all exons of a gene.
The region from the 500 bp downstream of TSS to the distal 3ʹ end of a gene was defined
as the gene body. Intergenic regions were downloaded from UCSC Genome Browser
using Table Browser function (http://genome.ucsc.edu/cgibin/hgTables?command=start). Intergenic regions with at least 1 kb in length were
included in subsequent analyses.

WGBS data mapping and methylation calling

The FASTQ raw data files were first processed by Trim Galore
(http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/) to remove adaptor
contamination, to trim lower-quality sequences, and to discard sequences shorter than
36 nucleotides. The Trim Galore parameters used were “-s 2 -length 36”. Bismark v0.7.4
(Krueger and Andrews, 2011) was used to map the WGBS data to the hg19 and the mm9
genomes. We used “-n 2 -l 40” and default parameters in Bismark. We excluded reads
that had three or more methylated cytosines in non-CpG contexts or had cytosine in the
reads but thymine in the corresponding location of the reference genomes. For mapped
reads from a library of the same PCR reaction with identical 5′ sites, the one with highest
average phred quality score was kept and the others were discarded to get rid of possible
PCR amplification artifacts. Libraries from multiple PCR reactions and from different
replicates for each cell line were merged together. SNPs between C57BL/6 and 129 were
downloaded from the Mouse Genome Project of the Sanger Institute (ftp://ftpmouse.sanger.ac.uk/REL-1003/SNPs/20100310-all-snps.tab.gz). For the mouse
methylomes, CpGs that overlapped with known SNPs were excluded from subsequent
analyses. The methylation status of both strands of a CpG pair were merged together.
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CpGs with 10 or more read coverage were included in subsequent analyses. The
methylation level for each CpG was calculated as follows:

mCpG =

RC + + RC −
( RC + + RT + ) + ( RC − + RT − )

where

RC + is the number of reads with C mapped to the sense strand of a CpG,
RT + is the number of reads with T mapped to the sense strand of a CpG,
RC − is the number of reads with C mapped to the antisense strand of a CpG,
RT − is the number of reads with T mapped to the antisense strand of a CpG.
Genome-wide and locus-specific comparisons of DNA methylation levels

For genome-wide analysis, the two-tailed Fisher’s exact test was used to compare the
methylomes between two cell lines at single-CpG resolution. The p-value for each CpG
was calculated as follows:
p-value
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is the binomial coefficient,
is the factorial operator,

C ESC

is the number of methylated reads that covered this CpG in ESCs,

TESC

is the number of non-methylated reads that covered this CpG in ESCs,

C Somatic

is the number of methylated reads that covered this CpG in somatic cells,
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TSomatic

is the number of non-methylated reads that covered this CpG in somatic cells.

Raw p-values were adjusted using the Benjamini and Hochberg method (Benjamini and
Hochberg, 1995) to control the False Discovery Rate (FDR). CpGs with an adjusted pvalue (FDR) less than 0.05 were defined as differentially methylated CpGs.
For locus-specific analysis, we developed an enrichment-based statistical approach to
compare and identify differentially methylated genomic regions (Figure 2A). We defined
promoter regions using stringent criteria (Figure S2A) and analyzed them in parallel.
To determine the distribution of CpGs and mCpGs at promoter regions (Figure 5A),
the region 5 kb upstream and 1 kb downstream of TSS for each gene was dissected into
600 bins with 10 bp in length. For each bin, we calculated the total number of genomic
CpGs, the ratio between the total number of mCpGs versus the total number of genomic
CpGs, the ratio between the total number of diff-mCpGs and the total number of mCpGs,
respectively.

ChIP-seq data mapping, peak calling, and sliding-window analysis

Bowtie version 0.12.7 (http://bowtie-bio.sourceforge.net/index.shtml) (Langmead et al.,
2009) was used to map the FASTQ files of ChIP-seq data to the genomes. “-v 2 -m 1 -p 10
” and default parameters were used. The mapping results for each replicate were merged
together.
FindPeaks in Homer version 4.2 (http://biowhat.ucsd.edu/homer/ngs/) (Heinz et
al., 2010) was used for peak calling using “-style histone” and default parameters. If the
region 1 kb upstream and 1 kb downstream of the TSS for a gene overlapped with
H3K27me3 or H3K9me3 peaks, we defined this gene as marked by that histone
modification.
All replicates for each histone modification in each cell type were merged together.
The total number of uniquely mapped reads was normalized to 40 million. For sliding
window analysis, the human and mouse genomes were partitioned into 1 kb sized
windows, and the number of normalized reads for each window was calculated. The fold
enrichment score for each histone modification at each window between ESCs and
somatic cells was calculated as follows:
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fold enrichment =

RSomatic + 1
RESC + 1

where RSomatic is the number of normalized reads in this window for somatic cells and

RESC is the number of normalized reads in this window for ESCs.
Based on the fold enrichment score for each window, we classified all windows into
three categories: those in which histone modifications are gained, lost, or remained. The
gain windows were defined as those that have higher read numbers in somatic cells than
in ESCs (fold enrichment score > 1), whereas the lose windows were defined as those that
have lower read numbers in somatic cells than in ESCs (fold enrichment score < 1). We
then obtained the top 2000 gain windows and the top 2000 lose windows based on their
fold enrichment scores, and termed them as the highly dynamic regions. Only those
dynamic regions with greater than or equal to 2 fold enrichment or depletion were
included in subsequent analyses. The DNA methylation change associated with each
highly dynamic region was calculated as follows:
n

n

∑S −∑E
i

methylation change =

i

i =1

i =1

n

where n is the total number of CpGs with 10 or more read coverage in both cells in this
region, Si is the methylation level of the number i CpG in somatic cells, and Ei is the
methylation level of the number i CpG in ESCs.

mRNA-seq data mapping and differential expression analysis

The mRNA-seq data for mouse frontal cortex were mapped to mouse NCBIM37/mm9
genomes by TopHat version 2.0.6 (Trapnell et al., 2009) using parameters “--bowtie1 -color --quals -p 5 -g 1 --no-coverage-search --no-novel-juncs --library-type frsecondstrand -G UCSC_mm9.gtf mm9_c”. The other mRNA-seq data in FASTQ files
were mapped to human GRCh37/hg19 or mouse NCBIM37/mm9 genomes by STAR for
MAC version 2.2.1d (Dobin et al., 2013). We used STAR parameters “-182

outFilterMultimapNmax 1 --outFilterMismatchNmax 3” to only report uniquely mapped
reads with no more than three mismatches.
The number of mapped reads in the exonic region of each gene was calculated using an
in-house Perl program. All replicates for each cell type were calculated separately. Reads
that overlapped with the exonic regions of multiple genes were excluded. The edgeR
Bioconductor package (Robinson et al., 2010) was used to perform the differential
expression analysis. The classic edgeR method, which is negative binomial model based
exact test, was used. For differential expression analysis, we only included genes with a
count per million (CPM) larger than 1 in at least two of the data sets. Genes with adjusted
p-values less than 0.05 were defined as differentially expressed. Gene Ontology
enrichment analysis was performed using DAVID v6.7 (http://david.abcc.ncifcrf.gov/)
(Huang da et al., 2009a, b).

Results

Global DNA hypomethylation in somatic cells

Given the essential role of DNA methylation in cellular differentiation, we first
examined global DNA methylation in terminally differentiated somatic cells compared to
ESCs using raw data from the NCBI GEO database (Hon et al., 2012; Lister et al., 2009;
Mann et al., 2013; Stadler et al., 2011; Xie et al., 2012). Thus, we compared the
methylomes from human H1 ESCs (hESC) and two distinct types of human somatic cells,
IMR90 fetal lung fibroblasts (hFB) and mammary epithelial cells (hEP)(Figure S1A). To
evaluate DNA methylation changes in a different species, we also compared the
methylomes of mouse ESCs (mESC), mouse primary dermal fibroblasts (mFB), and
mouse frontal cortex tissue (mFC)(Figure S1A).
We found that global mCpG levels are significantly lower in somatic cells
compared to ESCs (Figure 1). In human, 93% of the differentially methylated CpG sites
(diff-mCpGs) exhibit a decrease in methylation in hFB compared to hESC and 89% of
diff-mCpGs show a decrease in hEP (Figure 1A-B, two-tailed Fisher’s exact test,
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Benjamini and Hochberg (B-H) correction). Global DNA hypomethylation was also
found in mouse somatic cells (Figure 1A-B). Moreover, we found that hypomethylated
diff-mCpGs are evenly distributed across all autosomes in both species, indicating
widespread genome-wide DNA hypomethylation in somatic cells compared to ESCs
(Figure S1C). Of note, global mCpG levels are not significantly different across somatic
cell types (Figure S1B), suggesting that hypomethylation is found upon lineage
commitment, rather than across cell types.

DNA hypomethylation is locus- and cell type-specific

Next, we investigated whether changes in DNA methylation occur at particular
genomic features: intergenic regions, gene body, and promoter regions. To do so, we
developed an enrichment based statistical approach for identifying genomic regions in
which the ratio of diff-mCpGs is statistically higher than the ratio expected by chance
(Figure 2A). Thus, we were able to identify genomic regions that are differentially
methylated between different cell types.
Consistent with our finding of global hypomethylation, a significantly larger portion of
the differentially methylated regions is hypomethylated in somatic cells compared to
ESCs in both human and mouse (Figure S2A-C, FDR<0.0001, Hypergeometric test, B-H
correction). For example, >90% of differentially methylated promoter, gene body, and
intergenic regions are hypomethylated in hFB compared to hESC (Figure S2A-C).
Notably, approximately 60-80% of the identified differentially methylated genomic
regions are unique to that specific somatic cell type regardless of being in the promoter,
gene body, or intergenic region (Figure 2B; Figure S2D). Genomic feature-specific
alterations of DNA methylation are illustrated in the promoter regions of cell typespecific genes, including LHX8, SH3TC1, COL6A3, and FOXI2 (Figure 2C). Only 30% of
the genomic regions identified in hFB and hEP share the same changes in DNA
methylation when compared to hESC (Figure 2B), such as the promoter regions of
TMEM173 and TRIM4 (Figure 2C). Furthermore, we found that the changes in DNA
methylation are strictly confined in a locus-specific manner, as surrounding regions do
not show similar alterations (Figure 2C; Figure S2E-F). Together, these results
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demonstrate that the decrease in DNA methylation across cellular differentiation is
lineage-specific and restricted to particular loci.

Locus- and cell type-specific alterations of histone modifications in human

Modification of histone tails, such as methylation, acetylation, ubiquitination or
phosphorylation, is an evolutionarily conserved epigenetic mechanism crucial for gene
regulation in many biological processes (Berger, 2007; Jenuwein and Allis, 2001).
Characteristic histone modification features include H3K9me3 and H3K27me3 marks in
transcriptionally silent loci and H3K4me3 and H3K27ac in transcriptionally active
promoters (Turner, 2007). Moreover, genes that show transient transcriptional changes
in response to environmental stimuli versus genes that are persistently transcribed are
marked by distinct types of histone modifications (Metivier et al., 2003). Given the
importance of histone modifications in regulating cellular processes, we next analyzed
the extent to which histone modifications are altered in somatic cells compared to ESCs.
We acquired all publicly available ChIP-seq data sets for histone modifications in hESC
(26 data sets in total), hFB (26 data sets), and hEP (11 data sets) and compared the
enrichment profiles for each modification across cell types.
We found that 70-80% of the enriched sites for each of the 26 histone modifications
are altered in hFB compared to hESC and 60-90% of the 11 histone modifications are
altered between hEP and hESC, indicating a widespread epigenetic reorganization in
human somatic cells (Figure 3A). Comparison of histone modification profiles between
the two somatic cell types revealed that alterations of histone modifications are
predominately cell type-specific (Figure 3B). For example, 70% of the identified H2A.Z
sites that change during cellular differentiation are unique to each somatic cell type
(Figure 3B). Consistent with previous findings (Hawkins et al., 2010), we also found that
repressive histone modifications, such as H3K27me3 and H3K9me3, are markedly
enriched, including an increase in the total number of sites (Figure 3A) as well as a
significant expansion of occupancy for most of the enriched sites across cellular
differentiation (Figure 3 C-D, p<2.2×10-16, Student’s t-test). These results show that
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regions of histone modification occupancy change dramatically in a cell type-specific
manner across cellular differentiation.

Epigenetic switching from DNA methylation to histone modifications

We next examined whether changes in histone modifications are associated with
changes in DNA methylation across differentiation. To this end, we focused on genomic
regions in somatic cells that exhibited the most dynamic changes in histone
modifications relative to hESC. For each histone modification, these regions were
defined as those with an enrichment score ≥ 2, and we limited our analyses to the top
4,000 dynamic regions (2,000 gain and 2,000 loss).
We found that the majority of regions with increased histone modifications in somatic
cells also exhibited decreased DNA methylation levels compared to hESC (Green boxes
in Figure 4A-B). This correlation occurred for 85% of the histone modifications in hFB
and 73% of modifications in hEP (Green boxes in Figure 4A-B). Moreover, we observed
that many of the identified epigenetic switching from DNA methylation to histone
modifications during cellular differentiation are specific to each cell type (Gray regions in
Figure 4D; Gray regions in Figure S3C). For example, two sites in the RIN2 gene locus
with specific loss of DNA methylation in hEP, but not in hFB, are accompanied by an
increase in histone modifications in hEP, but not in hFB (Gray regions in Figure 4D).
Similarly, when we analyzed the relationship between DNA methylation and histone
modifications in mouse mESC and mFC, we found that gains of H3K4me3 and H3K27ac
are associated with a decrease in DNA methylation, while the loss of H3K4me3 and
H3K27ac are coupled with an increase in DNA methylation (Figure 4C). This epigenetic
switching is not found between regions exhibiting decreased histone modifications and
DNA methylation for the majority of regions (Figure S3A-B). Together, these data
demonstrate a cell type-dependent and locus-specific switching from DNA methylation
to histone modifications over cellular differentiation in both species.

Epigenetic switching at promoters is associated with distinct gene regulation
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We next set out to determine how switching from DNA methylation to histone
modifications during cellular differentiation affects gene expression. We focused on
promoter regions since changes in DNA methylation and histone modifications at
promoter regions are correlated with changes in transcription relative to other genomic
features (Ball et al., 2009). We found that proximal promoters, regions 0.5kb upstream
and downstream of transcriptional start sites (TSSs), have a higher CpG density and are
more dynamically methylated than distal promoter regions, defined as regions from 0.55kb upstream and 0.5-1kb downstream of TSSs (Figure 5A; Figure S4A). Given this
finding, we identified differentially methylated proximal promoters over differentiation
with the use of our enrichment-based statistical approach (Figure 2A). Compared to
ESCs, we found that the majority of differentially methylated promoters were
hypomethylated: 88% of the promoters in hFB, 82% of the promoters in hEP, 77% of the
promoters in mFB, and 65% of the promoters in mFC. Therefore, we focused on
hypomethylated promoters for subsequent analyses. Interestingly, gene ontology (GO)
analysis of genes with hypomethylated proximal promoters revealed significant
enrichment in processes characteristic of each somatic cell type as well as pathways
responsive to environmental signals (Figure S4B, Fisher′s exact test, B-H correction).
For example, many of the significant GO terms for hFB were related to cell adhesion,
which is an essential characteristic of hFB, and injury response, a pathway highly
dependent on external cues (Figure S4B). These findings suggest that hypomethylation
at promoter regions in somatic cells is important for defining cellular identity and
rendering them responsive to environmental cues.
Examination of transcriptional changes of genes with hypomethylated promoters
revealed that 25% of genes showed an increase in expression in hFB compared to hESC
(Red regions in Figure 5B). This is consistent with the prevailing model that a decrease
in DNA methylation at promoters correlates with an increase in gene expression (Ball et
al., 2009). However, 65% of genes identified in hFB did not exhibit changes in
transcription despite a significant decrease in DNA methylation at their promoters
(Black regions in Figure 5B, FDR<0.0001, Hypergeometric test, B-H correction), with
78% of these genes are transcriptionally silent in both hESC and hFB (RPKM<1).
Alternative promoter usage (Maniatis and Reed, 2002) may account for some of the
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genes in which promoter hypomethylation is associated with a decrease in gene
expression in hFB (Green regions in Figure 5B; Figure S5A). Similar percentages of
genes with hypomethylated promoters show an increase (34%), no change (50%), or
decrease (16%) in gene expression in hEP compared to hESC (Figure 5B). In mice,
promoter hypomethylation had similar effects on gene expression with the majority of
genes with hypomethylated promoters either showing an increase in gene expression,
47% in mFB and 67% in mFC, or no change in gene expression, 46% in mFB and 26% in
mFC, while only a small percentage exhibited a decrease in gene expression, 7% in mFB
and 7% in mFC)(Figure 5B). These data suggest that promoter hypomethylation during
cellular differentiation is not only important for increasing lineage specific transcripts,
but also for flexible gene repression facilitated by repressive histone modifications in
somatic cells.
To gain an insight into the mechanism by which genes with hypomethylated promoters
remain transcriptionally silent in human somatic cells, we examined the profiles of two
repressive histone modifications, H3K27me3 and H3K9me3, at the promoter regions of
these silent genes in hFB and hEP. We found that, 77% of these genes in hFB and 45% in
hEP are marked by one or both of H3K27me3 and H3K9me3 at their promoter regions
(Figure 5C-D; Figure S5B). Furthermore, these repressive histone modifications at the
promoter regions are either established de novo during cellular differentiation, such as
at the promoter regions of KBTBD5, ZPBP2, and VMO1 (Figure 5D), or inherited from
hESC, such as at the promoter region of LHX8 (Figure 5D). Given that DNA methylation
is known to be a stable repressive mechanism (Bird, 2002; Jones, 2012), the epigenetic
switching at the promoter regions of these genes during cellular differentiation may
allow them to be dynamically expressed in response to external cues in somatic cells
(Figure 5E). Together, these results uncover a potential role for epigenomic
reconfiguration in facilitating gene regulation, by which genes stably silenced by DNA
methylation in ESCs switch to flexible repression mediated by repressive histone marks
in somatic cells.
Discussion

Two longstanding questions in cellular differentiation are how ESCs maintain
pluripotency and how they give rise to a multitude of diverse types of somatic cells.
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Given that ESCs and somatic cells share identical genomic sequences, the establishment
and maintenance of each somatic cell identity has been attributed to epigenetic
modifications. This has led to an appealing model in which a flexible epigenome in ESCs
allows for a multitude of genes to be transiently activated or repressed to support
pluripotency.
In support of this model, studies have found an increase in DNA methylation at the
critically important pluripotency gene Oct4 (Ben-Shushan et al., 1993; Deb-Rinker et al.,
2005). Additionally, the promoters of key developmental regulators are enriched with
histone modifications, such as H3K27me3 or H3K4me3, rather than more stable DNA
methylation in ESCs compared to somatic cells (Azuara et al., 2006; Bernstein et al.,
2006; Pan et al., 2007). A limitation of these studies is the biased focus on loci involved
in pluripotency and development. Therefore, to fully understand the role of the
epigenome in differentiation, we took advantage of publicly available data sets from
ESCs and distinct types of somatic cells in both human and mouse and performed an
unbiased, genome-wide analysis of DNA methylation, histone modifications, and
transcription across differentiation. Our data provides evidence against the prevailing
model in which ESCs have a more flexible epigenome than somatic cells and instead
supports that somatic cells have a more adaptable epigenetic landscape.
By analyzing two components of the epigenome, DNA methylation and histone
modifications, across cellular differentiation in two somatic cell types in human and
mouse, we found extensive, cell type-specific changes. Global analysis of DNA
methylation revealed that millions of CpGs are differentially methylated across
differentiation, with 90% of these differentially methylated CpGs being hypomethylated.
Additionally, we found that 70% of these differentially methylated CpGs across
differentiation are unique to each somatic cell type, which is in agreement with a recent
finding of tissue-specific methylation patterns in mouse (Hon et al., 2013). Strikingly, we
found that genomic regions that are hypomethylated in somatic cells are accompanied by
a gain of 22 different histone modifications in a cell type-specific manner. This suggests
that the switching from DNA methylation to histone modifications is an important
epigenetic event for differentiation and lineage specification.
The association between DNA hypomethylation and the gain of histone modifications
has been suggested for only a few histone modifications, such as H3K27me3, H3K9me3,
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and H3K4me1 (Gifford et al., 2013; Hawkins et al., 2010; Lister et al., 2009). Our results
have identified 18 new histone modifications that correlate with hypomethylation. We
found that genes repressed in both ESCs and somatic cells are held silent in ESCs by
DNA methylation, a more permanent epigenetic modification, whereas in somatic cells
genes are repressed by histone modifications, a more transient modification. This
switching from DNA methylation to histone modifications at repressed genes across
differentiation supports that the epigenome is more flexible in terminally differentiated
cells than in ESCs.
Our finding that epigenomic reconfiguration occurs in a cell type-dependent and
locus-specific manner raises the importance of profiling epigenomic information in
homogeneous cell populations. Although cellular heterogeneity has been difficult to
address, especially for complex tissues such as the brain, advanced technology in
combination with newly designed approaches should make this feasible in the near
future. The data processing pipelines developed in this study can allow us to address the
extent of reconfiguration, and interplay with histone modifications, including recently
discovered hmCpG and non-mCpG, once genomic data for these modifications in
different cell types become available.
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Figure 1 Global DNA hypomethylation in somatic cells in both human and
mouse. (A) Methylation levels (ML) of differentially methylated CpGs (diff-mCpGs)
between ESCs and two somatic cell types in human and mouse. Each circle represents a
CpG. The deeper the shade of blue, the higher the point density (number of CpGs). (B)
The percentage of diff-mCpGs (FDR<0.05, two-tailed Fisher’s exact test, B-H correction)
that are hypomethylated or hypermethylated during cellular differentiation. Confident
CpGs are those with 10 or more read coverage in both ESCs and somatic cells.
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Figure 2 DNA hypomethylation during cellular differentiation is locus- and
cell type-specific. (A) A schematic of the enrichment-based statistical approach used
to identify differentially methylated genomic regions (e.g. promoters). Confident CpG,
CpGs with 10 or more read coverage in both data sets; diff-mCpGs, differentially
methylated CpGs. (B) Heat maps of differentially methylated genomic regions between
hESC and the two human somatic cell types after clustering analysis. (C) Browser
representation of methylation profiles of the genes with changes in methylation levels at
their promoter regions during cellular differentiation. Each green vertical bar represents
a CpG, and the height of the bar represents its methylation level (from 0 to 100%). Grey
arrows indicate the transcriptional orientation of each gene. Regions marked by orange
bars indicate the locus- and cell type-specific DNA methylation changes.
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Figure 3 Changes in histone modifications during cellular differentiation
are locus- and cell type-specific. (A) The percentage of enriched sites for each
histone modification that were gained (gain), lost (lose), and remained (remain) during
differentiation of hESC to hFB and hEP. (B) Heat maps of changes of enriched sites for
11 histone modifications during cellular differentiation in human after clustering
analysis. (C) The width of H3K27me3 and H3K9me3 enriched sites in hESC and hFB.
★★★, p-value < 2.2×10-16, Student’s t-test. (D) Browser representation of two regions
with H3K27me3 and H3K9me3 expansion during cellular differentiation in human.
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Figure 4 A switching from DNA methylation to histone modifications during
cellular differentiation. (A) DNA methylation changes in the highly dynamic regions
that gain histone modifications during the differentiation of hESC to hFB. Green regions,
histone modifications that are associated with a decrease in DNA methylation; Gray
regions, histone modifications that are not associated with a change in DNA methylation;
Red regions, histone modifications that are associated with an increase in DNA
methylation. (B) DNA methylation changes in the highly dynamic gain regions during
the differentiation of hESC to hEP. (C) DNA methylation changes in the highly dynamic
regions that gain or lose H3K4me3 and H3K27ac during the differentiation of mESC to
mFC. Enrichment score for each region was calculated by dividing the number of
normalized reads aligned in a particular region in mFC by that in mESC. (D) Browser
representation of three regions that exhibit switching from DNA methylation to histone
modifications during cellular differentiation in human. Regions marked by grey bars
indicate the cell type-specific switching. The track scale for all histone modifications is
from 0 to 50 normalized reads.
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Figure 5 Switching from DNA methylation to repressive histone
modifications at promoter regions uncovers a change of gene regulation
from ESCs to somatic cells. (A) Scatter plots of the number of genomic CpGs, the
ratio of mCpG, and the ratio of diif-mCpG in 10 bp bins within the region 5 kb upstream
and 1 kb downstream of known transcription start site (TSS). (B) Heat map-pie charts of
the expression changes of the genes with hypomethylated promoters. FC, fold change,
gene expression levels in somatic cell types divided by that in ESCs. (C) Pie charts of
percentages of genes, which are hypomethylated at the promoter regions but with no
expression changes during cellular differentiation, marked by H3K27me3 or H3K9me3
or both in somatic cells. (D) Browser representation of four genes with epigenomic
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reconfiguration at their promoter regions. These genes were silent in both hESC and
somatic cell types. The track scale for all mRNA-seq is from 0 to 45 normalized reads.
The track scale for all histone modifications is from 0 to 50 normalized reads. (E) A
model depicting gene regulation changes during cellular differentiation.
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Supplemental Materials
Figure S1. Global DNA methylation levels decrease during cellular differentiation in
both human and mouse. (A) Distributions of CpG methylation levels in hESC, hFB, hEP,
mESC, mFB, and mFC. M, million. (B) The percentage of diff-mCpGs that are
hypomethylated or hypermethylated between somatic cells. (C) The percentage of diffmCpGs that are hypomethylated or hypermethylated on each autosome during cellular
differentiation.
Figure S2. The decrease in DNA methylation levels during cellular differentiation is
locus- and cell type-specific. (A) Different promoter definitions used in this study and
the percentage of differentially methylated promoter regions that are hypomethylated or
hypermethylated during cellular differentiation. Red rectangle indicates the
transcription start site (TSS). (B) The percentage of differentially methylated gene body
regions that are hypomethylated or hypermethylated during cellular differentiation. (C)
The percentage of differentially methylated intergenic regions that are hypomethylated
or hypermethylated during cellular differentiation. (D) Heat maps of differentially
methylated genomic regions between mESC and the two mouse somatic cell types after
clustering analysis. (E,F) Browser representation of methylation profiles of the genes
with changes in methylation levels at their promoter regions during cellular
differentiation. Each green vertical bar represents a CpG, and the height of the bar
represents its methylation level (from 0 to 100%). Red arrow indicates the
transcriptional orientation of each gene.
Figure S3. A switch from DNA methylation to histone modifications during cellular
differentiation in human. (A) DNA methylation changes in the highly dynamic lose
regions that lose histone modifications during the differentiation of hESC to hFB. (B)
DNA methylation changes in the highly dynamic lose regions during the differentiation
of hESC to hEP. (C) Browser representation of regions that switch from DNA
methylation to histone modifications during cellular differentiation in human. The track
scale for all histone modifications is from 0 to 50 normalized reads.
Figure S4. Epigenomic reconfiguration at promoter regions. (A) Scatter plots of the
number of genomic CpGs, the ratio of mCpG, and the ratio of diff-mCpG in 10 bp bins
within the regions of 5 kb upstream and 1 kb downstream of known transcription start
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site (TSS). (B) Top 10 enriched GO terms of genes with hypomethylated promoters. ★
indicates GO terms with Benjamini-corrected p-values < 0.05.
Figure S5. Epigenomic reconfiguration at promoter regions. (A) Browser
representation of six genes with alternative promoter usage. Red arrow indicates the
transcriptional orientation of each gene. The track scale for all mRNA-seq is from 0 to 45
normalized reads. (B) Browser representation of twelve genes with epigenomic
reconfiguration at their promoter regions during cellular differentiation. The track scale
for all mRNA-seq was from 0 to 45. The track scale for all histone modifications is from
0 to 50 normalized reads.
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